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ABSTRACT  
 
 Lipocalin-2 (Lcn2; also termed neutrophil gelatinase-associated lipocalin (NGAL)) 
is a proinflammatory factor which is elevated in obese individuals. It has also been 
implicated in the pathogenesis of heart failure and as a potential biomarker. This thesis 
exaimed: project 1: Regulation of autophagy by Lcn2 and its functional significance in 
leading to insulin resistance in cardiomyocytes, project 2: Changes in cardiac function, 
autophagy and cell death in wild type and Lcn2-knockout mice subjected to chronic 
myocardial ischemia, and project 3: Effect of iron on insulin sensitivity in 
cardiomyocytes and mechanistic role of oxidative stress. 
 
 Findings from project 1 indicated that Lcn2 treatment caused insulin resistance 
and use of gain and loss of function approaches elucidated a causative link between 
autophagy inhibition and regulation of insulin sensitivity in response to Lcn2. Project 2 
data demonstrated that Lcn2 attenuated autophagy to worsen the extent of apoptosis 
induced by chronic myocardial ischemia in mice. Finally, in project I showed that iron 
directly induced insulin resistance in cardiomyocytes and that this involved regulation of 
the crosstalk between autophagy and oxidative stress. 	
In summary, my studies demonstrated that Lcn2 promoted cardiac dysfunction 
and that lack of Lcn2 in mice was protective against surgically-induced heart failure. 
Inhibition of autophagy played a central mechanistic role in mediating the detrimental 
effects of Lcn2 on the heart, which included elevated oxidative stress, cell death and 
insulin resistance. 
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Chapter One:  Introduction 
1.1. Heart failure in obesity and diabetes 
 
Obesity and the associated metabolic syndrome (a cluster of chronic symptoms 
including insulin resistance, hyperglycemia, dyslipidemia, hypertension, and systemic low-
grade inflammation) predispose individuals to developing cardiovascular dysfunctions [1-
3]. Heart failure is one potential cardiovascular outcome and the consequences in the obese 
and aging population can be devastating owing to the high risk for mortality or loss of 
quality of life. However, the mechanisms of obesity and diabetes-induced heart disease are 
multifaceted and remain to be fully defined [4, 5]. Accordingly, there is currently great 
interest in resolving the various ways, and stages, via which obesity can influence 
myocardial remodeling. Central to the pathogenesis of heart failure in obesity are changes 
in cardiac metabolism and cardiomyocyte cell death [4]. One potentially important 
mechanism for altered myocardial metabolism is due to altered circulating, or local, 
adipokine profiles [4, 6, 7]. Various adipokines have also been suggested as potentially 
useful biomarkers for various aspects of cardiovascular disease. They have proven useful 
in identifying those at risk for heart failure or its progression and improving prediction of 
complications.  
	
1.1.1. Lipocalin-2: introduction and changes in obesity, diabetes and heart failure 
Lipocalin-2 (Lcn2; also often termed neutrophil gelatinase-associated lipocalin or 
24p3) is a small, secreted adipokine and belongs to a diverse family of lipocalins [8-11] 
(fig1.1).  Lcn2 is abundantly produced from adipocytes and recent studies show that Lcn2 
is a proinflammatory marker associated with insulin resistance and obesity-related 
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metabolic disorders [12-17](Fig 1.2). An increased Lcn2 expression in adipose tissue is 
observed in various experimental models of obesity and in obese humans [14, 18-20].  In 
mice, the permissive role of Lcn2 in development of aging- and obesity-induced insulin 
resistance is highlighted by studies indicating that these processes are attenuated by 
knockout of Lcn2 [16]. Measurement of serum Lcn2 has also been proposed as a useful 
means for evaluating obesity-related cardiovascular diseases including heart failure, based 
upon reports of an association between elevated circulating Lcn2 levels and cardiac 
dysfunction [12, 14, 21]. For example, circulating Lcn2 levels have been shown to increase 
at an early stage of experimental autoimmune myocarditis and remain high until recovery 
phase [22]. Elevated Lcn2 content in the myocardium is also induced by ischemia 
reperfusion, likely via production from infiltrating polymorphonuclear cells [23]. Lcn2 
expression is significantly augmented in patients with coronary heart disease and 
myocardial infarction [15, 24]. Furthermore, measurements of Lcn2 within a few days after 
ischemic stroke can be used to stratify patients according to mortality risk during the 
following four-year period [25]. Plasma Lcn2 was increased after carotid artery injury in 
rats [26] and in a heterotopic mouse transplanted heart after ischemia/reperfusion (I/R) [23]. 
Finally, it is interesting to note that Lcn2 has bacteriostatic properties and may play a role 
in linking infection, innate immunity and heart disease [27, 28]. 
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Figure 1.1. The structure for Lcn2. Lcn2 family members have a well conserved 
structure; 3 dimensional, eight stranded antiparallel beta-barrel with a repeated +1 topology 
enclosing an internal ligand binding site. Taken from 
http://www.rcsb.org/pdb/ngl/ngl.do?pdbid=1NGL 
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Figure 1.2.  Altered profile of Lcn2 in obese individuals. 
Schematic diagram indicated that an increase in Lcn2 levels in the body, it altered various 
health disease such as inflammation, insulin resistance, lipotoxicity, cardiovascular disease 
and dyslipidemia [12] . (Reprinted from the Clinical and Experimental Pharmacology and 
Physiology, Vol. 39, Jang et al., Emerging clinical and experimental evidence for the role 
of lipocalin-2 in metabolic syndrome, Page No. 194, Copyright (2012), with permission 
from John Wiley and Sons) 
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1.1.2. Evidence linking Lcn2 with metabolic syndrome.  
1.1.2.1. Metabolism and inflammation 
Numerous human studies have highlighted that serum Lnc2 level was associated 
with various metabolic parameters and inflammatory markers [14, 18, 29, 30]. Increased 
Lcn2 concentration clearly correlated with body mass index, body fat percentage, 
hypertriglyceridaemia, hyperglycaemia and the insulin resistance [14]. Previous research 
also demonstrated that elevated serum Lcn2 levels occurred in obese patients with 
metabolic syndrome and there was strong correlation between Lcn2 and insulin resistane 
in these obese patients. Increased circulating LPS concentrations are sufficient to 
dysregulate the inflammatory status and initiate the onset of obesity and insulin resistance 
[31]. Indeed, LPS can induce increases in systemic Lcn2 by 150 fold within 24 hours [32]. 
Lcn2 deficient mice were shown to have delayed LPS-induced hypoferremia in induced 
sepsis, indicating a role for Lcn2 in limiting circulating iron levels by enhancing 
intracellular iron content during inflammatory states [32]. Mice deficient in Lcn2 also had 
exacerbated endotoxin-induced sepsis, increased immune cell apoptosis and increased 
mortality [32]. MyD88-dependent signaling is required for the induction of Lcn2 and iron 
sequestration to maintain the hypoferric response during endotoxemia [33]. Thus, Lcn2 
can act as an influencer for the development of endotoxemia and derived metabolic 
disease by its effect on LPS.  As indicated above, elevated Lcn2 levels associated with 
obesity and insulin resistance [12, 14]. In studies of diabetic patients, it was found that 
serum Lcn2 concentration significantly associated with fasting triglycerides and insulin 
and homeostasis model assessment of insulin resistance (HOMA-IR) [29]. Similarly, 
serum level or adipose tissue Lcn2 content was found to be elevated in overweight 
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pregnant women and associate with several insulin resistance markers including HOMA-
IR, fasting plasma insulin and glucose [34, 35]. Gene and protein expression of Lcn2 
increased in visceral adipose tissue of obese compared to lean subjects [36, 37]. Weight 
loss caused a significant reduction of circulating Lcn2 in overweight/obese women with 
polycystic ovary syndrome [38], but a similar response was not seen in pre-pubertal 
children with obesity [39]. One established mechanism via which Lcn2 leads to obesity 
induced insulin resistance may be its capacity to stimulate the expression of 12-
lipoxygenase, an enzyme that metabolizes arachidonic acid, and consequently induces 
TNFα in adipose tissue [16].  
 
1.1.2.2. Heart failure  
In clinical settings, Lcn2 is now regarded as one of the best biomarkers for acute 
kidney injury, and is also emerging as a promising biomarker for HF [40].  A close 
interdependent relationship means that renal dysfunction often accompanies cardiac failure; 
and that cardiac dysfunction is frequently seen with renal failure [40]. Therefore, many 
biomarkers for kidney or tubular dysfunction, for example, KIM-1 (kidney injury molecule 
1), NAG (N-acetyl-beta-D-glucosaminidase) and cystatic C, also predict prognosis and 
outcomes in patients with HF [41]. However, unlike other renal biomarkers, Lcn2 level 
was not affected by diuretic withdrawal in patients with chronic systolic HF [42]; and 
administration of Lcn2 in an animal model of acute ischemic renal injury actually 
attenuated tubular injury [43]. Moreover, in patients with chronic HF, Lcn2 has been 
shown to be a more effective marker than creatinine for cardiorenal syndrome; Lcn2 could 
detect renal injury earlier than creatinine, and was an independent and novel risk predictor 
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of mortality in chronic HF [44]. Indeed, the elevation of Lcn2 seen in HF and its 
association with different parameters of HF has affirmed its potential as a HF biomarker. 
Firstly, serum Lcn2 predicted the outcome of HF, for example, the GALLANT (Lcn2 
evaLuation Along with B-type NaTriuretic peptide in acutely decompensated heart failure) 
trial concluded that plasma Lcn2 at the time of discharge was a strong prognostic indicator 
of 30 days outcomes in patients admitted for acute HF [45]; it independently predicted 
worse short term prognosis in patients with acute HF [46] and Lcn2 levels correlated well 
with HF-related functional assessment parameters including the 6 min walk test [47]. 
Secondly, the CORONA (COntrolled ROsuvastatin multiNAtional trial in heart failure) 
study suggested that Lcn2 associated with the severity of HF [48]; the elevated serum Lcn2 
in patients with acute post myocardial infarction and chronic HF was found to be 
associated with more adverse outcome [28]; the Lcn2 level was shown to be correlated 
with HF severity and hemodynamic improvements after lefy ventricular assist device 
(LVAD) placement [49]. Thirdly, serum LCN2 predicted severity of chronic HF in terms 
of NYHA classification and mortality in elderly patients [50]; and plasma Lcn2 also 
predicted mortality in HF patients with or without CKD [51]. Clearly, there is strong 
evidence associating Lcn2 with HF in various individual cohorts in terms of HF severity, 
prognosis and mortality (figure 1.3).  
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Figure 1.3. Lcn2 is a useful biomarker for evaluating the outcomes in various clinical 
and basic researches in cardiovascular diseases. Developing clinical and animal model 
data have been shown that changes in Lcn2 levels in the heart and vasculature under a 
variety of ‘stresses’. This schematic diagram highlighted Lcn2 leads to damaging effects 
on the cardiovascular system [12]. (Reprinted from the Clinical and Experimental 
Pharmacology and Physiology, Vol. 39, Jang et al., Emerging clinical and experimental 
evidence for the role of lipocalin-2 in metabolic syndrome, Page No. 194, Copyright 
(2012), with permission from John Wiley and Sons) 
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1.2. Cellular mechanisms involved in pathogenesis of heart failure 
1.2.1. Insulin signalling  
Insulin binds to the insulin receptor (IR), inducing a conformational change that 
results in the autophosphorylation of tyrosine residues present in the β subunit [52]. 
Members of the insulin receptor substrate (IRS) family bind to IR via phosphotyrosine 
binding (PTB) domains [53]. Subsequently, this leads to the phosphorylation of tyrosine 
residues on IRS proteins and then bind to phosphatidlyinositol-3-kinase (PI3K) through the 
Src homology 2 (SH2) domain of the p85 regulatory subunit. The catalytic subunit p110 is 
then activated and phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to 
phosphatidylinositol 3,4,5-triphosphate (PIP3) at the plasma membrane. PDK1 and Akt are 
recruited to the plasma membrane by binding to PIP3 through their PH domains. 
Specifically, interaction with the activating kinase phosphoinositide-dependent kinase-1 
(PDK-1) phosphorylates Akt at threonine (308) in its kinase-domain activation loop, 
causing partial activation of Akt/protein kinase B (PKB). However the complete activation 
of Akt requires phosphorylation at serine (473), located in the hydrophobic C-terminal 
domain, by mammalian target of rapamycin complex 2 (mTORC2), previousy known as 
PDK-2. Another alternative is that Shc recruits Grb2/SOS, which stimulates the MAPK 
signaling pathway. Substrates activated by the MAPK and PI3K/Akt pathways mediate 
various downstream biological responses of insulin, including cell survival and glucose 
metabolism [53]. 
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Figure 1.4. Insulin signalling pathway. Insulin stimulates the autophosphorylation 
of its receptor leading to binding and tyrosine phosphorylation. Phosphorylated 
tyrosine residues on IRS act as docking sites with SH2 domains such as PI3K, which is 
central for AKT activation. AKT requires the phosphorylation of threonine residue in the 
catalytic domain, and serine residue in the hydrophobic motif by PDK1 and the 
mTORC2 complex, respectively [54]. (Reprinted from the Trends in Endocrinology & 
Metabolism, Vol. 23, Kim et al., Insulin resistance in nervous system, Page No. 133, 
Copyright (2012), with permission from Elsevier) 
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1.2.2. Autophagy 
Autophagy is a general term now used to describe the processes by which capture of 
cytoplasmic components for lysosomal degradation occurs [55]. Three types of autophagy 
have been characterized: macroautophagy, chaperone-mediated autophagy and 
microautophagy. Macroautphagy has been the most extensively studied form and involves 
firstly the formation of a double membrane vesicle called the autophagosome. Chaperone-
mediated autophagy involves the binding of proteins containing a KFREQ motif to a 
chaperon protein for translocation to lysosomes where it binds to lysosome-associated 
membrane protein type 2A (LAMP-2A) receptor and is subsequently internalized and 
degraded. Lastly, microautophagy involves the direct sequestration of cellular components 
via the lysosome through the invagination of the lysosomal membrane [56]. Autophagy has 
been called a “double-edged sword” [57] as it can either be beneficial or detrimental to the 
cell, depending on the context. The basal autophagy is essential for maintaining cellular 
homeostasis and for the turnover of cytosolic components, as it degrades long-lived 
proteins, defective organelles and intracellular pathogens, thus protecting the cell and 
replacing it with molecules for future anabolic purposes [55, 56].   
Autophagosome formation utilizes 18 different Atg proteins and is comprised of 
three major steps: initiation, nucleation and elongation/enclosure [56]. The initiation step is 
controlled by the ULK1 (UNC-51-like kinase 1)–FIP200 (FAK family kinase-interacting 
protein of 200 kDa) ATG13 ATG101 complex. The serine/threonine kinase mammalian 
target of rapamycin (mTOR) inactivates ULK1 by phosphorylation. Under starvation 
conditions, autophagy is induced via the inactivation of mTOR that results in ULK1 
(Ser757) activation and phosphorylation of Atg13 and FIP200 A. Another pathway is that 
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AMPK is activated by AMP and activates ULK (Ser555). Anti-apoptotic proteins from the 
BCL-2 family usually inactivate this complex, but when it is active it enables the 
nucleation of the isolation membrane. The final elongation and enclosure step requires the 
recruitment of two ubiquitin-like protein conjugation systems. Firstly, the conjugation of 
Atg12–Atg5 is mediated by ligases Atg7 and Atg10. Atg5 also associates with Atg16 to 
form the Atg12–Atg5–Atg16 complex. Second, the microtubule-associated protein light 
chain 3 (LC3), which is the mammalian homolog of yeast Atg8, is cleaved at its carboxyl 
terminus by Atg4, giving rise to the soluble, cytosolic form LC3-I, which is then 
conjugated to phosphatidylethanolamine (PE) through the actions of Atg7 and Atg3. This 
lipid conjugated form, LC3-II, is localized to the autophagosomal membrane, and allows 
the closure of the autophagic vacuole [56, 58]. LC3 is to date the only protein that has been 
identified on the inner membrane of the autophagosome and hence is the most commonly 
used experimental protein marker for autophagic vacuoles. An increase in LC3-II reflects 
an increase in autophagsome formation. Another protein important in the assessment of 
autophagy is P62, which delivers ubiquitinated proteins to the autophagosome for 
degradation by binding to the polyubiquitin chains and LC3 [56]. P62 is then preferentially 
degraded by autophagy [59]. Experimentally, autophagic flux is concluded to increase 
when LC3-II levels increase and P62 levels show a corresponding decrease. Two 
additional proteins which participate in the recruitment of molecules to the isolation 
membrane are the transmembrane proteins, ATG9 and vacuole membrane protein 1 
(VMP1), which recycle between the golgi, endosomes and autophagosomes, probably 
shuttling lipids for degradation [60]. 
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Figure 1.5. The major stages of autophagy. (a) The initiation step of autophagsome 
formation is controlled by the ULK1-FIP200-ATG13-ATG101 complex, and inhibited by 
mTOR. (b) VPS34-Beclin 1-class III PI3K complex, which is inactivated by anti-apoptotic 
BCL-2 family proteins. (c) Transmembrane proteins ATG9 and VMP1 recruit molecules to 
the isolation membrane. (d) The elongation and enclosure step of autophagosome 
formation requires two ubiquitin-like protein conjugation systems. (e) Fusion between 
autophagosomes and (f) various lysosomal enzymes hydrolyse proteins, lipids and nucleic 
acids in the autolysosome [60]. (Reprinted from the Nature Reviews Molecular Cell 
Biology, Vol. 15, Marino et al., Self-consumption: the interplay of autophagy and 
apoptosis, Page No. 2, Copyright (2014), with permission from Nature Publishing Group) 
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1.2.3. Apoptosis 
There are different processes that lead to cell death and they must be carefully 
controlled in order for the organism to survive, grow and carry out its necessary functions. 
In most cases, unwanted cells are destroyed by programmed cell death in a process called 
apoptosis.  Apoptosis is a highly regulated type of programmed cell death or cell suicide 
characterized by morphological changes [61]. There are two main pathways in the cell for 
the initiation of apoptosis: extrinsic pathway and intrinsic pathway [60]. The extrinsic 
pathways that recruit apoptosis involve transmembrane receptor-mediated interaction. 
These receptors are members of the tumor necrosis factor (TNF) receptor gene superfamily 
that contain a cytoplasmic domain of about 80 amino acids termed the “death domain”. 
This death domain plays a critical role in transmitting the death signal from the cell surface 
to intracellular signaling pathways. The binding of Fas ligand to Fas receptor results in the 
binding of the adapter protein FADD, and the binding of TNF ligand to TNF receptor 
results in the binding of the adapter protein TRADD with subsequent recruitment of 
proteins FADD and RIP. FADD then associates with procaspase-8, leading to caspase 8 
dimerization and activation [60]. Once active, caspase 8, an “initiator caspase” [62], can 
directly cleave and activate “effector or executioner caspases” caspase 3 and caspase 7 [61, 
63], leading to caspase-dependent apoptosis. The intrinsic pathway of apoptosis is 
characterized by one central injurious event – mitochondrial outer membrane 
permeabilization (MOMP) [60]. Non-receptor-mediated stimuli activate B cell lymphoma 
2 (Bcl-2) homology 3 (BH3)-only proteins, which stimulate MOMP by inducing the 
oligomerization of BCL-2 associated X protein (BAX) and/or BCL-2 antagonist or killer 
(BAK) in the outer mitochondrial membrane. Cytochrome c is released form damaged 
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mitochondria and binds apoptotic protease-activating factor 1 (APAF1). Via 
oligomerization a structure called the apoptosome is formed that recruits and activates an 
“initiator caspase”, caspase 9. Subsequently caspase 9 cleaves and activates “effector or 
executioner caspases”, caspase 3 and caspase 7, leading to caspase-dependent apoptosis.  
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Figure 1.6. The two main pathways for apoptosis. (a) The extrinsic signalling pathways 
that initiate apoptosis contain transmembrane receptor mediated interactions. (b) The 
intrinsic signalling pathways that initiate apoptosis involve a various array of non-receptor 
mediated stimuli that produce intracellular signals that act directly on targets within the cell 
and are mitochondrial-initiated events. Additional details about the specific information are 
given in the text [60]. (Reprinted from the Nature Reviews Molecular Cell Biology, Vol. 
15, Marino et al., Self-consumption: the interplay of autophagy and apoptosis, Page No. 2, 
Copyright (2014), with permission from Nature Publishing Group) 
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1.2.4. Oxidative stress 
Oxidative stress is a disturbance in the balance between the production of reactive 
oxygen species (free radicals) and antioxidant defenses [64]. It is thus an altered 
accumulation of reactive oxygen species (ROS). These ROS can cause pathological 
alterations in the cell due to DNA damage, oxidation of amino acids, proteins and lipids 
[64]. ROS designates not only a range of free radicals such as superoxide radical anion 
(O2•–), carbonate radical anion (CO3•–), hydroperoxyl radical (HOO•), hydroxyl radical 
(HO•), peroxyl radical (ROO•), and alkoxyl radical (RO•), but also non-radicals like 
hydrogen peroxide (H2O2), hypochlorous acid (HClO) and ozone (O3). Among them, H2O2 
and O2•– are the major ROS in living organisms and are continuously produced by cells and 
in excess must simultaneously be removed by antioxidant enzymes. Neither H2O2 nor O2•– 
are strong oxidizing agents, but extremely reactive hydroxyl radical HO• can be produced 
upon reacting with iron or iron-containing molecules through Fenton reaction [65]. H2O2 
oxidizes Fe2+ to Fe3+, producing hydroxyl radical HO• and hydroxide ion OH- (1); Fe3+ is 
then reduced back to Fe2+ by another H2O2 molecule, forming a hydroperoxyl radical 
HOO• and a proton H+ (2); or by superoxide radical anion (O2•–) to produce oxygen (O2) 
(3). In this way, iron acts as a catalyst to generate plentiful amounts of ROS.  
Fe2+ + H2O2 → Fe3+ + HO• + OH–   (1)  
Fe3+ + H2O2 → Fe2+ + HOO• + H+   (2) 
Fe3+ + O2•– → Fe2+ + O2                  (3)  
Although ROS has important physiological functions, for example, to combat 
invading pathogens, excess ROS can result in oxidative stress that damage intracellular 
protein, lipids and nucleic acid. Indeed, specific parts of the genome were found to be 
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damaged by Fenton reaction, and are termed “genomic sites vulnerable to the Fenton 
reaction” [65].  
 
1.3. Iron metabolism and regulation by Lcn2 in cardiomyopathy 
1.3.1. Systemic and myocardial iron metabolism   
Iron homeostasis is essentially a closed system - iron is acquired from food as 
inorganic or heme iron, which are primarily absorbed in the duodenum via processes 
mediated by divalent metal ion transporter 1 (DMT-1) and heme carrier protein 1 (HCP-1), 
respectively. Iron in the cytoplasm can either be stored as ferritin, or be released to the 
bloodstream via ferroportin (FPN), where ferrous iron (Fe2+) can be oxidized to ferric iron 
(Fe3+) by hephaestin to facilitate its binding to transferrin (Tf) and be transported in the 
circulation. Most cells express transferrin receptor 1 (TfR1) such that holo-Tf can be 
endocytosed to acquire iron, where the ferric iron gets reduced to ferrous iron by 
metalloreductase STEAP3. It is then transported across the cell membrane by DMT-1. 
Hepcidin is a peptide hormone that induces the intracellular degradation of FPN, the only 
know iron exporter, and therefore is a vital and major iron regulatory hormone that 
controls plasma iron concentration and tissue iron distribution by inhibiting intestinal iron 
absorption, iron recycling by macrophages and iron mobilization from hepatic stores [66]. 
Various processes mediate iron transport in the cardiovascular system. Iron deposition in 
the heart is a gradual process, and has been suggested to occur in the ventricular 
myocardium before the atrial myocardium [67]. Sequential appearance has been further 
documented, beginning initially in the epicardium, then myocardium and eventually 
endocardium. Myocardial iron levels are normally regulated through transferrin mediated 
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uptake mechanisms, mainly through TfR1 [68]; although in the case of iron overload 
where transferrin-mediated transport becomes saturated, non-transferrin bound iron (NTBI) 
in the circulation increases and can also enter cardiac myocytes through DMT-1, T-type 
calcium channels (TTCCs), L-type calcium channels (LTCC) [68, 69], ZRT/IRT-like 
protein 14 (Zip14 or Slc39a14) [70] and also Lcn2 receptor which facilitates the entry of 
LCN2 bound iron [71]. FPN1 is expressed in cardiomyocytes as an exporter of iron into 
circulation (Figure 1. 7.)[72].  
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Figure 1.7. Schematic overview of cellular iron transport in cardiomyocytes. The role 
of DMT-1 as well as other transporters such as LTCC and TTCC as possible portals for 
iron into cardiomyocytes. In addition Tf binds to TfRs o the external surface of the cell. 
The role of NGAL(Lcn2) is to donate iron to cell via the NGAL-R. Internalization of 
NGAL (Lcn2) and its receptor leads to the uptake of iron from siderophore-iorn complex, 
although the exact mechanism remains unclear. However, accumulation of iron 
subsequently induces mitochondrial dysfunction, oxidative stress, ER stress and autophagy 
in cardiomyocyte [73]  (Reprinted from Clinical Science, Vol. 129, Chan et al., Iron 
metabolism and regulation by neutrophil gelatinase-assocoated lipocalin in 
cardiomyopathy, Page No. 851, Copyright (2015), with permission from Portland Press) 
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1.3.2. Observational changes and diagnosis of iron status in cardiomyopathy  
Heart failure (HF) is a highly prevalent chronic progressive condition in which the 
heart is incapable of pumping enough blood to meet the body’s demand. The heart 
compensates with various remodeling measures including initial enlargement (hypertrophy) 
to increase pumping capacity [74]. Ejection fraction (EF), the measurement of the amount 
of blood the left ventricle pumps out in each contraction, is an important indicator for heart 
function and diagnosis of HF. In patients who have heart failure with reduced ejection 
fraction (HFrEF), EF drops from a normal range of between 55 and 70% to below 40%; 
yet half of the patients with HF are observed to have preserved EF (HFpEF) [75]. In the 
ongoing search for novel treatments of HF, there is strong emerging evidence showing the 
significance of disturbed iron homeostasis in HF regardless of the degree of change in EF 
[76], thus establishing excellent therapeutic potential if our understanding of the 
mechanisms responsible for the association of iron homeostasis and HF can be enhanced. 
The normal range of circulating ferritin is from 30-300 µg/L, where <30 µg/L is 
defined as iron deficiency. However, heart failure has an inflammatory component were 
serum ferritin, as an acute phase protein, is often elevated without changes in body iron 
store. Therefore, recently the European Society of Cardiology (ESC) guidelines for 
diagnosis and treatment of heart failure have recommended a systematic measurement of 
iron parameters in all patients suspected of having heart failure. Serum ferritin <100 µg/L 
is regarded as absolute iron deficiency; where serum ferritin 100-299 µg/L and a 
transferrin saturation of <20% is defined as functional iron deficiency [77]. On the other 
hand, a serum ferritin >300ug/L and a transferrin saturation of >55% is diagnosed as iron 
overload cardiomyopathy (IOC). The level of serum ferritin at which iron deposition is 
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detected in the heart has not yet been conclusively identified. Taking heart biopsy is not 
only invasive, but technical difficulty often renders the results variable and non-definitive. 
Both iron overload and iron deficiency have been linked to cardiomyopathy, with the 
former primarily associated with an enhanced oxidative stress and the latter with 
mitochondrial dysfunction, impaired heart efficacy [78], hypercoagulable state, increased 
cardiac burden and also oxidative stress due to anemia [79]. Cardiomyopathy associated 
with iron overload or deficiency will be reviewed in more detail in the following sections.  
 
1.3.2.1. Iron overload cardiomyopathy (IOC) 
IOC is defined as the presence of systolic or diastolic cardiac dysfunction 
secondary to increased deposition of iron in the heart independent of other concomitant 
processes [80]. IOC is typically associated with dilated cardiomyopathy with left 
ventricular hypertrophy and reduced EF [81]. The prevalence of IOC is increasing and is 
the leading cause of death in patients receiving chronic blood transfusion therapy [82]. 
While patients may remain asymptomatic in the early disease process, severely overloaded 
patients can rapidly experience terminal HF. Accumulation of iron in the myocardium may 
occur via increased iron absorption from gastrointestinal enterocytes (hemochromatosis); 
excess exogenous iron intake such as by dietary supplements, or blood transfusions 
(hemosiderosis). The association of IOC with hemochromatosis, an autosomal disorder 
involving mutation of specific genes involved in iron metabolism that leads to increased 
gastrointestinal absorption, is well characterized [83]. In fact, this accounts for one third of 
deaths in hereditary hemochromatosis, especially in young male patients [84]. Chronic 
blood transfusion is the treatment for hereditary and acquired anemia including 
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thalassemia and myelodysplastic syndromes. However, since excess body iron cannot be 
actively excreted, repeated blood transfusion can result in iron deposition in multiple 
organs. There are numerous mechanisms via which excess iron can reduce cardiac function. 
Once the antioxidant capacity of cardiomyocytes is exceeded, iron can produce excess 
oxidative stress by the Fenton reaction (see below) and lead to apoptosis [85]. In addition, 
excess free iron in blood is suggested to be responsible for the generation of insoluble 
parafibrin, which is highly resistant to proteolytic dissolution and initiates inflammatory 
reactions upon deposition on the arterial wall [86]. Association of iron and atherosclerosis 
is well established in animal studies, for example, iron accumulation is observed in 
atherosclerotic plaques [87] and decreasing tissue iron by chelating therapy, dietary iron 
restriction or phlebotomy showed decreased atheroma plaque size with improved stability 
[88-91]. Such association is also supported in clinical studies – a study involving 12033 
men showed increased ferritin concentration was associated with early coronary artery 
atherosclerosis, independent of traditional cardiovascular risk factors [92]; another study 
that involved 196 subjects showed a strong association between serum ferritin and pulse 
wave velocity or aortic stiffness in women [93]. The 6 years long Iron and Atherosclerosis 
STudy (FeAST) also established correlations between levels of ferritin, inflammatory 
biomarkers and mortality in a subset of patients with peripheral arterial disease [94]. Iron 
availability may have contributed to atherosclerosis by impairing nitric oxide action as 
demonstrated by improvement in nitric oxide mediated, endothelium-dependent 
vasodilation in patients with coronary artery disease by chelating iron with deferoxamine 
[95]. While further mechanisms are yet to be defined, the Atherosclerosis Risk In 
Communities (ARIC) study has rejected the hypothesis that excess iron stores would 
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promote low density lipoprotein (LDL) oxidation [96]. It was shown that dietary iron 
intake and body iron stores had no direct link to altered structure and function of large 
arteries in subjects free of cardiovascular disease, cancer or hemochromatosis [97].  
 
1.3.2.2. Iron deficiency (ID) and cardiomyopathy  
ID is the most common nutritional deficiency worldwide [98]. It is frequent, has a 
high occurrence rate from 30% to 50% in patients with HF and presents as an important 
co-morbidity [99]. Two types of ID can be distinguished – absolute and functional ID. 
Absolute ID reflects depleted iron stores while iron homeostasis mechanisms and 
erythropoiesis often remain intact. Absolute ID development in humans can result from 
inadequate dietary iron intake, impaired gastrointestinal absorption/ transport, drug 
interactions and gastrointestinal blood loss [100]. On the other hand, functional ID 
presents a dysregulated iron homeostasis where cells and tissues might be rendered with 
inadequate iron supply despite normal whole body iron storage. This can be a result of 
elevated circulating hepcidin concentration, and had been reported in patients with acute 
phase myocardial infarction [101].  ID is often accompanied by anemia, although both can 
exist independently and ID usually appears before the onset of anemia. It is important to 
differentiate anemia from ID – while ID is marked by the insufficiency of iron, anemia is 
defined by insufficient hemoglobin. ID that is independent of anemia was reported to have 
a higher risk of death than those with anemia [102, 103]; it has been reported as an 
independent predictor of mortality and associates with disease severity [104]. In recent 
years there have been several clinical trials to test whether administration of intravenous 
iron could improve functional parameters related to HF. One of the most well-known 
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studies includes the Ferinject Assessment in patients with IRon deficiency and chronic 
Heart Failure (FAIR-HF). It involved 459 patients with iron deficiency and chronic heart 
failure of New York Heart Association (NYHA) functional class II or III. The treatment 
with intravenous ferric carboxymaltose over 24 weeks improved NYHA functional class, 
functional capacity and quality of life in terms of EQ-5D (EuroQol-5 Dimension) and 
KCCQ (Kansas City Cardiomyopathy Questionnaire) with an acceptable side effect profile 
[105]. A simplified ferric CarboxymaltOse evaluatioN on perFormance in patients with 
IRon deficiency in coMbination with chronic Heart Failure (CONFIRM-HF) trial that has 
enrolled 304 stable, symptomatic HF patients from 41 sites across 9 European countries is 
currently in progress to confirm the efficacy and safety of iron therapy using intravenous 
ferric carboxymaltose solution in chronic HF patients with iron deficiency as in the FAIR-
HF study [106]. Other clinical trials including the FERRIC-HF [107] and IRON-HF [108] 
trials have also showed encouraging results with iron therapy using intravenous iron 
sucrose in improving functional capacity in HF patients with ID. Thus, ID can serve in 
many cases as a promising therapeutic target for HF. Furthermore, the importance of ID as 
a marker in the context of HF and its assessment was highlighted and recommended by the 
ESC [77]. As for anemia, it has also been shown to have a relatively high prevalence (37%) 
in patients with HF [109]. With less oxygen availability during anemia, the heart 
compensates by increasing heart rate and stroke volume. Moreover, anemia has been 
reported to be an independent risk factor for adverse outcomes in HF, both in terms of 
morbidity and mortality rates [110-117]. Efforts have been made to restore hemoglobin 
levels as a potential therapeutic approach to HF using erythropoietin-stimulating agents 
(ESA) and this resulted in improvements in exercise tolerance, peak VO2, NT-proBNP and 
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left ventricular performance in patients with HF [118]. However, other studies have also 
distinguished anemia as being independent from HF [119] – the correction of anemia by 
ESA darbepoitin alfa demonstrated no difference in the primary end point for HF, and was 
even associated with elevated embolic and thrombotic events [120]. Thus, it is suggested 
that anemia may only serve as a surrogate marker instead of an endpoint target in HF.  
 
1.3.3. Cellular mechanisms that underlie the association of iron and cardiomyopathy  
1.3.3.1. Iron & oxidative stress  
Free iron is highly redox reactive and can participate in redox reaction that leads to 
generation of reactive oxygen species (ROS). Ferroptosis, as the name implies, is a 
recently identified form of cell death that is morphologically, biochemically and 
genetically distinct from apoptosis and necrosis and is found to be dependent on 
intracellular iron, and can be prevented by iron chelators and antioxidants [121]. The use 
of iron chelator deferoxamine has demonstrated significant reduction of neutrophil-
mediated free radical production and amplification of the inflammatory response during 
cardiopulmonary bypass in human [122] and in vivo studies [123-125]. In summary, iron 
can potently enhance oxidative stress and consequently contribute to cardiomyopathy. 
 
1.3.3.2. Iron and mitochondrial dysfunction     
In eukaryotic cells, mitochondria are the main consumers of intracellular iron [126]. 
With mitochondria being the respiratory centre of the cell, plentiful oxygen can rapidly 
react with unregulated free iron to produce ROS. To avoid ROS induced damage, 
mitochondrial iron level and homeostasis is tightly regulated by different transport, storage 
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and regulatory proteins [127]. Through different biosynthesis pathways, iron is transferred 
in the mitochondria to its bioactive forms, heme and iron sulphur cluster (ISC). Mitoneet is 
an ISC-containing protein tethered to the outer mitochondrial membrane that facilitates 
transfer of iron into the mitochondria [128]. Not only does it play an essential role in redox 
signaling [129], it also dictates metabolic functions of mitochondria [128, 130-132]. An 
increased level of mitoneet can lead to accumulation of iron within the mitochondria, 
which in turn results in dysfunction [133, 134], a hallmark of various diseases. Mitoneet is 
recognized as a target for the thiazolidinedione class of antidiabetic drugs [129, 135], and 
its genetic manipulation was shown to have striking antidiabetic effects [136]. 
Mitochondrial ferritin stores and supplies iron within the mitochondria. Its expression is 
restricted to highly metabolically active cells such as cardiomyocytes in order to supply 
iron when demand is increased during active respiration or intense metabolic activities. 
Frataxin is another mitochondrial protein that handles iron in the mitochondrial matrix 
assembling ISC [137]. It can either act as a chaperone for ferrous iron, or as an iron storage 
protein that can mineralize iron as ferrihydrite. There is great interest in improving 
mitochondrial dysfunction as a potential therapeutic approach for heart failure [138, 139] 
and the underappreciated contribution of iron homeostasis is worthy of more consideration. 
 
1.3.3.3. Iron & endoplasmic reticulum (ER) stress  
Various pathophysiological situations can elevate ER stress. One of the major 
functions of ER is proper protein folding, and accumulation of misfolded proteins can 
normally be relieved by cellular responses such as ER-associated protein degradation 
(ERAD) and unfolded protein response (UPR). These ER stress responses are important 
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defense mechanisms when the amount of unfolded protein exceeds the folding capacity of 
ER [140]. ER stress has been strongly implicated in cardiovascular disease. For example, 
ER stress can lead to cardiomyocyte death in vivo and ex vivo [141] and in patients with 
HF [142]. Interestingly, it was suggested that ER stress may be cardioprotective during 
constriction-induced hypertrophy [143], perhaps by inducing compensatory cellular 
mechanisms such as autophagy (see below). Similarly, ER stress induction protected 
cardiomyocytes from oxidative damage [144]. Iron overload induced ER stress was shown 
in vivo in heart under acute and chronic conditions [145], and had been demonstrated in 
other tissue types including neurons [146] and liver [147]. In reverse, ER stress can 
modulate iron metabolism. Hepcidin, as mentioned above, degrades the iron efflux 
transporter FPN, thus leading to a systemic hypoferremic environment. ER stress was 
found to induce hepcidin expression [148]; the UPR signaling pathway was further shown 
to increase the transcription of ferroportin and ferritin [149]. Thus, based upon available 
evidence, ER stress and iron homeostasis appear to have a reciprocal relation such that they 
can tightly regulate each other. ER stress and UPR related proteins will serve as interesting 
targets to be studied in future clinical studies    
 
1.3.3.4. Iron & autophagy  
Macroautophagy (hereafter referred to as autophagy) is an intracellular degradation 
system that involves the sequestration of cytoplasmic components within a double-
membrane vesicle termed autophagosome, in which the cargo content is degraded by the 
acidic hydrolases upon the fusion with a lysosome [55]. It has a wide variety of 
physiological and pathophysiological roles including energy homeostasis, cell survival and 
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host defense against pathogen invasion [150].  In the heart, autophagy typically occurs at 
low levels yet is nevertheless important in maintaining cellular homeostasis under normal 
conditions. Autophagy is typically upregulated in times of stress, for example during 
ischemia/reperfusion, pressure overload and cardiac toxicity induced by chemicals such as 
the athracycline doxorubicin [151]. While increased autophagy can promote cell survival 
by degrading damaged organelles such as mitochondria and protein aggregates to recycle 
catabolites and maintain ATP production; either excess or lack of autophagy can both 
result in cell death and cardiac dysfunction. Thus, the role of autophagy can often appear 
controversial among different studies when different degrees of autophagy, time course 
and pathological conditions being studied have led to variable observations. In vivo data 
has shown that expression of multiple autophagy related genes were altered in iron 
overload cardiomyopathy, possibly contributing to cardiac diastolic dysfunction [152].  
 
Specifically, it is now appreciated that iron can regulate autophagy and that 
autophagy has an important role in iron homeostasis. Nuclear receptor coactivator 4 
(NCOA4) was recently identified using quantitative proteomics to be the cargo receptor 
that mediates autophagy of ferritin - a process termed ferritinophagy. NCOA4 is required 
for the delivery of ferritin to the lysosome; without NCOA4 cells are malfunctional in 
ferritin degradation and this can result in a decreased bioavailability of intracellular iron 
[153]. However, excessive ferritinophagy may result in insufficient ferritin thus reducing 
its buffering effect on binding intralysosomal low mass iron and can lead to lysosomal 
fragility and increased sensitivity to oxidative stress [154]. Analysis of autophagy in iron 
associated cardiomyopathy is relatively new with limited mechanistic and clinical studies; 
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however we believe this must be rapidly developed since it is of great potential as a 
therapeutic target.  
 
1.3.4. Regulation of cardiomyopathy by Lcn2 
The maintenance of optimal iron levels in the body is largely controlled and 
influenced by endocrine regulation, and this is likely to be of major significance in 
cardiomyopathy. In this section I will introduce the importance of Lcn2 in the regulation of 
iron homeostasis and other possible mechanisms in the context of cardiomyopathy.  
 
1.3.4.1. Possible mechanisms via which Lcn2 may mediate cardiomyopathy  
1.3.4.1.1. Iron transport    
Lcn2 is most well-known for its participation in innate immunity to limit bacterial 
growth by sequestrating iron. One way to secure iron from the host by bacteria is by 
synthesizing and secreting siderophores to extract iron from iron containing compounds 
such as transferrin and lactoferrin. Lcn2 is secreted by the host to tightly bind to bacterial 
catecholate-type ferric siderophores to compete for iron and prevent such uptake [155]. 
Lcn2 saturated with iron (holo form) can increase intracellular iron level by transporting it 
then releasing iron in the cytoplasm; in contrast, when Lcn2 is iron free (apo-form) it can 
deplete intracellular iron and transport it to the extracellular space via its receptor LCN2-R 
[156]. Bacterial infection is often associated with hypoferremia that limits iron availability 
to pathogens; accordingly, mice deficient in Lcn2 exhibit elevated intracellular labile iron 
and lowered circulating iron level [32]. Overall, Lcn2, as an iron-trafficking protein, can be 
regarded as an alternative to transferrin-mediated iron-delivery pathway [157].  Although 
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limited studies are available, it is speculated that circulating Lcn2 levels may reflect the 
body iron status, especially in hemodialysis patients. Indeed, it was found that plasma Lcn2 
in hemodialysis patients was significantly lower within those who had ID – with transferrin 
saturation (TSAT) lower than 20%; and that the level of Lcn2 was positively correlated 
with circulating iron, TSAT and ferritin. Lcn2 was significantly increased after correction 
of ID with intravenous iron administration [158]. Similar results were also observed in 
another two studies supporting the potential use of Lcn2 to identify iron deficiency in 
hemodialysis patients [159, 160]. Likewise, a lowered Lcn2 level was also recorded in 
patients with iron deficiency anemia [161]; and in patients with chronic HF (both HFpEF 
and HFrEF), the significantly higher circulating Lcn2 levels also correlated with higher 
serum iron concentrations in the EPOCARES study [162]. As circulating Lcn2 is often 
recorded significantly increased in patients experiencing HF [28, 46, 49-51], and that local 
Lcn2 production in the heart is also increased significantly [22, 28], we believe it will be of 
great interest to further elucidate the role of Lcn2 in iron associated cardiomyopathy. 
Interestingly, we previously identified that Lcn2 led to cardiomyocyte apoptosis by causing 
intracellular iron accumulation [71]. Further mechanistic studies are definitely warranted.  
 
1.3.4.1.2. Proinflammatory actions of Lcn2 
As Lcn2 is involved in defending the host during bacterial infection, it comes as little 
surprise that Lcn2 is regarded as a proinflammatory cytokine. In the fourth Copenhagen 
Heart Study that involved more than 5000 patients and a follow up period of 10 years, it 
was shown that plasma Lcn2 strongly associated with all inflammatory markers 
investigated, including hsCRP, total leukocyte and neutrophil count; increased Lcn2 was 
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also shown to correspond to increased risk of all-cause mortality and major adverse 
cardiovascular events [163]. It was suggested that Lcn2 expression and secretion can be 
induced by IFNγ and TNFα, and that the transcription factors STAT1 and NF-kappa B 
were shown to bind to the human Lcn2 promotor [164]. Likewise, in elucidating the 
inflammatory mechanisms of Lcn2 with animal models, Lcn2 mRNA and proteins were 
upregulated upon vascular injury in an NF-kappa B dependent manner [26]. Lcn2 can 
enhance cardiac inflammation by promoting macrophage proinflammatory M1 phenotype 
polarization [165]. Thus, a vicious cycle exists whereby Lcn2 can intensify inflammation 
by inducing the expressions of TNFα and other pro-inflammatory mediators [166]. 
Interestingly, preventing the clearance of Lcn2 from the circulation was shown to promote 
vascular inflammation and endothelial dysfunction [167]. In both HFpEF and advanced 
HFrEF, elevated systemic and local inflammations with increased circulating TNFα have 
indispensable roles in disease pathogenesis [168]. It will be interesting to explore how 
Lcn2 contributes to cardiomyopathy in an inflammation dependent and independent 
manner.  
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1.4. HYPOTHESIS AND RESEARCH AIMS 
The preceding discussion indicating that a variety of remodeling events occur 
throughout the progressive development of heart failure in obesity [4, 169]. These include 
changes in inflammation, mitochondrial dysfunction, autophagy, fibrosis, cell death, 
endoplasmic reticulum (ER) stress, oxidative stress and insulin sensitivity. I hypothesized 
that Lcn2 is an important component of the cardiac response to myocardial infarction, 
directly regulates cardiac remodeling and contributes to development of heart failure. The 
research aim of this project was to elucidate the effects of Lcn2 on cardiac remodeling, 
the impact of these changes on cardiac function, and Lcn2 mechanism of action.  
 
My specific research objectives are: 
 
• Aim 1: To examine the effect of Lcn2 on cardiomyocyte insulin sensitivity and 
what is the mechanism of action.  
• Aim 2: To use Lcn2-knockout mice and investigate whether lack of Lcn2 protects 
against cardiac remodelling and dysfunction induced by chronic myocardial 
ischemia and the mechanisms via which this occurs. 
• Aim 3: To investigate whether iron directly caused insulin resistance in 
cardiomyocytes and the mechanisms via which this occurred, with a focus on 
oxidative stress. 
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2.1. Summary 
Lipocalin-2 (Lcn2; also known as neutrophil gelatinase associated lipocalin, NGAL) 
levels are increased in obesity and diabetes and associate with insulin resistance. 
Correlations exist between Lcn2 levels and various forms or stages of heart failure. Insulin 
resistance and autophagy both play well-established roles in cardiomyopathy. However, 
little is known about the impact of Lcn2 on insulin signaling in cardiomyocytes. In this 
study, we treated H9c2 cells with recombinant Lcn2 for 1 hour followed by dose- and 
time-dependent insulin treatment and found that Lcn2 attenuated insulin signaling assessed 
via phosphorylation of Akt and p70S6K. We used multiple assays to demonstrate that Lcn2 
reduced autophagic flux. First, Lcn2 reduced pULK1 S555, increased pULK1 S757 and 
reduced LC3-II levels determined by Western blotting. We validated the use of DQ-BSA 
to assess autolysosomal protein degradation and this together with MagicRed cathepsin B 
assay indicated that Lcn2 reduced lysosomal degradative activity. Furthermore, we 
generated H9c2 cells stably expressing tandem fluorescent RFP/GFP-LC3 and this 
approach verified that Lcn2 decreased autophagic flux. We also created an autophagy-
deficient H9c2 cell model by overexpressing a dominant-negative Atg5 mutant and found 
that reduced autophagy levels also induced insulin resistance. Adding rapamycin after 
Lcn2 could stimulate autophagy and recover insulin sensitivity. In conclusion, our study 
indicated that acute Lcn2 treatment caused insulin resistance and use of gain and loss of 
function approaches elucidated a causative link between autophagy inhibition and 
regulation of insulin sensitivity by Lcn2.  
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2.2. Introduction  
Lipocalin 2 (Lcn2), also termed 24p3 and neutrophil gelatinase-associated lipocalin 
(NGAL), is a proinflammatory hormone predominantly expressed by adipose tissue [12]. 
Various studies have previously reported the close association of circulating Lcn2 levels 
with hyperglycemia and insulin resistance [14, 16]. Elevated Lcn2 levels in obese or 
diabetic individuals were normalized by rosiglitazone and this correlated significantly with 
improved insulin sensitivity and inflammatory status [14]. Similarly, Lcn2 was also found 
associated with insulin resistance in other in vitro [18] or in vivo [17] studies and clinical 
settings [29, 170]. More recently, elevated Lcn2 was observed in patients with heart failure 
[51]. Furthermore, Lcn2 was shown capable of predicting the severity and mortality of 
acute and chronic heart failure [46, 50, 51, 171-173]. Lcn2 was also implicated in higher 
thrombotic risks in patients with atherosclerosis [26, 174]. Currently used as an excellent 
biomarker for acute kidney damage [175], Lcn2 has also been proposed as an attractive and 
promising biomarker for heart failure [171-173].  
 
Obesity and diabetes increase the incidence of myocardial infarction and heart 
failure at least in part via insulin resistance [74, 176]. Cardiac insulin resistance is well 
established to influence heart failure via multiple mechanisms, including regulation of 
glucose and fatty acid uptake and metabolism, protein synthesis and vascular function [176, 
177]. More recently, numerous studies have shown that autophagy can play a critical role 
in cardiac metabolic health [178] as well as regulating insulin sensitivity [179, 180]. 
Disruption of autophagy by cardiac-specific knockdown of Atg5 in adult mice leads to 
cardiomyopathy [181]. The dogma arising from studies in rodent or pig models is that 
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autophagy, triggered by various forms of cardiac stress, is a protective mechanism by 
which apoptosis is inhibited and the detrimental effects of cardiac ischemia are limited 
[182, 183]. However prolonged activation of autophagy can result in cell death [183] and 
cardiomyocyte dysfunction [184, 185]. Interestingly, patients with longstanding idiopathic 
cardiomyopathy show accumulation of autophagosomes in cardiomyocytes [186]. Aortic 
banding has been shown to induce autophagic activity which peaked at 48 hours and 
remained significantly elevated for at least 3 weeks [184]. This was attenuated by 
heterozygous disruption of the gene coding for Beclin 1, a protein required for early 
autophagosome formation. Subsequent studies have shown increases in markers including 
LC3-II and p62 levels in the heart 8 weeks post-banding [187, 188]. The role of autophagy 
in heart failure is clearly complex to study and is likely to influence cardiac remodeling in 
different ways depending on the magnitude of changes in autophagic flux and timing 
during the progression of heart failure. 
 
Although elevated Lcn2 levels correlate with heart failure and insulin resistance can 
contribute to development and progression of heart failure, the impact of Lcn2 on cardiac 
insulin sensitivity remains unclear. Furthermore, little is known about the mechanisms of 
action via which Lcn2 impacts upon cardiac function. In this study, we first established 
that Lcn2 blunted insulin signaling in H9c2 cells, derived from rat heart ventricle. We used 
multiple assays to assess the effect of Lcn2 on autophagic flux and then used gain and loss 
of function strategies to determine the functional significance of Lcn2-induced alterations 
in autophagy. These studies will be important in developing our understanding of cardiac 
insulin resistance in obesity and diabetes and other inflammatory conditions. 
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2.3. Materials and methods  
2.3.1. Cell culture  
H9c2 (ATCC® CRL-1446) rat cardiomyoblasts were grown in Gibco® normal 
glucose Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS) and 1% (v/v) penicillin streptomycin at 37°C and 5% CO2. For 
microscopy assays (except TEM), cells were grown on cover slips and treated with or 
without recombinant apo-lipoclain 2 (Lcn2) (1µg/ml) in DMEM with 0% FBS mimicking 
starvation at approximately 80% confluency (unless specified otherwise) for 1 hour. A 
dose response using 1-5µg/ml was previously studied and 1µg/ml was selected based upon 
preliminary results and used in several publications since (Law, et al. 2010; Xu, et al. 
2012). For other assays, cells were grown and treated the same way on 6 or 12 well plates 
without coverslips. Where appropriate, rapamycin (Sigma) (250nM) was post treated for 
30 minutes after incubation with Lcn2. 
 
2.3.2. Recombinant Lcn2 production  
The expression of His-tagged Lcn2 (University of Hong Kong) in BL21 Competent 
E. Coli (NEB Biolab) was induced by SOC growth medium (NEB Biolab). Lcn2 was 
purified from bacterial lysates using the HIS-select® nickel affinity gel (Sigma) according 
to the manufacturer’s protocol. The purity of Lcn2 was confirmed using SDS-PAGE gel. E. 
Coli strain B21 lack siderophore enterobactin, thus Lcn2 derived from this strain lacks iron 
(apo-Lcn2), as contrast to those purified from E. Coli strain XL1 Blue that constitutively 
expressing siderophore enterobactin that could derive iron loaded Lcn2 (holo-Lcn2) [156].   
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2.3.3. Western blotting  
H9c2 cells were grown to 90% confluency in 6 well plates. After the experimental 
endpoint, cells were washed in PBS and solubilized in 1x Lysis buffer (50mM Tris, 
150mM NaCl, 0.1% SDS 1% Triton X-100 and 0.5% sodium deoxycholate) containing 
protease inhibitor cocktail – complete ULTRA Tablets, Mini (Roche). Lysates were 
centrifuged at 12,000 rpm for 5 min at 4°C. Supernatant was collected, heated at 90°C for 
5 min and equivalent amounts of lysate were loaded to an SDS-PAGE gel, followed by 
protein transfer onto PVDF membrane (Bio-Rad). Membranes were first blocked in 3% 
BSA for 1 hour, incubated in primary antibody at 4°C overnight, washed, incubated in 
appropriate horse-radish peroxidase (HRP)-linked secondary antibody for 1 hour, washed, 
then followed by chemiluminescence enhancement using Western Lightning Plus ECL 
(Perkin Elmer) before developing and exposing the membrane to CL-XPosure Film 
(Thermo Scientific). The band intensities were quantified using Image J. The following 
primary antibodies were used: pAkt T308, pAkt S473, pULK1 S555, pULK1 S757, LC3B, 
p70S6K T389 and β-actin (1:1000, Cell Signaling). The following secondary antibodies 
were used; anti-rabbit IgG HRP-linked antibody and anti-mouse IgG HRP-linked antibody 
(1:10,000, Cell Signaling).  
 
2.3.4. RT-PCR analysis of autophagy genes expression  
H9c2 cells were grown to 90% confluency in 6 well plates. After the experimental 
time point, RNA was isolated using the RNeasy® Mini Kit (Qiagen) following the 
manufacturer’s protocol, quantified using NanoDropTM (Thermo Scientific) followed by 
reverse transcriptionwith GoScript Reverse Transcriptase (Promega). The 20µl reaction 
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mixture containing a total of 60ng cDNA and primers at a final concentration at 5µM were 
prepared for real-time PCR using the iQTM SYBR® Green Supermix (Bio-Rad). Real-time 
PCR was conducted using Real-Time PCR Detection System (CFX96, Bio-Rad), with a 
hot start at 95°C for 2min, 40 cycles of denaturation at 95°C for 5s, annealing at 60°C for 
5s and extension at 72°C for 5s, followed by a final extension at 72°C for 1 min. The 
melting curve analysis was done by a serial increment of 1°C from 55°C to 95°C. 18S was 
used as the reference gene for calculating the relative target gene expression using the delta 
delta CT method. The primer sequences were in-house designed with the 5’ to 3’ 
sequences as follow: Atg5 – Forward: TAGAGCCAATGCTGGAAACC; Reverse: 
TGTTGCCTCCACTGAACTTG; Atg7 – Forward: CGAAGGTCAGGAGCAGAAAC; 
Reverse; AGGCACCCAAAGACATCAAG; Atg8 – Forward: 
GTCTGGAGCATTGGACTTGC; Reverse: AGCCACACCCTTTCACTCAG; Atg9 – 
Forward: GGAATCTACCATCGCATCC; Reverse: CGGGTGAAGAAGACAACCTC; 
and Atg12 – Forward: TGACCTGGAACAGGAGTGTG; Reverse: 
GGGATGAGCCAGAAATGAAC.  
 
2.3.5. Analysis of autophagic degradation by DQ-BSA assay using flow cytometry 
H9c2 cells were seeded in 6-well plates, and underwent starvation for 4 hours. 
DQ™ green BSA was added in each well at 20ug/mL and incubated for 15 minutes. Cells 
were harvested and fixed with 4% PFA, and run in flow cytometer machine (Gallios ™, 
Beckman Coulter Inc.) to analyze green fluorescent (BODIPY) signal intensity in each cell 
within a population of 10,000. 
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2.3.6. Analysis of DQ-BSA co-localization with autophagy and lysosomal markers 
H9c2 cells were seeded in 12-well plates with cover slips and underwent starvation 
for 4 hours. DQ™ green BSA was added in each well at 20ug/mL, and incubated for a 
minimum of 30 minutes after treatment. Cells were fixed with 4% paraformaldehyde (PFA) 
and quenched with 1% glycine then permeablized with 0.1% Triton X-100 for 5 minutes 
and blocked with 5% BSA for 1 hour. Cells were incubated with primary antibody at 
different concentration (LC3B, 1:400, p62, 1:400, and Cathepsin D, 1:250) for 1 hour. 
After three washes, cells were incubated with corresponding secondary antibody (Goat 
anti-Rabbit/anti-Mouse secondary antibody, AlexaFluor®594, 1: 800) before mounting on 
a glass slide. Confocal images were taken using a x60 objective (Olympus, BX51 
Microscope). 
2.3.7. Lysosomal cathepsin B activity measured using Magic Red  
 H9c2 cells were grown to 80% confluency on coverslips in 12 well plates. At the 
experimental endpoint, cells were fixed in 4% paraformaldehyde, quenched in 1% glycine, 
permeabilized with 0.1% Triton X-100 and blocked with 3% BSA before incubation of 
Magic red stain (Magic RedTM in vitro Cathepsin B kit, ImmunoChemistry Technologies) 
as per manufacturers’ instructions. Coverslips were mounted with Prolong® Gold antifade 
reagent and Vectashield with DAPI on glass slides. Images were captured at 600x with 
confocal microscope (Olympus, BS51). At least 6 images at different fields of view were 
taken per coverslip. Quantitative analysis of Magic Red or TRIC fluorescence intensity in 
the cytoplasmic area, normalized by the number of cells, was performed using Definiens 
Tissue Studio® 3 (Definiens). For FACS analysis H9c2 cells were grown to 90% 
confluency in 6 well plates. At the experimental endpoint, cells were fixed with 4% 
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paraformaldehyde, quenched in 1% glycine, permeabilized with 0.1% Triton X-100, 
blocked with 3% BSA before incubation with Magic red stain. Fluorescence intensities of 
10,000 cells per sample were measured by flow cytometry using GalliosTM Flow 
Cytometer (Beckman Coulter) and analyzed using Flowing Software 2 (Perttu Terho).   
 
2.3.8. Generation of H9c2 cells stably overexpressing tandem fluorescent RFP/GFP-
LC3 and analysis of autophagic flux 
 Stable H9c2 cells expressing tf-RFP/GFP-LC3 were created essentially as 
described by us previously for another cell type [179]. Cells were grown to 80% 
confluence on coverslips in 12 well plates. At experimental endpoint, cells were carefully 
washed with PBS before fixing at 4% paraformaldehyde and washing before mounting 
with Prolong® Gold antifade reagent and Vectashield with DAPI on glass slides. At least 6 
images at different fields of view were taken per coverslip with confocal microscope (LSM 
700, ZEISS). Quantitative analysis of the RFP:GFP ratio was performed using ZEN 
software (blue edition, 2012). 
 
2.3.9. Transmission electron microscopy (TEM)   
H9c2 cells were grown on 6 well plate to 80% confluency. After the experimental 
endpoint, cells were washed with PBS and immediately fixed with 2.5% glutaraldehyde in 
0.1M sodium cacodylate buffer followed by post-fixation with 1% osmium tetroxide for 1 
hour at room temperature. Cells were then dehydrated with ascending concentration of 
ethanol (50% to 100%) and embedded in Spurr’s Epoxy resin. Thin sections at 60 – 80nm 
were cut with an ultramicrotome (Porter Blum, Ivan Sorvall Inc.) and mounted on copper 
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mesh grids. The sections were contrasted with 1% uranyl acetate and lead citrate before 
examining with a transmission electron microscope (CM100, FEI). At least 10 random 
fields of view were taken per sample using the Kodak Megaplus camera.  
 
2.3.10. Generation of H9c2 cells stably overexpressing a dominant negative ATG5 
(K130R) mutant  
We generated an autophagy-deficient cell model by generating H9c2 cells stably 
expressing dominant negative ATG5 mutant in which lysine 130 was mutated to arginine, 
essentially as described by us previously for another cell type [179]. Cells were grown 
to >90% confluence in 6 well plate before treatment with insulin (10 or 100nM) for 10min 
and preparation of protein lysate for Western blotting as described above. 
  
2.3.11. Statistics  
Data are presented as mean ± SEM. Effect of Lcn2 was calculated with student 
unpaired t test and Mann-Whitney test for parametric and non-parametric data respectively 
(GraphPad Prism). Values of P<0.05 were considered significant.  
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2.4. Results  
 
2.4.1. Lcn2 attenuated dose- and time-dependent insulin signaling  
We first showed that H9c2 ventricular cardiomyocyte cells responded dose 
dependently to insulin as shown by increased phosphorylation of Akt T308 (Figure 2.1.A), 
Akt S473 (Figure 2.1.B) and 70S6K (Figure 2.1.C) and that these responses to insulin were 
attenuated in cells pretreated with Lcn2 (Figure 2.1.).  
 
2.4.2. Lcn2 inhibited initiation of autophagy   
As shown in Figure 2A and B, Lcn2 directly elicited significant up and down 
regulation of phosphorylation of ULK1 at Ser757 and Ser555, respectively (Figure 2.2. 
A&B). These observations on regulation of proteins involved in autophagy initiation 
corresponded with reduced levels of LC3-II after Lcn2 treatment (Figure 2.2. A&B). The 
short term time period of Lcn2 treatment used in this study had no significant effects in 
altering the gene expressions of various autophagy related genes (Figure 2.2. C).  
 
2.4.3. Measurement of lysosmal degradative activity with DQ Green BSA   
To further investigate the effects of Lcn2 on autophagic flux we developed a novel 
assay to investigate protein degradation via autolysosomal activity using DQ Green BSA. 
DQ-BSA is a derivative of BSA that is heavily conjugated with BODIPY® dye that 
confers self-quenching, yet releases fluorophores upon enzymatic cleavage in acidic 
intracellular lysosomal compartments. We first confirmed that BODIPY signals from 
exogenously added DQ-BSA strongly co-localized with autophagy markers LC3B and p62 
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as well as the lysosomal marker cathepsin D (Figure 2.3.A). This indicated that DQ-BSA 
de-quenching occurred at subcellular locations relevant to autophagosome and lysosome. 
The intensity of BODIPY signals from DQ-BSA was measured quantitatively by flow 
cytometry and also by immunofluorescence. The intensity of BODIPY signals in 10,000 
cells, with or without starvation to induce autophagy, was plotted and the population of 
green fluorescence shifted rightward in H9c2 cells with starvation (Figure 2.3.B). 
Importantly, this shift which reflects elevated levels of protein degradation was reduced in 
autophagy-deficient Atg5K130R cells. Immunofluorescent analysis of cells pulsed with 
DQ-BSA supported the conclusion that significant green puncta appeared in H9c2 cells 
after starvation yet this response was attenuated in ATG5K130R cells (Figure 2.3.B & C). 
 
2.4.4. Lcn2 decreased lysosomal enzyme activity and autophagic flux  
After verifying the use of DQ-BSA, it was observed using this approach that Lcn2 
significantly reduced the autolysosomal activity in H9c2 cells (Figure 2.4.A, B). Magic red 
dye was then used as a well-established approach to measure cathepsin B activity. Both 
immunofluorescence (Figure 2.4.C&E) and flow cytometry (Figure 2.4.D&E) analysis of 
MagicRed indicated a reduction in response to Lcn2. To further assess autophagic flux, we 
generated H9c2 cardiomyoctyes stably overexpressing tandem fluorescent RFP-GFP-LC3. 
Given that GFP and RFP have different pH stability, only GFP weakens in acidic 
environment, the degradation of autophagic vacuoles can be inferred from a lower 
RFP/GFP ratio. As shown in Figure 4F, an increase in yellow LC3 puncta was observed 
after the addition of Lcn2. In contrast, addition of rapamycin restored the autophagic flux 
as shown by a significant increase in red puncta (Figure 2.4.F).  
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The gold standard technique to visualize autophagic vacuoles in mammalian cells is by 
transmission electron microscopy (TEM). In H9c2 cardiomyocytes, plentiful autophagic 
vacuoles including autophagosomes and autolysosomes were observed in the control 
conditions (Figure 2.5.) yet only a few, and mostly autophagosomes were seen upon the 
treatment with Lcn2 (Figure 2.5.). This observation correlated well with our above 
mentioned results. 
 
2.4.5. Regulation of insulin signaling by alterations in autophagy and effect of Lcn2  
Based on the observations that Lcn2 inhibited both insulin signaling and autophagy, 
we investigated if crosstalk occurred between the two. We first generated autophagy-
deficient H9c2 cells by stably overexpressing a mutant inactive Atg5 (Atg5K). While we 
observed a dose dependent increase in phosphorylation of Akt T308 in wild type (WT) 
H9c2 cells upon stimulation with an increasing dose of insulin this response was 
significantly decreased in Atg5K cells (Figure 2.6.A&B). We then further examined the 
potential contribution of autophagy to insulin sensitivity regulation by restoration of 
autophagy with rapamycin in Lcn2 treated cells. As shown in Figure 2.6.C/D/E, while 
Lcn2 inhibited insulin-stimulated phosphorylation of Akt T308 and Akt S473, post-
treatment with rapamycin significantly increased their phosphorylation by insulin.  
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Figure 2.1. Insulin signaling in cardiomyocytes was decreased by Lcn2 as indicated by 
decreased dose-dependent insulin-stimulated phosphorylation of Akt T308, Akt S473 
and p70S6K. H9c2 cells pretreated without (con) or with Lcn2 (1µg/ml, 1 hour) were then 
treated with insulin (0, 10 or 100nM) for 10 minutes. Representative Western blots 
showing pAkt T308 (A), pAkt S473(B) and p70S60K T389 (C) and the respective 
reference protein β-actin and their quantification # indicates significant difference from 
control H9c2 cells without insulin; * indicates significant difference from the control with 
respective insulin dosage. # p<0.05, ## p<0.01, ### p<0.001; *p<0.05, **p<0.01. n ≥ 3.  
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Figure 2.2. Initiation of autophagy was inhibited by Lcn2 in cardiomyocytes. H9c2 
cells were treated with Lcn2 (1µg/ml ) (Lcn2) or without (Con) for 1 hour. Western blots 
showing pULK1 S555, pULK1 S757, LC3II and the reference protein β-actin (A) and their 
quantifications (B). Gene expression of autophagy related genes Atg5, Atg7, Atg8 (LC3), 
Atg9 and Atg12 by qPCR was quantified with 18S as the reference gene using the delta 
delta CT method (C). ***p<0.001. n ≥ 3. 
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Figure 2.3. Validation of DQ-BSA degradation as a measure of proteolytic autophagy. 
Representative confocal images of H9c2 cells labelled with LC3B/p62/Cathepsin D and 
DQ-BSA (20ug/mL) which was pulsed for ≥ 30 minutes (A). Distribution of green 
fluorescence (BODIPY) intensity of 10,000 H9c2 cells (WT, wild type, and ATG5K130R 
H9c2 cells) pulsed with DQ-BSA ± starvation (B). Representative confocal images of 
H9c2 cells (WT and ATG5K130R H9c2 cells) pulsed with DQ-BSA ± starvation (C) and 
quantification (D). Results are represented as mean ± SEM (n=10 images). *p<0.05 
**p<0.01 versus control. Scale bar = 20 um. 
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Figure 2.4. Lcn2 decreased lysosomal cathepsin B activities and autophagic flux. H9c2 
cells were treated with Lcn2 (1µg/ml) (Lcn2) or without (Con) for 1 hour. The overall 
proteolysosomal activity was examined by quantifying fluorophore released by DQ-BSA 
using flow cytometry and representative data are shown in (A) and quantified in (B).  The 
lysosomal cathepsin B activity was further examined using the Magic red dye with 
immunofluorescence microscopy (C), flow cytometry (D) and these data were both 
quantitated as shown in (E). Autophagic flux was further evaluated using the RFP/GFP 
ratio of LC3 puncta in the tf-GFP/RFP-H9c2 cell line. Rapamycin, an inducer of autophagy, 
was used as a positive control and both representative images and quantitative data are 
shown in (F). * indicates significant difference from the control. **p<0.01; ***p<0.001. 
Scale bar = 50µm in C; 20 µm in F. n ≥ 3. 
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Figure 2.5. Lcn2 decreased number of autophagosomes and autolysosomes in 
cardiomyocytes. H9c2 cells were treated with Lcn2 (1µg/ml) (Lcn2) or without (Con) for 
1 hour. Autophagy was evaluated using transmission electron microscopy. Selected areas 
from lower magnification (6500x) images were magnified to 29000x with white arrows 
indicating the presence of autophagic vacuole structures. Shown here is one representative 
image for each treatment, at different magnifications, from multiple independent samples.  
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Figure 2.6. Inhibiting autophagy decreased and elevating autophagy rescued insulin 
signaling in cardiomyocytes. Insulin sensitivity was decreased in autophagy deficient 
cells overexpressing mutant Atg5, as indicated by decreased phosphorylation of Akt T308; 
representative Western blots in (A) and quantification in (B). Wild type H9c2 cells were 
treated with Lcn2 (1µg/ml) (Lcn2) or without (Con) for 1 hour and rapamycin (Rap) 
(250nM) was added 30 minutes after Lcn2 treatment for the final 30 minutes of treatment. 
Rap elevated insulin signaling indicated by increased phosphorylation of Akt T308 and 
Akt S473 in Western blots (C) and quantification (D). * indicates significant differences. 
*p<0.05, **p<0.01, ***p<0.001. n ≥ 3 
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2.5. Discussion   
Strong rationale for this study comes from observations of an increased circulating 
Lcn2 level and increased expression in adipose tissue of various experimental models of 
obesity and in obese humans [12]. For instance, a study with 2519 subjects showed that 
serum Lcn2 was significantly higher in those with impaired fasting glucose and/or 
impaired glucose tolerance even after adjusting for anthropometric measures, genetic 
predispositions, life style and other diabetic associated biomarkers [189]. Type 2 diabetic 
patients were shown to have a significant elevation of serum Lcn2 that associated with 
declining pancreatic beta cell function [190] and a cross sectional study showed that insulin 
resistance and hyperglycemia were positively correlated with elevated circulating Lcn2 
[14]. Rosiglitazone treatment decreased circulating Lcn2 and this correlated significantly 
with improved insulin sensitivity [14]. Further studies in mice demonstrated the permissive 
role of Lcn2 in the development of obesity- and aging-induced insulin resistance since 
these processes were attenuated in Lcn2-KO mice [16]. Measurement of serum Lcn2 has 
also been proposed as a useful means for evaluating obesity-related cardiovascular diseases 
including heart failure [171-173], however the direct effects of Lcn2 on cardiomyocyte 
insulin sensitivity and its possible mechanisms of action remain unclear. 
 
We first investigated whether Lcn2 altered insulin sensitivity in a cell line derived 
from rat heart ventricle and found that 1 hour treatment with Lcn2 reduced insulin 
sensitivity. Cardiac insulin resistance is well established to influence heart failure via 
multiple mechanisms such that exacerbated cardiomyopathy may occur in an insulin-
insensitive myocardium [176]. In fact, in type 2 diabetes insulin resistance can be present 
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for several years before hyperglycaemia develops and at this time contribute to adverse 
cardiac remodeling [191]. We observed that Lcn2 reduced insulin stimulated signaling to 
Akt and  p70S6K.  
 
Although little is known about the mechanisms of Lcn2 action in cardiomyocytes, 
previous work has included evidence for a role of increasing intracellular iron levels [71]. 
Our current study indicates that inhibition of autophagy, by Lcn2 or by generating an 
autophagy-deficient cell line, can serve as an important contributor to insulin resistance in 
cardiomyocytes. This is important both from the perspective of our current realization of 
the critically important role autophagy plays in heart failure [192] and also in emerging 
evidence that autophagy can regulate insulin sensitivity and metabolism [179, 180].   
 
Autophagy is the major intracellular degradation process where cytoplasmic 
materials get delivered to lysosomes for degradation and recycling [178, 181, 183, 193]. 
The entire dynamic process of autophagosome synthesis, fusion with lysosome and the 
degradation of the autophagic substrates is termed “autophagic flux”, and is important to 
measure as a reliable indicator of autophagic activity [194]. Several studies have now 
shown that the degree of autophagy changes in the failing heart and directly in response to 
ischemia and/or reperfusion [195-198], although the functional significance is still 
somewhat uncertain. Indeed, autophagy may be regarded as a double edged sword with 
potential beneficial and detrimental effects in the heart [199]. At low levels autophagy is 
important in recycling damaged organelles and nutrients, however excessive autophagy 
contributes to tissue dysfunction [184, 199-202]. Our current study is the first to 
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demonstrate attenuation of autophagy by Lcn2 in cardiomyocytes and only one previous 
study examined Lcn2-induced changes in autophagy [203]. These authors investigated 
autophagy as one potential mechanism underlying its tumorigenic effects. They generated 
mouse embryonic fibroblasts (MEFs) from WT and Lcn2-/- mice, and immortalized these 
cells. By Western blotting  they found a significant decrease in total LC3 in Lcn2-/- MEFs 
compared to the WT MEF cells. No further markers of autophagy were analyzed and the 
authors concluded that Lcn2 is an important regulator in autophagy, possibly via an 
indirect mechanism. Accurate experimental analysis is critical to allow conclusions on 
alterations in autophagic flux [192, 200]. Thus, we took an extensive approach using 
numerous assays designed to examine different stages of autophagic flux in order to 
carefully characterize the effect of Lcn2. Our conclusion of reduced flux is based on 
several lines of evidence; increased pULK1 S757, reduced pULK1 S555 and reduced 
LC3II levels detected by Western blotting, reduced degradation of DQ-BSA, reduced 
cathepsin B activity, reduced appearance of red puncta in cells stably expressing tandem 
fluorescent RFP/GFP-LC3, and an overall of reduction in autophagosome and 
autolysosome content observed by transmission electron microscopy. Thus, our data 
showing that Lcn2 inhibits autophagic flux are of great interest given the above evidence 
on the critical role of autophagy in the heart and our need to further understand its 
regulation and significance. 
 
We further investigated the mechanistic role of autophagy in cardiac insulin 
sensitivity. First, we stably transfected H9c2 cells to overexpress a dominant-negative Atg5 
mutant (Atg5K) [204] to create an autophagy-deficient cell line. This is accepted as a 
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preferred means of generating reduced levels of autophagy [200] and we confirmed these 
cells had lower basal LC3II levels (data not shown). Furthermore, disruption of autophagy 
by cardiac-specific knockdown of Atg5 in adult mice leads to cardiomyopathy [202]. In the 
current study, we found that when autophagy was impaired in Atg5K H9c2 cells, insulin 
signaling was subsequently reduced. This was in keeping with the observation that 
inhibition of autophagy by Lcn2 correlated with insulin resistance. Similarly, defective 
insulin signaling was observed as a result of Atg7 suppression, the restoration of which 
enhanced systemic glucose tolerance in obese mice [205]. Numerous studies have shown 
that increased autophagy improved insulin sensitivity [179, 201, 206, 207]; for example 
resulting in insulin-stimulated glucose transport in cardiomyocytes [208]. These are in 
keeping with our observations that reducing autophagic flux led to insulin resistance and 
when we used rapamycin, commonly used as an activator of autophagy [192] post-Lcn2 
treatment we found that increased autophagy correlated with increased insulin signaling.  
 
The results of this study are likely to have important physiological significance. It 
is likely that the elevated circulating Lcn2 levels found in obesity, diabetes and upon 
inflammation contribute to adverse cardiac remodeling leading to heart failure by virtue of 
reducing levels of autophagy and inducing insulin resistance. Furthermore, it is 
conceivable that elevated Lcn2 is both a causative factor in inducing myocardial infarction 
and a primary constituent of the response to it. Indeed, Lcn2 levels have been shown to be 
elevated rapidly after myocardial ischemia [23, 24]. Future studies to determine whether 
Lcn2 influences stress-induced alterations in cardiac autophagy and their functional 
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significance will need to be performed. Use of both Lcn2-KO and autophagy deficient 
mice will be necessary to further establish the significance of these effects.  
 
In conclusion, we treated H9c2 cells with recombinant Lcn2 and observed reduced 
insulin-stimulated Akt and p70S6K. With autophagy initiated using a serum starved 
condition, we used multiple approaches, including Western blotting for LC3II, TEM, DQ-
BSA degradation, MagicRed assay of cathepsin B activity and tandem fluorescent 
RFP/GFP-LC3, to demonstrate that Lcn2 reduced autophagic flux. We also generated an 
autophagy deficient H9c2 cell line by overexpressing a dominant-negative Atg5 mutant 
and again found that reduced autophagy correlated with lower insulin sensitivity and that 
adding rapamycin to acutely stimulate autophagic flux restored insulin action. This 
indicated that autophagy can be beneficial to the myocardium in terms of its insulin 
sensitizing effect. Thus, an acute effect of Lcn2 on H9c2 cells is to decrease insulin 
sensitivity and this can occur via its inhibitory effect on autophagic flux.  
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3.1. Summary  
Lipocalin-2 (Lcn2; also termed neutrophil gelatinase-associated lipocalin (NGAL)) 
levels correlate positively with heart failure yet mechanisms via which Lcn2 contributes to the 
pathogenesis of HF remian unclear. In this study we used coronary artery ligation surgery to 
induce ischemia in wild type (wt) mice and this induced a significant increase in myocardial 
Lcn2. We then compared wt and Lcn2 knockout (KO) mice and observed that wt mice 
showed greater ischemia-induced caspase-3 activation and DNA damage measured by 
TUNEL than Lcn2KO mice. Analysis of autophagy by LC3 and p62 Western blotting, LC3 
immunohistochemistry and transmission electron microscopy (TEM) indicated that Lcn2 KO 
mice had a greater ischemia-induced increase in autophagy. Lcn2KO were protected against 
ischemia-induced cardiac functional abnormalities measured by echocardiography. Upon 
treating a cardiomyocyte cell line (h9c2) with Lcn2 and examining AMPK and ULK1 
phosphorylation, LC3 and p62 by Western blot as well as tandem fluorescent RFP/GFP-LC3 
puncta by immunofluorescence, MagicRed assay for lysosomal cathepsin activity and TEM 
we demonstrated that Lcn2 suppressed autophagic flux. Lcn2 also exacerbated hypoxia-
induced cytochromc c release from mitochondria and caspase-3 activation. We generated an 
autophagy-deficient h9c2 cell model by overexpressing dominant-negative Atg5 and found 
significantly increased apoptosis after Lcn2 treatment. In summary, our data indicate that 
Lcn2 can suppress the beneficial cardiac autophagic response to ischemia and that this 
contributes to enhanced ischemia-induced cell death and cardiac dysfunction. 
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3.2. Introduction 
Sustained ischemia leads to myocardial infarction (MI) which is often fatal [209], [210, 
211]. Lcn2 levels have been positively associated with heart failure [12, 14, 21]] yet little is 
known about direct effects of lipocalin-2 on cardiac remodeling, and in particular autophagy 
[8-11, 13, 212]. Lcn2 has been shown to have pro-inflammatory effects and to induce insulin 
resistance and metabolic dysfunction [15, 16, 23, 24, 213, 214]. Ischemia and/or reperfusion 
elevated Lcn2 content in the heart, most likely via production from infiltrating neutrophils and 
macrophages [215]. Lcn2 expression is also significantly augmented in patients with coronary 
heart disease and myocardial infarction [156, 216]. Lcn2-KO mice showed improved 
functional recovery and reduced infarction size after hypoxia compared to wild type [179].  
 
During prolonged ischemia, lack of oxygen and nutrients leads to myocardial cell 
death [217]. Cardiac regeneration is rare and so irreversible loss of cardiomyocytes will lead 
to reduced ability to sustain contractile function and progression to heart failure. Extensive 
research and clinical efforts have developed our understanding of structural and functional 
changes in the heart after MI, yet the role of Lcn2 and mechanisms via which it acts remain to 
be fully defined. Previous work has shown that Lcn2 can directly induce cardiomyocyte 
apoptosis [71] and attenuate autophagy leading to insulin resistance in h9c2 cells [218]. 
Numerous studies have shown that autophagy plays an important role in heart failure [219]. 
Autophagy is induced by various stressors and maintains an optimal cellular environment 
through removing protein aggregates and damaged organelles [55, 57, 60, 220]]. Inadequate 
autophagy leads to adverse effects in the myocardium and subsequent cardiac dysfunction 
[221, 222].  
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 In this study, we hypothesized that Lcn2 is induced by ischemia and is an important 
regulator of cardiac remodeling, including inhibition of autophagic flux in cardiomyocytes. 
Lcn2-KO or wt mice underwent coronary artery ligation (CAL) to induce chronic myocardial 
ischemia in the left ventricle, or sham surgery, then we performed analysis of cardiac function, 
apoptosis and autophagy. We also exposed H9c2 cells to hypoxia in the presence or absence 
of Lcn2 to test direct effects on autophagy and apoptosis. The functional significance of 
changes in autophagy was investigated via generating autophagy deficient H9c2 cells by 
overexpressing a dominant-negative mutant of Atg5. Our data contribute to elucidating the 
role of Lcn2 in ischemia-induced cardiac remodeling and function as well as the mechanisms 
via which it acts. 
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3.3. Materials and methods 
3.3.1. Animal models  
In house bred lipocalin2 knockout (Lcn2KO) mice and age matched C57BL/6 (wild 
type, WT) mice (The Jackson Laboratory, USA) were fed ad libitum on regular chow diet 
until 6-8 weeks of age and randomly separated into treatment groups (n=4-8 per group) (C57 
Sham, n=6; C57 CAL, n=6; Lcn2KO Sham, n=6, Lcn2KO CAL, n=8). All animals were kept 
in temperature and humidity-control rooms (21 ± 2°C, 35-40%) with a daily 12:12h light-dark 
cycle in the animal care facility of York University in accordance to the guidelines of the 
Canadian Council on Animal Care. All study protocols were approved by the Animal Care 
Committee of York University.  
 
3.3.2. Induction of ischemia via coronary artery ligation surgery  
Myocardial infarction (MI) was induced with ligation of the left anterior descending 
coronary artery (CAL) as previously described [213]. Briefly, left anterior descending 
coronary artery was ligated with a 8-O suture at 3mm below the tip of the left atrium for 24 
hours, resulting in an infarct area of ~30-40% of the left ventricle. The sham animals 
underwent the same procedure except for the suture ligation around the coronary artery. Mice 
were sacrificed 24hours after MI.   
 
3.3.3. Analysis of cardiac function using echocardiography  
Echocardiography was performed as we previously described [214] using the 
Vevo2100 system (Visual Sonics, Canada) equipped with an MS550D transducer. Mice were 
lightly anesthetized using 2.0% isofluorane mixed with 1000% O2 during the time of imaging. 
M-mode images of parasternal short-axis view at papillary level was used to calculate cardiac 
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systolic and diastolic functions. B-mode movie files of parasternal short-axis view were used 
to perform Speckle-tracking cardiac strain rate analysis. All parameters were averaged at least 
5 cardiac cycles for analysis. 
 
3.3.4. Immunofluorescent analysis of LC3 puncta and caspase-3 activation in heart 
tissue sections 
Heart were fixed with 10% buffered formalin and embedded in paraffin. 
Immunofluorescence staining was performed on 5-µm-thin sections using Abs against cleaved 
caspase 3 and LC3B (Cell Signaling). Images were captured and analyzed under an Olympus 
IX71 inverted fluorescent microscope (Olympus Canada, Richmond Hill, ON, Canada).  
 
3.3.5. Cell culture  
H9c2 rat embryonic cardiac myoblasts (ATCC® CRL-1446TM) were grown in 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco®) supplemented with 10% fetal 
bovine serum and 1% (vol/vol) streptomycin/penicillin (Gibco, Invitrogen) at 37°C and 5% 
CO2. When cells reached approximately 80% confluence they were incubated in 0.5% fetal 
bovine serum-DMEM with or without Lipocalin2 (Lcn2) at 1µg/ml in normoxia and hypoxia 
condition. Lcn2KO was produced as we previously described [223].  
Hypoxia condition was achieved by placing cells in hypoxic chamber filled with pre-analyzed 
gas mixture of 5% CO2 and 95% N2, and supplemented with Anaeropouch ™(Mitsubishi™, 
Japan) [215]. 
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3.3.6. Recombinant Lcn2 production 
The expression of His-tagged Lcn2 (a kind gift from Aimin Xu and Yu Wang, 
University of Hong Kong) in BL21 Competent E. Coli (NEB Biolab) was induced by SOC 
growth medium (NEB Biolab). Lcn2 was purified from bacterial lysates using the HIS-
select® nickel affinity gel (Sigma) according to the manufacturer’s protocol. The purity of 
Lcn2 was confirmed using SDS-PAGE gel.  
 
3.3.7. Western blotting 
LV heart tissue was snap frozen and pulverized with mortar and pestle in liquid 
nitrogen. The powdered tissue was then suspended in RIPA lysis buffer as we previously 
described [216]. H9c2 cells were grown to 90% confluency in 6 well plates. After the 
experimental endpoint, cells were washed in PBS and solubilized in 1x Lysis buffer (50mM 
Tris, 150mM NaCl, 0.1% SDS 1% Triton X-100 and 0.5% sodium deoxycholate) containing 
protease inhibitor cocktail – complete ULTRA Tablets, Mini (Roche). Lysates were 
centrifuged at 12,000 rpm for 5 min at 4°C. Supernatant was collected , heated at 90°C for 5 
min and equivalent amounts of lysate were loaded to an SDS-PAGE gel, followed by protein 
transfer onto PVDF membrane (Bio-Rad). Membranes were first blocked in 3% BSA for 1 
hour, incubated in primary antibody at 4°C overnight, washed, incubated in appropriate horse-
radish peroxidase (HRP)-linked secondary antibody for 1 hour, washed, then followed by 
chemiluminescence enhancement using Western Lightning Plus ECL (Perkin Elmer) before 
developing and exposing the membrane to CL XPosure Film (Thermo Scientific). The band 
intensities were quantified using Image J. The following primary antibodies were used: 
pAMPKα T172, pULK1 S555, LC3B, Caspase 3, β-Actin and GAPDH (1:1000, Cell 
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Signaling), P62 (BD Biosciences), Lcn2 (University of Hong Kong). The following secondary 
antibodies were used; anti-rabbit IgG HRP-linked antibody and anti-mouse IgG. 
 
3.3.8. Generation of H9c2 cells stably overexpressing tandem fluorescent RFP/GFP-LC3 
and analysis of autophagic flux and autophagy-deficient H9c2-ATG5K130R cells 
Stable H9c2 cells expressing tf-RFP/GFP-LC3 were created essentially as described 
by us previously for another cell type [179]. Cells were grown to 80% confluence on 
coverslips in 12 well plates. At experimental endpoint, cells were fixed in 4% para 
formaldehyde (PFA) and quenched with 1% glycine before mounting on a glass slide. 
Confocal images were taken using a x60 objective (Olympus, BX51 Microscope). Pearson 
and Overlapping coefficients were calculated using ImageJ with the JACoP plug-in to 
quantify the extent of GFP and RFP co-localization. To generate H9c2 cells stably over-
expressing mutant ATG5 proteins (ATG5K130R), H9c2 cells were transduced with retroviral 
vector carrying pmCherry-ATG5K130R.  
 
 
3.3.9. Transmission electron microscopy (TEM) 
TEM was performed as described previously [224]. Briefly, LV tissues were cut into 
small pieces (roughly 1 mm3) and H9c2 cells were grown on 6 well plate to 80% confluency. 
After the experimental endpoint, cells were washed with PBS and immediately fixed in 2.5% 
glutaraldehyde in 0.1M sodium cacodylate buffer followed by post-fixation with 1% osmium 
tetroxide for 1 hour at room temperature. The specimens were then dehydrated with ascending 
concentrations of ethanol in series (50%–100%) and embedded in Spurr’s Epoxy resin. 
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Afterwards, thin sections (60–80 nm) were cut with an ultramicrotome and mounted on 
copper mesh grids. The sections were then contrasted with 1% uranyl acetate and lead citrate, 
and examined with a FEI CM100 TEM and Kodak Megaplus camera.  
 
3.3.10. Analysis of cellular caspase-3/7 activity using immunofluorescence 
H9c2 cells were seeded in 12-well plates with cover slip, and treated with/without 
Lcn2 (1ug/mL) in normoxia or hypoxia condition for 24 hour. After treatment, cells were 
loaded with CellEvent® Caspase-3/7 Green Detection Reagent according to manufacturer’s 
protocol. Cells were fixed in 4% PFA, quenched with 1% glycine before mounting. Nuclei of 
cells were countered stained with Vectashield Antifade Mounting Medium with DAPI (Vecotr 
Laboratories). Images were taken using a 60X objective with confocal microscope (Olympus, 
BX51). 
 
3.3.11. Analysis of cytochrome C release from mitochondria 
H9c2 cells were seeded in 12-well plates with cover slip, and treated with/without 
recombinant globular Ad (1ug/mL) in normoxia or hypoxia conditions for 48 hour, after 
treatment, cells were incubated with mitoTracker® Red CMXRos (ThermoFisher Scientific) 
at 250nM for 30 minutes. Then, Cells were fixed in 4% PFA and quenched with 1% glycine 
then blocked with 5% BSA. After blocking, cells were incubated with cytochrome C (clone 
6H2.B4, BD Pharmingen™, 1:400) followed by Goat anti-Mouse IgG, Alexa Fluor 488 
(ThermoFisher, 1:800). Pearson or Manders’ Coefficients (M1 & M2) were calculated using 
ImageJ with the JACoP plug-in to quantify the extent of GFP and RFP co-localization. 
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Images were taken using a 60X objective with Laser Scanning Microscope (ZEISS, LSM700) 
and 3D images were using Imaris 3D/4D analysis sofeware. 
 
3.3.12. Statistics  
Data was presented as mean±SEM. Statistical significance between treatment groups 
were calculated using the unpaired Student t test when comparing 2 groups. For comparisons 
of more than 2 groups, One Way ANOVA followed by Dunnett’s posttest and Two Way 
ANOVA with Bonferroni post-test were performed to adjust multiple comparisons. P value 
<0.05 was considered statistically significant. 
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3.4. Results  
3.4.1. Lipocalin-2 deficiency attenuated ischemia-induced apoptosis  
We first assessed the expression of Lcn2 and found a significant increase in the total 
expression of Lcn2 in the ischemic myocardium (Figure 3.1.A&B). Using both Western 
blotting and immunofluorescent detection we showed that myocardial cleaved caspase 3 was 
significantly increased after ischemia in wt, although to a lesser extent in Lcn2KO mice and 
was further decreased with the Lcn2KO (figure 3.1.A-C).  
 
3.4.2. Lipocalin-2 contributes to suppression of autophagy during ischemia 
Autophagy flux was assessed by examining cardiac expression of key proteins 
involved in autophagy: LC3II and P62. LC3II, a marker of autophagosome content, was 
increased after ischemia in wt mice (Figure 3.2.A&B). Lcn2KO mice showed higher basal 
levels of LC3II with no further change induced by ischemia (Figure 3.2.A&B). We also 
examined autophagic flux by testing p62 expression and found this was unaltered in wt mice, 
but significantly decreased in Lcn2KO mice after ischemia (Figure 3.2.A&C). We used LC3 
immunofluorescence to study autophagosome content. The presence of LC3-positive puncta 
reflects the presence of autophagic vacuoles, whereas a diffuse cytoplasmic staining is 
indicative of an absence of autophagic vacuoles [225]. We found greater induction of LC3 
puncta in Lcn2KO mice (Figure 3.2.D&E). To further investigate whether autophagic 
structures are altered in wt or Lcn2KO mice hearts after ischemia we used transmission 
electron microscopy (TEM). Autophagic vacuole content did increase somewhat after 
ischemia in wt mice, yet this increase was further enhanced in Lcn2 KO mice, as shown in 
representative images in figure 3.2.F. Another striking change was the markedly increased 
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mitochondria damage after 24 hours of ischemia in WT mice, which was evidently attenuated 
in Lcn2 KO mice (Figure 3.2.F).  
 
3.4.3. Adverse remodeling with cardiac dysfunction in Lcn2KO mice after ischemia 
Wt and Lcn2KO mice were subjected to ligation of the left anterior descending 
coronary artery (CAL) to induce MI, and compared with sham surgery. 1 day after the surgery, 
wt mice developed systolic dysfunction, increase in end systolic diameter and volume. 
However, changes in end systolic diameter and volume are comparable between sham and 
ischemic groups in Lcn2KO mice (Figure 3.3.A). To provide additional details on regional 
cardiac dysfunction induced by ischemia, we used speckle tracking echocardiography to 
calculate 3-dimentional strain rate, an indicator of how much the myocardial tissue has 
physically disabled. Radial strain rate at systole and diastole significantly decreased after the 
surgery in wt mice yet such change was not observed in Lcn2KO mice (Figure 3.3.B). As 
visualized clearly in representative images of circumferential strain rate of six segmented wall 
regions, the synchronicity of two opposing walls (anterior/posterior) of endocardium were 
disrupted in wt mice whereas the synchronicity was maintained in Lcn2KO mice after 
ischemia (Figure 3.3.C). 
 
3.4.4. Lipocalin-2 attenuated autophagic flux in cardiomyocytes 
As seen in Figure 3.4.A-C, Lcn2 was shown to decrease autophagy initiation by its 
down regulation of phosphorylation of AMPK and ULK1 S555. Furthermore, Lcn2 decreased 
the amount of LC3II (Figure 3.4.A&D), the lipidated form of LC3 that is a marker of 
autophagosome formation. In a complete autophagic pathway or autophagic flux, 
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autophagosomes will eventually fuse with lysosomes to form autolysosomes where cargo 
materials get degraded. We used P62 which is a widely used marker as autophagic cargo 
protein and we found that hypoxia induced P62, and this was exacerbated after treatment with 
Lcn2 (Figure 3.4.A&E). To directly assess autophagic flux, we transfected H9c2 
cardiomyoctyes with tandem fluorescence (RFP-GFP)-LC3. GFP-loses fluorescence due to 
lysosomal acidity but RFP does not. Thus, increased degradation of autophagosomes can be 
interpreted via a lower RFP/GFP ratio and appear more red in colour. Under the control 
conditions, most LC3 punctae appeared red; while an increase in yellow punctate was 
observed with the addition of Lcn2 (Figure 3.4.F&G). To visualize autophagic structures, 
mitochondria and endoplasmic reticulum (ER) we used transmission electron microscopy 
(TEM) of H9c2 cardiomyocytes. Numerous autophagic vacuoles including autophagosomes 
and autolysosomes were observed after 24 hours of hypoxia conditions (Figure 3.4.H). In 
particular, we found a large number of autophagic vacuoles, swollen ER and a large number 
of damaged mitochondria after 24 hours hypoxia with Lcn2 treatment (Figure 3.4.H).  
 
3.4.5. Regulation of apoptosis by alterations in autophagy and effect of lipocalin-2 
We investigated Lcn2-induced apoptosis and the role of reduced autophagy in 
cardiomyocytes via generating autophagy-deficient H9c2 cells by stably overexpressing a 
mutant inactive Atg5 (ATG5K130R). Cells transduced with retrovirus with empty vector (EV) 
were used as control. EV and ATG5K130R H9c2 cells underwent 48hr hypoxia treatment, 
with or without Lcn2 and then we observed caspase 3 levels by Western blotting and activity 
of caspase-3/7 using activatable fluorescent substrates, respectively (Figure 3.5.A-D). After 
48 hours of hypoxia, the expression of cleaved forms of capsase-3 was significantly increased 
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in both EV and ATG5K130R cells, especially in the latter and with Lcn2 treatment (Figure 
3.5.A&B). As indicated by representative confocal images and quantification of green 
intensity, there was a significant increase in caspase-3 activity in ATG5K130R cells following 
long term hypoxia and Lcn2 treatment (Figure 3.5.C&D). We then further examined the 
cellular mechanisms of Lcn2-induced caspase-3 activation by studying cytochrome C 
colocalization with mitochondria (Mitotracker) (Figure 3.5.E&F). Upon hypoxia treatment 
(48 hour) or Lcn2, cytochrome C and mitochondrial colocazation decreased (Figure 3.5.H&I). 
In ATG5K130R cells neither hypoxia nor Lcn2 alone caused significant release of 
cytochrome c from mitochondria. 
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Figure 3.1. Myocardial infarction induced cell death and apoptosis in Wt but less in 
Lcn2KO mice. (A) Western blotting was performed to examine the protein levels of Lcn2 
and apoptosis was analyzed by examining the protein expression of cleaved caspase 3 in heart 
tissue homogenates from from WT and Lcn2KO mice that have undergone either sham or 
CAL surgery. (B, C) Densitometric quantifications of Wwestern blots in A. (D) 
Immunofluorescence was performed for cleaved capase 3 in heart tissue sections collected 
from WT and Lcn2KO mice subjected to either sham or CAL surgery and (E) quantification. 
Quantitative data in graphs are shown as mean ± SEM (n=3-5). *P<0.05 versus corresponding 
Wt sham, # P<0.05 versus corresponding Lcn2KO sham. Scale bar = 50 µm. 
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Figure 3.2. Lcn2 deficiency accelerated autophagy. (A) Autophagic flux was analyzed by 
examining the protein expression of LC3II and P62 in heart tissue lysates from WT and 
Lcn2KO mice that have undergone either sham or CAL surgery. (B) Densitometric 
quantifications of Western blots in A. (C) Immunofluorescence was performed for LC3II in 
heart tissue sections collected from WT and Lcn2KO mice subjected to either sham or CAL 
surgery. (D) Densitometric quantifications of Western blots in C. (E) Autophagic vacuoles 
were evaluated using TEM from heart tissue of WT and Lcn2KO mice that had undergone 
either sham or CAL surgery. Quantitative data in graphs are shown as mean ± SEM (n=3-5). 
*P<0.05 versus corresponding Wt, # P<0.05 versus corresponding Lcn2KO. Low: 6,500 and 
high magnification 19,000, Scale bar = 2 µm and 500nm. 
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Figure 3.3. Ischemia-induced cardiac dysfunction was reduced in Lcn2KO mice. A. 
Cardiac function parameters ejection fraction and fractional shortening analyzed 24hrs  after 
CAL surgery using echocardiography. B. Changes in radial strain and peak strain rate (/s) at 
systole and diastole 24hrs after CAL. C. Representative images of radial strain rate changes 
between two segments (anterior/posterior apex) during four cardiac cycles. PL: pre-ligation. 
Results are presented as mean ± SEM (n=4 for wt and n=4 for Lcn2KO mice). aP<0.05 vs 
corresponding sham. bP<0.05 vs PL. *P<0.05, vs corresponding sham. #p<0.05 vs wt CAL 
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Figure 3.4. Lcn2 and hypoxia reduced autophagic flux in cardiomyocytes. H9c2 cells 
were treated with recombinant Lcn2 (1ug/ml) or without (Con) for 24hour in normoxic or 
hypoxic conditions. (A) Western blots showing protein expression of pAMPK, pULK1S555, 
LC3II, P62, GAPDH and (B-E) their quantifications. (F) Autophagic flux was evaluated by 
looking at the RFP/GFP ratio of the LC3 puncta in the tf-GFP/RFP-H9c2 cells and (G) 
quantification. Scale bar = 20µm. (H) Autophagy was evaluated using transmission electron 
microscopy. Selected areas were magnified, with white arrows indicating the presence of 
autophagolysosome.  Low: 6,500 and high magnification 19,000, Scale bar = 2 µm and 
500nm. 
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Figure 3.5. Reduced autophagy exacerbated cell death in H9c2 cells. (A) Western blot 
analysis of cleaved caspase 3 level in WT and ATG5K cells after long-term hypoxia (48 hour) 
± treatment with Lcn2 (1ug/mL) and (B) quantification. (C) Representative confocal images 
of caspase 3/7 activity and (D) quantification. (E) Representative 3D confocal images of WT 
and ATG5K cells immunolabeled with cytochrome C (green), stained with mitotracker (red) 
and (F, G) quantifications. (H) Representative confocal images of WT and ATG5K cells 
showing cytochrome C and mitotracker ± hypoxia and ± Lcn2 and (I) quantitative and 
statistical analysis of green/red co-localization coefficients. Experiments were performed at 
least three times and results are presented as mean ± SEM. *P<0.05 versus EV normoxia 
control and # P<0.05 versus ATG5K130R normoxia control, Scale bar = 20µm. 
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3.5. Discussion 
Although clinical studies have established a strong correlative relationship between 
Lcn2 levels and cardiac dysfunction [12, 73] there have been few studies examining the direct 
effects of Lcn2 action on the myocardium. In this case we first of all used an ischemic model 
of heart failure and using echocardiography confirned that mice lacking Lcn2 fared better than 
wt mice [23], suggesting an important permissive role for Lcn2 in ischemia-induced cardiac 
dysfunction. Importantly, we showed here that cardiac Lcn2 content increased significanctly 
after ischemia but not sham surgery. 
 
To investigate mechanisms via which Lcn2 may induce heart failure we focused on 
autophagy, and cardiomyocyte cell death as an end point. Rationale for this focus comes from 
recent work by ourselves and others showing that Lcn2 inhibited autophagic flux in H9c2 
cells or hepatic chaperone-mediated autophagy [218, 226]. Translating our previous in vitro 
studies to the animal model of cardiac ischemia used here, we found that ischemia-induced 
autophagy was exaggerated in mice lacking Lcn2, perhaps reflecting endogenous suppression 
of autophagy by Lcn2. This is significant since cardiac autophagy is thought to be induced in 
response to various stressors and act as a protective cellular mechanism [227, 228]. Indeed, 
we found that the reduced levels of ischemia-induced autophagy correlated with enhanced cell 
death. Collectively, the data indicated that Lcn2KO mice had enhanced autophagic flux with 
reduced cell death and cardiac dysfunction after ischemia.  
 
To further investigate this relationship between autophagy and cell death and their 
regulation by Lcn2 we again used H9c2 cardiomyoblasts and exposed them to hypoxic stress, 
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with or without presence of Lcn2. Via observing responses such as reduced AMPK(Thr172) 
and ULK1(Ser555) phosphorylation, reduced LC3-II and increased P62 levels and less 
evident autophagosomal structures using TEM we concluded that autophagic flux decreased 
when Lcn2 and hypoxia were used in combination.  These data supported our observations in 
cardiac tissue of mice with ischemia, and to more accurately conclude that these conditions 
restricted autophagic flux we transduced cells with tandem fluorescent RFP/GFP-LC3 [218] 
expressing retroviral constructs. Using this approach, cells express LC3 tagged with both GFP 
and RFP and thus autophagosomes appear as yellow puncta. Upon fusion with lysosome, the 
acidic pH quenches green but not red fluorescence allowing flux to be viewed by more red 
puncta. Confocal microscopy analysis showed that Lcn2 reduced appearance of red puncta, 
indicating that Lcn2 reduced autophagic flux by attenuating autophagosome to lysosome 
fusion. This suppression of autophagic flux by Lcn2 was also evident when we used a 
pharmacological stimulant of autophagy, rapamycin [229]. Overall, these multiple approaches 
also support the conclusion that Lcn2 attenuates autophagic flux. 
 
Apoptosis is established as a cardiac remodeling event which contributes to heart 
failure and as such is a potentially important therapeutic target [230, 231]. Indeed, previous 
research [232] showed attenuation of myocardial injury brought by a caspase inhibitor. We 
next further investigated the mechanistic role of autophagy in Lcn2- and hypoxia-induced 
cardiomyocyte cell death. To do so, we stably transfected H9c2 cells to overexpress a 
dominant-negative Atg5 mutant to create an autophagy-deficient cell line [179, 218]. Previous 
studies showed that Lcn2 induced Bax translocation to mitochondria, caspase-3 activation and 
apoptosis in primary cardiomyocytes and H9c2 cells [71]. Hypoxia has also been shown to 
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independently cause activation of intrinsic apoptotic cell death [233]. First of all, we observed 
that autophagy deficiency mimicked Lcn2 in that elevated caspase-3 activation was observed, 
and no further increase was observed when Lcn2 was added. Interestingly, hypoxia-induced 
caspase-3 activation was still observed in autophagy-deficient cells. We also analyzed 
cytochrome c release from mitochondria as a measure of intrinsic apoptosis and found that in 
normal cells this was induced by both Lcn2 and hypoxia which together had a synergistic 
effect. Autophagy-deficiency reduced cytochrome c and mitochondria colocalization and 
although there was an apparent further reduction by Lcn2 or hypoxia, these were not 
statistically significant. Therefore, we conclude that attenuation of cardiomyocyte autophagy 
by Lcn2 or molecular engineering of cells confers increased susceptibility to stress-induced 
cell death. This is in keeping with literature in which mouse models of autophagy deficiency 
develop agre-related cardiomyopathy [234], show enhanced hemodynamic stress induced 
dysfunction [202] and angiotensin-II stimulated inflammation and injury [235]. 
 
In summary, our study indicates that Lcn2 is an important suppressor of 
cardiomyocyte autophagic flux and that this contributes to intrinsic apoptosis.  In a mouse 
model of cardiac ischemia, Lcn2 levels increase and contribute to attenuation of cardiac 
autophagy with increased cell death and dysfunction. Mice lacking Lcn2 are able to elicit a 
higher autophagic response after ischemia and are protected from cell death and cardiac 
dysfunction. These dats suggest that further studies are warranted to investigate the usefulness 
of Lcn2 as both a biomarker and therapeutic target in heart failure. 
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4.1. Summary 
Inadequate supply of iron can elicit health defects yet there is also strong evidence that 
too much iron induces detrimental cellular effects. Accordingly, disturbed iron homeostasis is 
associated with various pathological conditions, including diabetes and heart failure.  Insulin 
resistance is an established contributor to heart failure and in this project I tested the 
hypothesis that iron induces cardiomyocyte insulin resistance via oxidative stress. In primary 
adult and neonatal cardiomyocytes as well as H9c2 cells, derived from rat heart ventricle, iron 
(FeSO4, 100µM/ml 4hours) induced insulin resistance as determined by Western blotting and 
immunofluorescent detection of Akt phosphorylation. Using CellROX Deep Red assay we 
also observed that iron increased generation of reactive oxygen species (ROS), and that anti-
oxidant pretreatment attenuated iron-induced insulin resistance. I used multiple assays to 
monitor autophagic flux and observed that iron suppressed autophagy. First, we determined 
pULK1(S757), LC3II and P62 levels by Western blotting and immunofluorescence.  The 
increase autopahgosome content was validated by an increase in puncta detected using Cyto 
ID assay. To study the functional significance of changes in autophagy we created an 
autophagy-deficient cell model by overexpressing a dominant-negative Atg5 mutant in H9c2 
cells and autophagy deficiency both induced insulin resistance. In conclusion, our study 
indicated that iron reduced autophagy and stimulated ROS production, causing insulin 
resistance in cardiomyocytes. Future studies will further investigate mechanisms via which 
iron regulates cardiac remodeling and their physiological significance. I anticipate that our 
findings will provide new knowledge relevant to current diagnostics and therapeutics related 
to altered iron status in clinical settings.  
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4.2. Introduction  
Iron is an essential micronutrient and its crucial role in many physiological functions 
is often underestimated [236]. Altered iron metabolism is implicated in a vast array of 
diseases, including type 2 diabetes [236], neurodegenerative diseases [237], cardiovascular 
diseases [79], cancer [238], osteoporosis [239] and many more. In particular, both iron 
deficiency (ID) and iron overload (IO) have been associated with cardiomyopathy [79, 81]. 
Recently iron overload cardiomyopathy (IOC) has been presented to define a secondary form 
of cardiomyopathy resulting from the accumulation of iron in the myocardium mainly 
because of genetically determined disorders of iron metabolism or multiple transfusions [81, 
240]. Iron is a vital structural component of haemoglobin, myoglobin, oxidative enzymes and 
respiratory chain proteins that are collectively responsible for oxygen transport, storage and 
energy metabolism [78]. Iron-overload cardiomyopathy is the most common reason of 
mortality in patients with secondary iron-overload or patients with genetic hemochromatosis 
[241-247]. In essence, altered iron homeostasis leads to uncontrolled iron deposition in 
different organs, including the heart, leading to progressive tissue damage [67, 248]. Iron-
induced oxidative stress plays an important role in the pathogenesis of iron-overload mediated 
heart disease [249-251]. The formation of labile NTBI alters the pro-oxidant/antioxidant 
balance, leading to a pro-oxidant state with increased free radical production, oxidative stress 
and cellular damage [250, 252, 253]. Previous studies indicated that oxidative stress can lead 
to mitochondrial dysfunction and accumulation of lipotoxic metabolites which have been 
shown to contribute to insulin resistance. 
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Autophagy is the major intracellular degradation process where cytoplasmic materials 
get delivered to lysosomes for degradation and recycling [178, 183, 193, 254]. Several studies 
have now shown that the degree of autophagy changes in the failing heart and directly in 
response to ischemia and/or reperfusion [195] [196-198], although the functional significance 
is still somewhat uncertain. Indeed, autophagy may be regarded as a double edged sword with 
potential beneficial and detrimental effects in the heart [199]. At low levels autophagy is 
important in recycling damaged organelles and nutrients, however excessive autophagy 
contributes to tissue dysfunction and non-apoptotic programmed cell death in pathological 
myocardial remodeling [184, 199-202]. Recent evidence indicated that dysregulation of 
autophagy resulted in ER stress, insulin resistance and glucose intolerance [255]. Our own 
research also has shown that induction autophagy can be beneficial to the myocardium in 
terms of its insulin sensitizing effect and reducing apoptosis [218, 256]. In various tissue 
types it has been found that ROS production results in increased autophagy [257]. In the heart, 
elevated autophagy is activated post-ischemia in association with ROS upregulation and this 
is thought to be an endogenous self-protective mechanism [258]. ROS also play an early role 
in the development of insulin resistance [259, 260]. Evidence suggested that downstream of 
the PI3K/Akt insulin signaling pathway may be the target of exogenous inducers of autophagy 
[261]. 
The precise molecular mechanisms of iron-overload cardiomyopathy have not been 
elucidated yet. In this study, I test the hypothesis that iron induces insulin resistance in 
cardiomyocytes, and that this involves regulation of autophagy and/or oxidative stress and 
crosstalk between them. To do so I used primary adult or neonatal cardiomyocytes, human 
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stem cell derived cardiomyocytes and H9c2 cells as cellular models and treated with iron for 
up to 24h and tested ROS production, autophagic flux and insulin sensitivity. 
 
4.3. Materials and methods  
4.3.1. Cell culture  
H9c2 (ATCC® CRL-1446) rat cardiomyoblasts were grown in Gibco® normal glucose 
Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS) and 1% (v/v) penicillin streptomycin at 37 °C and 5% CO2. For microscopy assays 
(except TEM), cells were grown on cover slips and treated with or without recombinant 
FeSO4 2 (100 µM/ml) in DMEM with 0% FBS mimicking starvation at approximately 80% 
confluency (unless specified otherwise) for 1, 4 and 24hrs.  
Primary cells; The left ventricles of 1-3 day Wistar rat pups were isolated by 
decapitation, and a small ventricle incision through the sternum. Hearts were perfused in 
CFBHH (Calcium and Bicarconate Free Hanks with Hepes) buffer, and torn apart into small 
pieces with fine tweezers. Samples were transferred to a flat bottom 50ml conical tube with 
10ml of trypsin (1:250) and a small stir bar. Heart pieces were stirred in the fume hood for 10 
min. The supernatant was collected and neutralized with 10ml of 10% FBS DMEM (1% 
PenStep, 50mg/L gentamycin sulfate). 10ml of trypsin was added to the remaining sample and 
was repeated until all tissue was digested. Supernatant was spun down at 2000RPM for 10min, 
supernatant was removed, and pellet was resuspended in 101%FBS DMEM. Cells were plated 
in a regular coated 10cm2 culture dishes for 1 hour in order to separate fibroblasts from 
cardiomyocytes. After incubation in a CO2 incubator at 37ºC, supernatant containing 
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cardiomyocytes was filtered through a 70µm strainer. Filtrate was supplemented with 
additional 10%FBS DMEM, and plated on primaria coated culture dishes. 24 hours after 
isolation, cells were washed with PBS, and treatment media was added to begin experiments.  
4.3.2. Colorimetric Intracellular Iron Assay  
H9C2 cells were grown to 80% confluency on 24-well plates in 10% FBS DMEM 
with 1% w/v streptomycin/penicillin where they were treated with 100uM of FeSO4 for 1, 4 
and 24 hour durations ending simultaneously. After the treatment had ended, each well was 
washed 3 times with 0.5ml PBS, lysed with 200ul of 50mM NaOH followed by 200ul of 
10mM HCL and 200ul of freshly prepared iron releasing agent thereafter. The 24 well plates 
were sealed in aluminum foil and incubated at 60°C for a duration of 2 hours. Afterward, 60ul 
of iron detecting reagent was added to each well and left to incubate for 30 minutes at room 
temperature (RT). 280ul of each mixture was transferred to a 96 well plate and the absorbance 
of each well was measured at a wavelength of 550nm using a spectrophotometer. Data was 
normalized by the control treatment without iron. 
4.3.3. PG SK Intracellular Iron Assay  
H9C2 cells were grown to 80% confluency on coverslips in 12-well plates in 10% 
FBS DMEM with 1% w/v streptomycin/penicillin where they were treated with 100uM of 
FeSO4 for 1, 4 and 24 hour durations 30 minutes after treatment with 3uM of PG SK 
diacetate. Coverslips were washed 4 times with 0.5 ml PBS++, fixed by covering coverslips 
with 10% formalin solution for 30 minutes, washed again 3 times in PBS++, quenched by 
covering coverslips in 1% glycine solution for 15 minutes, washed once more 3 times in 
PBS++ and transferred on slides using DAPI Mounting Media for fluorescence nuclear 
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staining and ProLong antifade gold standard reagent (in a 1:2 ratio respectively). Prepared 
slides were viewed via laser scanning microscopy. PG SK fluorescence was viewed using 
FITC and quantified by average fluorescent intensity per cell by dividing the total green 
fluorescence by cell number using ImageJ. 
4.3.4. Western blotting 
H9c2 cells were grown to 90% confluency in 6 well plates. After the experimental 
endpoint, cells were washed in PBS and solubilized in 1× Lysis buffer (50 mM Tris, 150 mM 
NaCl, 0.1% SDS 1% Triton X-100 and 0.5% sodium deoxycholate) containing protease 
inhibitor cocktail – complete ULTRA Tablets, Mini (Roche). Lysates were centrifuged at 
12,000 rpm for 5 min at 4 °C. Supernatant was collected, heated at 90 °C for 5 min and 
equivalent amounts of lysate were loaded to an SDS-PAGE gel, followed by protein transfer 
onto PVDF membrane (Bio-Rad). Membranes were first blocked in 3% BSA for 1 h, 
incubated in primary antibody at 4 °C overnight, washed, incubated in appropriate horse-
radish peroxidase (HRP)-linked secondary antibody for 1 h, washed, then followed by 
chemiluminescence enhancement using Western Lightning Plus ECL (Perkin Elmer) before 
developing and exposing the membrane to CL-XPosure Film (Thermo Scientific). The band 
intensities were quantified using Image J. The following primary antibodies were used: pAkt 
T308 and β-actin (1:1000, Cell Signaling). The following secondary antibodies were used; 
anti-rabbit IgG HRP-linked antibody and anti-mouse IgG HRP-linked antibody (1:10,000, 
Cell Signaling). 
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4.3.5. CellROX® deep Red Oxidative Stress assay 
CellROX® deep Red Oxidative Stress Reagents (Life Technologies) was utilized. The 
cell-permeable reagents are non-fluorescent or very weakly fluorescent while in a reduced 
state and upon oxidation exhibit strong fluorogenic signal. Fluorescence signal was then 
detected with confocal fluorescence microscopy. H9c2 cells were seeded in 6-well plates, and 
treated 100uM of FeSO4 for 1, 4 and 24hr. CellROX® deep Red was added in each well at 
10 ug/mL and incubated for 15 min. Cells were harvested and fixed with 4% PFA, and run in 
flow cytometer machine (Gallios ™, Beckman Coulter Inc.) to analyze red fluorescent signal 
intensity in each cell within a population of 100,000. Confocal images were taken using 40 or 
60X objective (LSM 700). 
 
4.3.6. Generation of H9c2 cells stably overexpressing tandem fluorescent RFP/GFP-LC3 and 
analysis of autophagic flux and autophagy-deficient H9c2-ATG5K130R cells 
Stable H9c2 cells expressing tf-RFP/GFP-LC3 were created essentially as described 
by us previously for another cell type [179] Cells were grown to 80% confluence on 
coverslips in 12 well plates. At experimental endpoint, cells were fixed in 4% para 
formaldehyde (PFA) and quenched with 1% glycine before mounting on a glass slide. 
Confocal images were taken using a x60 objective (Olympus, BX51 Microscope). Pearson 
and Overlapping coefficients were calculated using ImageJ with the JACoP plug-in to 
quantify the extent of GFP and RFP co-localization. To generate H9c2 cells stably over-
expressing mutant ATG5 proteins (ATG5K130R), H9c2 cells were transduced with retroviral 
vector carrying pmCherry-ATG5K130R.  
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4.3.7. Cyto-ID® Green autophagy dye staining procedure for autophagy detection 
The Cyto-ID® Green autophagy dye was prepared following the protocol from the 
manufacturer. The 10X assay buffer was allowed to warm to room temperature and then 
diluted to 1X with 9 ml of deionized H2O and 1 ml of the buffer. The Cyto-ID® Green 
autophagy dye solution was prepared by mixing 8 µl of the dye and 4 ml of 1× assay buffer. 
The sample is shielded from exposure to direct light and incubated for 30 min at 37°C, 
followed by a wash and resuspension with 500 µl of 1X assay buffer before imaged-based 
analysis. Confocal images were taken using 40 or 60X objective (LSM 700). 
 
4.3.8. hiPS-CMs cell culture 
hiPS-CMs (iCell Cardiomyocytes), cell culture thawing, and maintenance media were 
purchased from Cellular Dynamics International (Cat. No. CMM-100-120-005). hiPS-CMs 
were cultured on gelatine-coated 384 well according to the manufacturers protocol. Briefly, 
iCell cardiomyocytes (hiPS-CMs) were supplied cryopreserved at a density of more than 
1.0 × 106/ml and stored at −150°C until use. Cryopreserved cells were thawed in a 37°C water 
bath without shaking for 5 min, transferred to a 50 ml falcon tube in a drop wise manner, 
before addition of 9 ml iCell thawing media. Viability was determined using a manual 
hemocytometer and total cell count determined taking into account the cell lot plating 
efficiency. Cells were seeded at 4000/well in gelatine-coated 24 well plates, or 
120 × 103/coverslip, in iCell thawing media and incubated at 37°C with 5% CO2 for 48 h. 
Following this, cells were washed twice with 50 µl iCell maintenance media per well and 
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returned to the incubator for a further 48 h. Following this, iCell maintenance media were 
then removed and replaced with 50 µl fresh iCell maintenance media.  
 
4.3.9. Analysis of glucose uptake and metabolism 
To determine glucose uptake cardiomyocytes were seeded in 24well plates and 
treated with or without FeSO4 (100µM) for periods of 1, 4 and 24 hr. Where indicated 
insulin was used at 100 nM for 10 min. Subsequently, glucose transport was assayed 
essentially as we previously described [262] and results are calculated as pmol of glucose 
uptake per min per mg protein.  
4.3.10. Statistics  
Data was presented as mean±SEM. Statistical significance between treatment groups 
were calculated using the unpaired Student t test when comparing 2 groups. For comparisons 
of more than 2 groups, One Way ANOVA followed by Dunnett’s posttest and Two Way 
ANOVA with Bonferroni post-test were performed to adjust multiple comparisons. P value 
<0.05 was considered statistically significant. 
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4.4. Results  
4.4.1. Intracellular iron accumulation induced insulin resistance in H9c2 cells 
I first determined iron accumulation in H9c2 cells after treatment with 100uM FeSO4 
for 1, 4 and 24 hours. PGSK was preloaded into cells 30 minutes before iron treatment and 
compared to cells cultured for the same time period but not treated with iron. Images of cells 
were captured after being fixed onto coverslips with mounting solution including DAPI, via 
confocal microscopy (Figure 4.4.1.A). Total green fluorescence per cell was quantified 
(Figure 1B) using ImageJ software and by subtracting background signal. Another method 
was also used to measure intracellular iron accumulation in H9c2 cells treated with 100uM of 
FeSO4 for 1, 4 and 24 hours (Figure 4.4.1.C). This colorimetric intracellular iron assay was 
conducted by adding ferrozine to H9c2 cell lysates after iron was liberated from ferritin. 
Absorbances of lysates were measured using a spectrophotometer set at a wavelength of 
550nm. Both assays showed an increase in intracellular iron accumulation after 100uM FeSO4 
treatment for 1, 4 and 24 hours. I next examined the effects of iron via Western blotting 
detection of Akt phosphorylation and the data indicated that the response to insulin was 
attenuated after iron overload (Figure 4.4.1. D&E). 
4.4.2. Iron overload induced insulin resistance in primary cardiomyocytes 
After the initial observation that iron induced insulin resistance in H9c2 cells, I 
examined whether iron blunted insulin signaling in primary cells. I first treated with 100 µM 
FeSO4 for 1, 4 and 24hr in primary neonatal cardiomyocytes and observed that the response to 
insulin was attenuated in cells treated with iron by immunofluorescent (Figure 4.4.2. A&B) 
and Western blotting detection of Akt phosphorylation (Figure 4.4.2.C&D). In addition, the 
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metabolic significance of these effects was examined by measuring glucose uptake and data 
indicated that iron reduced insulin-stimulated glucose uptake and metabolism in neonatal 
cardiomyocyte (Figure 4.4.2. E). Then I further confirmed insulin sensitivity was attenuated 
in primary adult cardiomyocyte cells via immunofluorescent analysis of Akt phosophorylation 
(Figure 4.4.2. F&G) 
4.4.3. Iron induced reactive oxygen species 
I then investigated the effect of iron (1 and 4 hours) on the alteration of intracellular 
reactive oxygen species (ROS). ROS production was measured in H9c2 cells by confocal 
microscope (Figure 4.4.3. A&B) and flow cytometry (Figure 4.4.3.C&D) with 
CellROX® reagent. The result showed that intracellular ROS significantly increased in the 
H9c2 cells treated with 100 µM FeSO4 as early as 1 hour and more significantly at 4 hours. A 
similar response was observed in human stem cell derived cardiomyocytes (Figure 4.4.3. D& 
E).  
4.4.4. Iron induced insulin resistance via increased generation of reactive oxygen species 
(ROS), and enhanced by antioxidant (MnTBAP) 
I next evaluated whether iron-induced oxidative stress had an effect on insulin 
sensitivity. To do so I first verified the effectiveness of the antioxidant reagent MnTBAP 
(100mM). To H9c2 cells were exposed to iron overload conditions for 4hr with 100 µM 
FeSO4 and antioxidant 100mM MnTBAP. The data from confocal microscopy (Figure 4.4.4. 
A&B) and flow cytometry experiments (Figure 4.4.4. C&D) suggested that iron overload 
conditions led to an increase in ROS which was diminished by MnTBAP. I then examined 
iron (FeSO4, 100µM) induced insulin resistance via Western blotting detection of Akt 
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phosphorylation (Figure 4.4.4.F&G) and iron significantly induced insulin resistance and 
attenuated by MnTBAP in H9c2 cells. 
4.4.5. Iron reduced insulin signaling due to inhibition of autophagy  
I next examined the regulation of autophagy by iron and it’s significance in 
determining insulin sensitivity. As seen in Figure 4.4.5A, iron caused a significant up 
regulation of phosphorylation of ULK1 at Ser757 (Figure 4.4.5.A). Furthermore, iron 
increased the amount of LC3II (Figure 4.4.5.B), the lipidated form of LC3 that is essential for 
closure of the autophagosome and is widely used as a marker for autophagy. The increase 
autopahgosome content after iron treatment was validated by a increase in puncta detected 
using Cyto ID assay and confocal microscopy (Figure 4.4.5.D&E). I also examined 
autophagic flux by testing p62 expression (Figure 4.4.5.C) and found this was elevated by 
iron, and chloroquine which is well known inhibitor of late stage autophagy flux. LC3-II and 
p62 data collectively suggests iron attenuates flux.  
Based on the observations that iron both induced insulin resistance and inhibited 
autophagy, I investigated if there were any causation effects between the two. First, I 
examined if insulin resistance may be caused by the impairment of autophagy.  With the use 
of Atg5K autophagy deficient H9c2 cells, as expected, there was a does dependent increase in 
phosphorylation of Akt Thr308 was observed in wild type (WT) H9c2 cells upon stimulation 
with an increasing dose of insulin, yet the response was significantly decreased in the ATG5K 
cell line (Figure 4.4.5.F&G). This indicated that an impairment of autophagy could lead to 
insulin resistance in cardiomyocytes. 
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Figure 4.1. Intracellular iron accumulation induced insulin resistance in cardiomyocyte.  
H9c2 cells were treated with FeSO4 (100µM) or without (Con) for 4 and 24 hr. Characterizing 
intracellular iron by PGSK assay (A), quantification (B) and Colorimetric assay was evaluated 
using spectrophotometer (C). H9c2 cells without (con) or with FeSO4 (100µM) were treated 
with insulin (100nM) for 10 minutes before experimental endpoint. Western blots showing 
phosphorylation of AKT Thr308 and the reference protein total AKT in H9c2 cells (D) and its 
quantification (E). *indicates significant difference from control *p<0.05, **p<0.01. n = 5 . 
Scale bar = 20µm, n ≥ 3. 
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Figure 4.2. Insulin signaling in cardiomyocyte indicated by increased phosphorylation of 
AKT Thr308 was all decreased by iron. In primary adult and neonatal cardiomyocytes, with 
FeSO4 (100µM) or without (con) were treated with insulin (100nM) for 10 minutes before 
experimental endpoint.  Representative confocal images of phosphorylation of pAKT Thr308 
in neonatal (A) and adult cardiomyocyte cells (F) and their quantifications (B&G). Western 
blots showing phosphorylation of AKT Thr308 and the reference protein total AKT in 
neonatal cardiomyocyte cells (C) its quantification (D). We examined the effect of FeSO4 
(100µM) for 1, 4 and 24 h on glucose uptake (Insulin: 28.30, 1hr FeSO4: 15.62, 4hr FeSO4: 
12.00, 24hr FeSO4: 14.48 (pmol/mg/min) (E). * indicates significant difference from control 
without insulin; # indicates significant difference from the control with respective insulin 
100nM. # p<0.05, ## p<0.01; *p<0.05, **p<0.01. Scale bar = 20µm, (A &D n = 3, E n=5, 
F&G n=3).  
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Figure 4.3. Iron increased reactive oxygen species (ROS) in H9c2 cells at 1 and 4hr. 
H9c2 cells with FeSO4 or without (con) were treated at 1 and 4hrs by CellROX Red assay by 
confocal microscope. Representative confocal images of 1hr control and FeSO4 (100µM) in 
H9c2 cells and quantification (A). 4hr control and FeSO4 (100µM) in H9c2 cells (B). The 
reactive oxygen species (ROS) production was examined by CellROX red assay using flow 
cytometry(C) and its quantification (D). Iron increased reactive oxygen species (ROS) in 
hiPS-CMs (human cardiomyocyte cells). Representative 3D confocal images showed in hiPS-
CMs cells (E) and its quantification (F). * indicates significant difference from control p<0.01; 
*p<0.05, **p<0.01. Scale bar = 20µm, n = 4.  
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Figure 4.4. Iron induced insulin resistance via increased generation of reactive oxygen 
species (ROS), and enhanced by antioxidant (MnTBAP, 100µM).  H9c2 cells were treated 
at 4hr with FeSO4 (100µM) and ± antioxidant (MnTBAP, 100µM). Representative confocal 
images of CellROX Red assay (A), flow cytometry (C) and their quantifications (B&D 
respectively). Western blots showing phosphorylation of pAKT Thr308 and the reference 
protein total AKT in H9c2 cells (E) its quantification (F). * indicates significant difference 
from control # indicates significant difference from the FeSO4 (100µM). # p<0.05, ## p<0.01; 
*p<0.05, **p<0.01. Scale bar = 20µm, (A-C n = 3, E&F n=4). 
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Figure 4.5. Iron reduced insulin signalling via inhibition of autophagy. H9c2 cells were 
treated with FeSO4 (100µM) with chloroquine (60nM) and without chloroquine for 4 hr. 
Western blots showing protein expression of pULK1 S757 (A), LC3II (B), P62(C) and the 
reference protein GAPDH and their quantifications. The increase autopahgosome by iron was 
validated by a Cyto ID assay using confocal microscope (D) and its quantification (E). 
Autophagy was verified essential for insulin signalling by decreasing phosphorylation of AKT 
T308 in autophagy impaired Atg5K cells dose dependently by western blots (F) and its 
quantification (G). * indicates significant difference from control # indicates significant 
difference from the FeSO4 (100µM). # p<0.05, ## p<0.01; *p<0.05, **p<0.01. Scale bar = 
20µm, (A-E n = 4, F&G n=3). 
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4.5. Discussion  
Iron may play an underappreciated role in the development of insulin resistance and 
insulin resistance-induced heart failure. Cardiac insulin resistance is well established to 
influence heart failure via multiple mechanisms such that exacerbated cardiomyopathy may 
occur in an insulin-sensitive myocardium [34]. In fact, in type 2 diabetes insulin resistance 
can be present for several years before hyperglycaemia develops and at this time contribute to 
adverse cardiac remodeling and iron both with insulin resistance and insulin deficiency [263-
268]. I first investigated whether iron altered insulin sensitivity in cardiomyocytes and found 
that iron reduced insulin sensitivity via increased oxidative stress. Iron accumulation in H9c2 
cells was done by treating them with 100uM of FeSO4. Using a colorimetric intracellular iron 
and PGSK assay, it was shown that there was significantly increased intracellular iron after 
treatment with iron for 1 4 and 24 hours. To assess the effect of iron overload on insulin 
resistance, pAKT T308 was examined in H9c2 cells after treatment to induce iron overload 
conditions by Western blotting. We observed same effect of iron in neonatal and adult 
cardiomyocyte cells and the data showed that reduced phosphrlation of AKT T 308 at 1,4 and 
24hours by Western blotting and immunofluorescence.  
Although little is known about the mechanisms of iron action in cardiomyocytes, 
previous work has included evidence iron induced oxidative stress is a key driver in the 
pathogenesis of myocardial tissue injury and progressive development of iron overload 
cardiomyopathy [251, 269, 270]. Excess iron promotes oxidative stress via the Fenton 
reaction, which plays a key pathogenic role in myocardial injury and heart failure [270-273]. 
Although many studies have described positive relationships between modulation of 
adipokines and insulin resistance, much importance has been placed on iron-mediated oxidant 
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stress and the role it plays in the development of insulin resistance [274].  Our study 
suggested that using CellROX Deep Red assay we also observed that iron increased 
generation of reactive oxygen species (ROS), and that using anti-oxidant (MnTBAP) to 
attenuate ROS production reduced iron effect.  
Autophagy is the major intracellular degradation process where cytoplasmic materials 
get delivered to lysosomes for degradation and recycling [178, 181, 183, 193] and many 
studies have now indicated that the degree of autophagy changes in the failing heart and 
directly in response to I/R [275-278]. Autophagy typically upregulated in times of stress, for 
example during ischemia/reperfusion, pressure overload and cardiac toxicity induced by 
chemicals such as the athracycline doxorubicin [151]. Previous in vivo studies also have 
shown that expression of multiple autophagy related genes were altered in iron overload 
cardiomyopathy, possibly contributing to cardiac diastolic dysfunction [152].  
To do so to study the functional significance of changes in autophagy we created an 
autophagy-deficient cell model by overexpressing a dominant-negative Atg5 mutant. Our data 
suggested that iron or autophagy deficiency both induced insulin resistance and autophagy is 
very important role of regulation insulin resistance in cardiomyocyte. Numerous studies 
suggested that dysregulation of autophagy leads to increases in oxidative stress [279-283]. For 
example inhibition of autophagy increased ROS by lysosome inhibitor chloroquine or the 
cathepsin D inhibitor pestatin A [284-288]. Additionally, disorder of initiation autophagy 
leads to accumulation of ubiquitiated proteins, induced ROS and mitochondrial dysfunction 
[289]. Reduction of Atg5 and Atg10 promote ROS via starvation[280].  
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In conclusion, our study indicated that iron induced insulin resistance in 
cardiomyocytes and this involved regulation of the crosstalk between autophagy and oxidative 
stress. Further studies will investigate mechanisms via which iron regulates cardiac 
remodeling and their physiological significance. We anticipate that our findings will provide 
new knowledge relevant to current diagnostics and therapeutics related to altered iron status in 
clinical settings.  
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Chapter Five:  Discussion & Conclusions 
5.1 Research summary  
Obesity and diabetes increase the incidence of myocardial infarction and heart failure 
[74, 176]. Lcn2 is most abundantly produced from adipocytes and neutrophils and previous 
studies showed that Lcn2 is a proinflammatory marker associated with insulin resistance and 
obesity-related metabolic disorders [7, 10, 155]. My working hypothesis was that Lcn2 
induction is an important component of the cardiac response to myocardial infarction, directly 
regulates cardiac remodeling and contributes to development of heart failure. A variety of 
remodeling events occur throughout the progressive development of heart failure in obesity 
[74]. During my PhD studies, I have examined direct effects of Lcn2 on cardiomyocytes and 
in the heart using mouse mdoels to determine mechanisms via which Lcn2 changes cardiac 
structure and function. In this concluding chapter I revisit the main results and conclusions 
from each chapter and bring these together in a unifying discussion. 
 
Project 1: Lcn2 inhibits autophagy leading to insulin resistance in cardiomyocytes.  
 Data from my first PhD project has been published in the Journal of Molecular 
Endocrinology [218] and forms a strong foundation for the continuation of related work in my 
thesis. Briefly, I treated H9c2 cardiomyocytes with recombinant Holo-Lcn2 for 1 hour 
followed by dose and time dependent insulin treatment and found that Holo-Lcn2 induced 
insulin resistance; assessed via Western blotting for phosphorylation of Akt, ERK and 
p70S6K. I used multiple assays to monitor autophagic flux and observed that Holo-Lcn2 
reduced autophagy. For example, we generated H9c2 cells stably expressing tandem 
fluorescent RFP/GFP-LC3 and this approach allowed me to demonstrate that Holo-Lcn2 
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decreased autophagic flux. Importantly, our lab created an autophagy-deficient H9c2 cell 
model by overexpressing a dominant-negative Atg5 mutant and using this I found that 
reduced autophagy levels also induced insulin resistance. In summary, this study indicated 
that Holo-Lcn2 treatment caused insulin resistance and use of gain and loss of function 
approaches elucidated a causative link between autophagy inhibition and regulation of insulin 
sensitivity by Holo-Lcn2. Cardiac insulin resistance is well established to influence heart 
failure via multiple mechanisms such that exacerbated cardiomyopathy may occur in an 
insulin-insensitive myocardium [176]. In fact, in type 2 diabetes insulin resistance can be 
present for several years before hyperglycaemia develops and during this time contribute to 
adverse cardiac remodeling [191]. More recently, numerous studies have shown that 
autophagy can play a critical role in cardiac metabolic health [178], including regulating 
insulin sensitivity [179, 180]. Several signalling pathways are also involved in the regulation 
of autophagy, including insulin signalling via PI3K/Akt/mTOR which leads to the inhibition 
of autophagy [57]. Indeed, disruption of autophagy by cardiac-specific knockdown of Atg5 in 
adult mice leads to cardiomyopathy [181]. Furthermore, measuring circulating Lcn2 was 
shown to be capable of predicting the severity and mortality of acute and chronic heart failure 
[46, 50, 51, 173, 174, 290], thus making it an attractive and promising biomarker for heart 
failure. The novel observation from my work that Holo-Lcn2 attenuated autophagy then led 
me to test the significance of this mechanism in mediating another important effect of Lcn2 in 
cardiomyocytes that our lab previously established, namely cell death [71].  
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Project 2: Lcn2 regulates autophagy to control apoptosis upon chronic myocardial ischemia. 
Another manuscript, containing data from this project, has been published in Journal 
of Cellular Physiology [256]. In this paper I showed that Holo-Lcn2 attenuates autophagy to 
worsen the extent of apoptosis induced by chronic myocardial ischemia in mice. Briefly, I 
used coronary artery ligation surgery to induce ischemia in wild type (wt) and Lcn2 knockout 
(KO) mice. Lack of Lcn2 protected against ischemia-induced cell death and cardiac 
dysfunction measured by echocardiography. I used multiple assays to monitor autophagic flux 
and observed that Lcn2 KO mice had a greater ischemia-induced increase in autophagy versus 
wt mice. Importantly, these changes correlated with increased cell death and reduced insulin 
sensitivity in response to Holo-Lcn2. A previous study indicated that Lcn2 KO mice had 
significantly decreased fasting glucose while their insulin level and sensitivity improved [16]. 
Moreover, fat mass enlargement, inflammation and accumulation of lipid peroxidation 
products were significantly attenuated in the adipose tissues of aging or HFD Lcn2 KO mice 
[16]. As I indicated above, measurement of serum Lcn2 has been proposed as a useful means 
for evaluating obesity-related cardiovascular diseases including heart failure. Previous 
literature indicated that mouse models of autophagy deficiency develop age-related 
cardiomyopathy [234], show enhanced hemodynamic stress induced dysfunction [202] and 
elevated levels of angiotensin-II stimulated inflammation and injury [235]. This study and 
project 1 collectively indicated that Holo-Lcn2 attenuated autophagic flux and induced both 
insulin resistance and cell death in cardiomyocytes; effects which collectively may play an 
important role in the pathogenesis of heart failure in obesity. 
Project 3: Iron induces insulin resistance in cardiomyocytes via regulation of oxidative stress. 
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 Data from my first PhD project indicated that Holo-Lcn2 caused insulin resistance and 
use of gain and loss of function approaches elucidated a causative link between autophagy 
inhibition and regulation of insulin sensitivity by Lcn2 [218]. My second project showed that 
Holo-Lcn2 regulates autophagy to control apoptosis upon chronic myocardial ischemia [256]. 
Together with our labs previous observation that Lcn2 induced cardiomyocyte apoptosis via 
elevating intracellular iron levels [71], this led me to appreciate the extensive literature 
showing that both iron overload and deficiency have been strongly associated with heart 
failure [92, 101, 106, 109, 179]. Importantly, as I indicated during my thesis introduction, 
Lcn2 plays important role in regulation of iron homeostasis, promoting iron accumulation in 
cardiomyocytes, and I thus hypothesized this could be an important mechanism in the context 
of cardiomyopathy. Circulating Lcn2 is often recorded to be significantly increased in patients 
experiencing HF [81, 238-240, 291] local Lcn2 produced in the heart is also increased 
significantly [256]. Hence, I believed it was of great interest to further elucidate the 
mechanisms of iron-associated cardiomyopathy.  
 Therefore, in my third project I investigated whether iron caused insulin resistance in 
cardiomyocytes and the mechanisms via which this occurred, with a focus on oxidative stress. 
Although little is known about the mechanisms of iron action in cardiomyocytes, previous 
work has included evidence iron induced oxidative stress is a key driver in the pathogenesis of 
myocardial tissue injury and progressive development of iron overload cardiomyopathy [251, 
269, 270]. Briefly, I used primary adult and neonatal cardiomyocytes as well as H9c2 cells, 
and observed that iron induced insulin resistance, as determined by Western blotting and 
immunofluorescent detection of Akt phosphorylation as well as glucose uptake. Using 
CellROX Deep Red assay I also observed that iron increased generation of reactive oxygen 
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species (ROS), and that anti-oxidant pretreatment attenuated iron-induced insulin resistance. 
Furthermore, various complementary assays indicated that iron suppressed autophagy. 
Although many studies have described positive relationships between modulation of 
adipokines and insulin resistance, much importance has been placed on iron-mediated oxidant 
stress and the role it plays in the development of insulin resistance [274]. Autophagy is the 
major intracellular degradation process where cytoplasmic materials get delivered to 
lysosomes for degradation and recycling [178, 181, 183, 193] and many studies have now 
indicated that the degree of autophagy changes in the failing heart and directly in response to 
I/R [275-278]. Autophagy typically upregulated in times of stress, for example during 
ischemia/reperfusion, pressure overload and cardiac toxicity induced by chemicals such as the 
athracycline doxorubicin [151]. Previous in vivo studies also have shown that expression of 
multiple autophagy related genes were altered in iron overload cardiomyopathy, possibly 
contributing to cardiac diastolic dysfunction [152]. This is in keeping with my Project 3 study 
which indicated that iron reduced autophagy causing insulin resistance in cardiomyocytes.  
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5.2 Future directions 
Future studies to expand the work presented in this thesis will continue to explore and 
focus on the mechanistic role of autophagy. Ultimatley, I expect this will have implications in 
i) establishing Lcn2 as a potential biomarker for the diagnosis of heart failure or it’s 
susceptibility and ii) validating Lcn2 and autophagy as potentially important therapeutic 
targets in the treatment of heart failure. 
 
As explained above in project 1 and 3, my data led me to place a strong emphasis on 
the study of autophagy and whether it is regulated by Lcn2 and iron. The pro-apoptotic effect 
of Lcn2 involved increased intracellular iron levels. It will great interesting point to 
investigate the role of altered intracellular iron on H/R-induced changes in apoptosis, 
authopagy, oxidative stress and ER stress. The role of iron in H/R mediated apoptosis is 
unclear [233, 292] although iron chelation has been proposed as a therapy for various 
cardiomyopathies [293]. Another study suggested that H/R damage in primary neonatal 
cardiomyocytes involves oxidative stress via the production of hydroxyl radicals mediated by 
iron [294]. Similarly to project 3, it would be possible to determine if elevated iron levels 
contribute to oxidative stress, whether this is part of the mechanism of Lcn2 or H/R-induced 
cell death and if chelating iron attenuates the apoptotic effects of Lcn2 or H/R. Interestingly, 
sustained autophagy upon transgenic Atg7 overexpression decreased cardiac fibrosis, 
hypertrophy and dysfunction [295]. Interestingly, one study showed that patients with 
longstanding idiopathic cardiomyopathy increased cardiac accumulation of autophagosomes 
[295]. Accordingly, my experiments are now designed to examine temporal and spatial 
changes in cardiac autophagy based on the hypothesis that autophagy is induced in the heart 
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as a protective mechanism in response to I/R and that Lcn2 suppresses this beneficial effect. 
Lack of Lcn2 may prevent this and allow autophagy to become elevated and confer protection. 
Furthermore, Atg7 is required for ATG conjugation mechanism and autophagosome formation. 
This has important consequences such as amino acid supply in neonates, and starvation-
induced bulk degradation of proteins and organelles in mice [296, 297]. Atg7 deficiency in 
mice led to multiple cellular abnormalities, such as appearance of concentric membranous 
structure and deformed mitochondria, and accumulation of ubiquitin-positive aggregates 
[296]. To examine the autophagy-deficient phenotype, I am currently breeding Atg 7F/F with a 
line of transgenic mice that express the Cre recombinase under the control of a cardiomyocyte 
specific promoter. These mice will be crossbred onto a background of Lcn2KO mice to create 
a completely novel mouse model to test our hypothesis. We will subject these mice to 
surgically induced heart failure (coronary artery ligation to induce ischemia and reperfusion 
(I/R)) then examine changes in autophagy, cell death, oxidative stress, mitochondrial function, 
inflammation and fibrosis as well as heart function using techniques well established in our 
lab [218, 256]. These will allow me to further explore the hypotheses that presence of Lcn2 is 
permissive in development of cardiac dysfunction whereas lack of Lcn2 may protect mice 
from I/R-induced dysfunction. Autophagy deficiency is also expected to exacerbate I/R 
induced heart failure, and we have promising preliminary evidence that lack of autophagy 
induced cardiac dysfunction. Furthermore, interestingly, whereas I/R induced a large increase 
in myocardial Lcn2 content in wt mice, it did not in this autophagy-deficient mouse model. 
This is an unexpected observation and clearly suggests further crosstalk between Lcn2 and 
autophagy. Previously my study indicated that Lcn2 attenuates autophagy to worsen the 
extent of apoptosis induced by chronic myocardial ischemia in mice and we observed 
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significantly increased Lcn2 level after chronic myocardial ischemia. We will also use in vitro 
studies to further examine direct cellular mechanisms of Lcn2 action with gain and loss of 
function approaches. 
 
One of the important discoveries made in my thesis was that Lcn2 regulates autophagy 
and apoptosis upon chronic myocardial ischemia. Now, to further advance this study we will 
use wt and Lcn2KO mice in which will also restore normal Lcn2 levels by adenoviral delivery, 
with the specific hypothesis that presence of Lcn2 is permissive in development of cardiac 
dysfunction whereas lack of Lcn2 may protect mice from I/R-induced dysfunction. This 
sytudy will be designed to examine mechanisms including autophagy, cell death, oxidative 
stress, mitochondrial function, inflammation and fibrosis. For example, a novel approach that 
our lab is developing over the last few months is the use of fluorescent molecular tomography 
to non-invasively measure autophagy in mice. This is based on the use of a cathepsin-
activatable near infra-red probe, is quantitative and will provide spatial and temporal readouts 
of changes in autophagy in the same mouse over the period of our experimental protocol. We 
anticipate that in wt, but not Lcn2-KO, there will be sufficient induction of autophagy to limit 
damage such as cell death or insulin resistance. Reintroduction of Lcn2 to Lcn2-KO by 
adenovirus will attenuate I/R-induced autophagy and promote dysfunction. This future study 
also will consider the alternative hypothesis that lack of Lcn2 may allow either too much or - 
if autophagy is transiently elevated only in the early period or I/R, as was suggested in one 
recent study - prolonged autophagic induction, both of which may also be detrimental to 
cellular events such as apoptosis [212]. In addition to examining autophagy, the following 
experimental measures will also be made: i) Echocardiography to examine cardiac function ii) 
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Insulin sensitivity iii) Cell death and iv) Fibrosis, all using methods that are established in our 
lab [9, 10]. 
 
5.3 Conclusion  
For my PhD studies, I examined effects of Lcn2 on the heart to determine changes in 
cardiac structure and function. Rationale for this work was based on the fact that obesity and 
the associated metabolic syndrome (a cluster of chronic symptoms including insulin resistance, 
hyperglycemia, hypertension, and inflammation) predispose individuals to developing heart 
failure. The consequences on an obese and aging population can be devastating owing to the 
high risk for mortality or loss of quality of life.  
The most significant observation that I made was that regulation of autophagy was an 
important mechanism via which Lcn2 altered insulin sensitivity as well as cell death in 
cardiomyocytes. Furthermore, I demonstrated that iron induced insulin resistance via 
oxidative stress. These novel cellular mechanistic discoveries led me to propose that future 
studies will continue to explore and validate the physiological significance of Lcn2-induced 
heart failure. As I explained above, Lcn2 is a hormone that previous research has suggested 
could be potentially useful as a biomarker or therapeutic target for heart failure, however 
much more research is needed to validate either of these possibilities. Knowledge produced 
by my research will thus have potential to impact improved diagnosis or treatment of heart 
failure in future.  
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Abstract
Neutrophil gelatinase-associated lipocalin (NGAL) has recently become established as an important contributor to
the pathophysiology of cardiovascular disease. Accordingly, it is now viewed as an attractive candidate as a
biomarker for various disease states, and in particular has recently become regarded as one of the best diagnostic
biomarkers available for acute kidney injury. Nevertheless, the precise physiological effects of NGAL on the heart
and the significance of their alterations during the development of heart failure are only now beginning to be
characterized. Furthermore, the mechanisms via which NGAL mediates its effects are unclear because there is no
conventional receptor signalling pathway. Instead, previous work suggests that regulation of iron metabolism could
represent an important mechanism of NGAL action, with wide-ranging consequences spanning metabolic and
cardiovascular diseases to host defence against bacterial infection. In the present review, we summarize rapidly
emerging evidence for the role of NGAL in regulating heart failure. In particular, we focus on iron transport as a
mechanism of NGAL action and discuss this in the context of the existing strong associations between iron
overload and iron deficiency with cardiomyopathy.
Key words: 24p3, autophagy, cardiomyopathy, ER stress, heart failure, iron deficiency, iron overload, lipocalin 2 (Lcn2), mitochondrial dysfunction, NGAL, oxidative stress.
INTRODUCTION
Iron is an essential micronutrient and its crucial role in many
physiological functions is often underestimated [1]. Altered iron
metabolism is implicated in a vast array of diseases, including
neurodegenerative diseases [2], cardiovascular diseases [3], can-
cer [4], osteoporosis [5] and many more. In particular, both iron
deficiency (ID) and iron overload have been associated with car-
diomyopathy [6,7]. With the heart being a highly metabolically
active organ, optimal iron homoeostasis is especially vital. Iron
is a vital structural component of haemoglobin, myoglobin, oxid-
ative enzymes and respiratory chain proteins that are collectively
responsible for oxygen transport, storage and energy metabolism
[8]. Although epidemiological studies investigating the role of
iron in various diseases are often inconsistent, this is not entirely
surprising given the differences in experimental criteria and nu-
merous methods used for assessment of iron status [3]. In the
present review, we aim to assess the altered iron status in cardi-
Abbreviations: CKD, chronic kidney disease; DMT-1, divalent metal ion transporter 1; EF, ejection fraction; ER, endoplasmic reticulum; ESA, erythropoietin-stimulating agent; ESC,
European Society of Cardiology; FAIR-HF, Ferinject Assessment in patients with IRon deficiency and chronic Heart Failure; FPN, ferroportin; Hb, haemoglobin; HCP-1, haem carrier
protein 1; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ID, iron deficiency; IFN-γ , interferon γ ; IOC, iron
overload cardiomyopathy; ISC, iron-sulfur cluster; Lcn2, lipocalin 2; LTCC, L-type calcium channel; NCOA4, nuclear receptor co-activator 4; NF-κB, nuclear factor κB; NGAL, neutrophil
gelatinase-associated lipocalin; NYHA, New York Heart Association; RED-HF, Reduction of Events with Darbepoetin α in Heart Failure; ROS, reactive oxygen species; Tf, transferrin; TfR,
transferrin receptor; TNF-α, tumour necrosis factor α; TREAT, Trial to Reduce cardiovascular Events with Aranesp (darbepoetin α) Therapy; TSat, transferrin saturation; TTCC, T-type
calcium channel; UPR, unfolded protein response.
Correspondence: Dr Gary Sweeney (gsweeney@yorku.ca).
omyopathy, to discuss the possible cellular mechanisms involved,
and to highlight the importance of regulation of iron metabolism
by neutrophil gelatinase-associated lipocalin (NGAL).
SYSTEMIC AND MYOCARDIAL IRON
METABOLISM
Essential concepts of systemic iron metabolism are briefly re-
viewed (see Figure 1), although readers are referred to some
excellent review articles for further details [9,10]. Iron homoeo-
stasis is essentially a closed system: iron is acquired from food as
inorganic or haem iron, which is primarily absorbed in the duo-
denum via processes mediated by divalent metal ion transporter 1
(DMT-1) and haem carrier protein 1 (HCP-1), respectively. Iron
in the cytoplasm can be either stored as ferritin or released to
the bloodstream via ferroportin (FPN), where ferrous iron (Fe2+)
can be oxidized to ferric iron (Fe3+) by hephaestin to facilitate
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Figure 1 Schematic overview of cellular iron transport in cardiomyocytes
The role of DMT-1 as well as other transporters such as LTCC and TTCC as possible portals for iron into cardiomyocytes.
In addition Tf binds to TfRs on the external surface of the cell. The role of NGAL is to donate iron to cells via the NGAL-R.
Internalization of NGAL and its receptor leads to the uptake of iron from the siderophore–iron complex, although the exact
mechanism remains unclear. However, accumulation of iron subsequently induces mitochondrial dysfunction, oxidative
stress, ER stress and autophagy in cardiomyocytes. Additional details about the specific information are given in the text.
its binding to transferrin (Tf) and transport in the circulation.
Most cells express transferrin receptor 1 (TfR1) such that holo-
Tf can be endocytosed to acquire iron, in which the ferric iron
is reduced to ferrous iron by the metalloreductase STEAP3. It is
then transported across the cell membrane by DMT-1. Hepcidin
is a peptide hormone that induces the intracellular degradation of
FPN, the only known iron exporter, and therefore it is a vital and
major iron-regulatory hormone controlling plasma iron concen-
tration and tissue iron distribution by inhibition of intestinal iron
absorption, iron recycling by macrophages and iron mobilization
from hepatic stores [11].
Various processes mediate iron transport in the cardiovas-
cular system. Iron deposition in the heart is a gradual process,
and has been suggested to occur in the ventricular myocardium
before the atrial myocardium [12]. Sequential appearance has
been further documented, starting initially in the epicardium,
then the myocardium and eventually the endocardium. Myocar-
dial iron levels are normally regulated through Tf-mediated up-
take mechanisms, mainly through TfR1 [13], although in the
case of iron overload, when Tf-mediated transport becomes satur-
ated, non-Tf-bound iron in the circulation increases and can also
enter cardiac myocytes through DMT-1, T-type calcium chan-
nels (TTCCs), L-type calcium channels (LTCCs) [13,14], zinc-
regulated transporter (ZRT)/iron-regulated transporter (IRT)-like
protein 14 (Zip14 or Slc39a14) [15] and also NGAL receptor,
which facilitates the entry of NGAL-bound iron [16]. FPN1
is expressed in cardiomyocytes as an exporter of iron into the
circulation [17].
OBSERVATIONAL CHANGES AND DIAGNOSIS
OF IRON STATUS IN CARDIOMYOPATHY
Heart failure (HF) is a highly prevalent chronic progressive con-
dition in which the heart is incapable of pumping enough blood to
meet the body’s demand. The ejection fraction (EF), the measure-
ment of the amount of blood that the left ventricle pumps out in
each contraction, is an important indicator for heart function and
diagnosis of HF. In patients who have HF with reduced ejection
fraction (HFrEF), the EF falls from a normal range of between
55% and 70% to <40%, yet half of the patients with HF are
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Figure 2 Schematic overview of pro-inflammatory actions of
NGAL
NGAL expression is induced by IFN-γ and TNF-α, and one potential
mechanism is via an NF-κB-dependent pathway. NGAL itself can also
induce NF-κB activation, and further induce IFN-γ and TNF-α expression.
In addition it enhances cardiac inflammation by promoting macrophage
pro-inflammatory M1 phenotype polarization. Additional details of the
various phenomena illustrated are provided in the text.
observed to have preserved EF (HFpEF) [18]. In the ongoing
search for novel treatments of HF, strong evidence is emerging
to show the significance of disturbed iron homoeostasis in HF,
regardless of the degree of change in the EF [19], thus establish-
ing an excellent therapeutic potential if our understanding of the
mechanisms responsible for the association of iron homoeostasis
and HF can be enhanced.
The normal range of circulating ferritin is from 30 μg/l to
300 μg/l. In healthy individuals, iron deficiency is defined when
the circulating ferritin concentration falls to <30 μg/l. However,
HF has an inflammatory component in which serum ferritin, as
an acute-phase protein, is often elevated without changes in body
iron stores. Therefore, it should be noted that there is a differ-
ence in the diagnostic criteria for ID between healthy individuals
and those with HF (and other chronic diseases). Recently the
European Society of Cardiology (ESC) guidelines for diagnosis
and treatment of HF have recommended a systematic measure-
ment of iron parameters in all patients suspected of having HF.
Serum ferritin <100 μg/l is regarded as absolute iron deficiency;
if serum ferritin is 100–299 μg/l and Tf saturation (TSat) <20%
this is defined as functional iron deficiency [20]. On the other
hand, TSat >55% and serum ferritin >200 μg/l or >300 μg/l
in women and men, respectively, is diagnosed as iron overload
cardiomyopathy (IOC), as proposed by 2005 American College
of Physicians guidelines [21]. The level of serum ferritin at which
iron deposition is detected in the heart has not yet been conclus-
ively identified. Not only is it invasive to take a heart biopsy,
but technical difficulty also often renders the results variable and
non-definitive. Both iron overload and ID have been linked to
cardiomyopathy, with the former primarily associated with an
enhanced oxidative stress and the latter with mitochondrial dys-
function, impaired heart efficacy [8], hypercoagulable state and
increased cardiac burden, and, in addition, oxidative stress due
to anaemia [3]. Cardiomyopathy associated with iron overload or
ID is reviewed in more detail below.
Iron overload cardiomyopathy
IOC is defined as the presence of systolic or diastolic cardiac dys-
function secondary to increased deposition of iron in the heart
independent of other concomitant processes [22]. It is typically
associated with dilated cardiomyopathy with left ventricular hy-
pertrophy and reduced EF [7]. Although patients may remain
asymptomatic in the early disease process, severely overloaded
patients can rapidly experience terminal HF. Accumulation of
iron in the myocardium may occur via increased iron absorp-
tion from gastrointestinal enterocytes (haemochromatosis), ex-
cess exogenous iron intake, such as via dietary supplements, or
blood transfusions (haemosiderosis). The association of IOCwith
haemochromatosis, an autosomal disorder involving mutation of
specific genes involved in iron metabolism, leading to increased
gastrointestinal absorption, is well characterized [23]. In fact, this
accounts for a third of deaths in hereditary haemochromatosis,
especially in young male patients [24]. Chronic blood transfu-
sion is the treatment for hereditary and acquired anaemia, in-
cluding thalassaemia and myelodysplastic syndromes. However,
as excess body iron cannot be actively excreted, repeated blood
transfusions can result in iron deposition in multiple organs, of
which the heart is one of the most sensitive organs to iron toxicity
[7]. As the cardiac clinical presentations can vary widely among
these patients, a recent review has provided recommendations and
clinical guidelines with regard to a decision on chelation therapy
by stratifying patients based on the presence or absence of heart
dysfunction and heart magnetic resonance imaging T2-weighted
values [25].
There are numerous mechanisms via which excess iron can
reduce cardiac function. Once the antioxidant capacity of cardio-
myocytes has been exceeded, iron can produce excess oxidative
stress via the Fenton reaction (see below) and lead to apoptosis
[26]. In addition, excess free iron in the blood is suggested as
responsible for the generation of insoluble parafibrin, which is
highly resistant to proteolytic dissolution and initiates inflam-
matory reactions on deposition on the arterial wall [27]. The
association of iron and atherosclerosis is well established in an-
imal studies, e.g. iron accumulation is observed in atherosclerotic
plaques [28], and decreasing tissue iron via chelating therapy, di-
etary iron restriction or phlebotomy showed decreased atheroma
plaque size with improved stability [29–32]. Such association is
also supported in clinical studies: a study involving 12033 men
showed that increased ferritin concentration was associated with
early coronary artery atherosclerosis, independent of traditional
cardiovascular risk factors [33]; another study involving 196 par-
ticipants showed a strong association between serum ferritin and
pulse wave velocity or aortic stiffness in women [34]. The 6-year-
long Iron and Atherosclerosis STudy (FeAST) also established
correlations of levels of ferritin, inflammatory biomarkers and
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mortality in a subset of patients with peripheral arterial disease
[35]. Iron availability may have contributed to atherosclerosis by
impairing nitric oxide action, as demonstrated by improvement
in nitric oxide-mediated endothelium-dependent vasodilatation
in patients with coronary artery disease, by chelating iron with
desferrioxamine [36]. Although further mechanisms have yet to
be defined, the Atherosclerosis Risk In Communities (ARIC)
study has rejected the hypothesis that excess iron stores would
promote low-density lipoprotein (LDL) oxidation [37]. It was
shown that dietary iron intake and body iron stores had no direct
link to altered structure and function of large arteries in individu-
als free of cardiovascular disease, cancer or haemochromatosis
[38].
Iron deficiency and cardiomyopathy
Iron deficiency (ID) is the most common nutritional deficiency
worldwide [39]. It is frequent, has a high occurrence rate of
30–50% in patients with HF and presents as an important co-
morbidity [40]. Two types of ID can be distinguished: absolute
and functional. Absolute ID reflects depleted iron stores, whereas
iron homoeostatic mechanisms and erythropoiesis often remain
intact. Absolute ID development in humans can result from in-
adequate dietary iron intake, impaired gastrointestinal absorp-
tion/transport, drug interactions and gastrointestinal blood loss
[41]. On the other hand, functional ID presents a dysregulated
iron homoeostasis in which cells and tissues might receive inad-
equate iron supplies despite normal whole body iron storage. This
can be a result of elevated circulating hepcidin concentrations,
and has been reported in patients with acute-phase myocardial
infarction [42].
ID is often accompanied by anaemia, although both can ex-
ist independently and ID usually appears before the onset of
anaemia. It is important to differentiate anaemia from ID; al-
though ID is marked by the insufficiency of iron, anaemia is
defined by insufficient haemoglobin (Hb). ID that is independ-
ent of anaemia was reported to have a higher risk of death than
that dependent on anaemia [43,44]; it has been reported as an
independent predictor of mortality and is associated with disease
severity [45].
In recent years there have been several clinical trials to test
whether administration of intravenous iron could improve func-
tional parameters related to HF. One of the most well-known
studies includes the Ferinject Assessment in patients with IRon
deficiency and chronic Heart Failure (FAIR-HF). This involved
459 patients with ID and chronic heart failure of New York Heart
Association (NYHA) functional class II or III. The treatment
with intravenous ferric carboxymaltose over 24 weeks improved
NYHA functional class, functional capacity and quality of life in
terms of EuroQol-5 Dimension andKansas City Cardiomyopathy
Questionnaire with an acceptable side-effect profile [46]. A sim-
plified ferric Carboxymaltose evaluatioN on perFormance in pa-
tients with IRon deficiency in combination with chronic Heart
Failure (CONFIRM-HF) trial, which has enrolled 304 stable
symptomatic HF patients from 41 sites across nine European
countries, is currently in progress to confirm the efficacy and
safety of iron therapy using intravenous ferric carboxymaltose
solution in chronic HF patients with iron deficiency, as in the
FAIR-HF study [47]. Other clinical trials including the FERRIC-
HF (FERRIC iron sucrose in Heart Failure) [48] and IRON-HF
[49] trials have also shown encouraging results with iron therapy,
using intravenous iron sucrose in improving functional capacity
in HF patients with ID. Thus, ID can serve in many cases as a
promising therapeutic target for HF.
Furthermore, the importance of ID as a marker in the context
of HF and its assessment was highlighted and recommended by
the ESC [20]. As for anaemia, it has also been shown to have a
relatively high prevalence (37%) in patients with HF [50]. With
less oxygen availability during anaemia, the heart compensates
by increasing heart rate and stroke volume. Moreover, anaemia
has been reported to be an independent risk factor for adverse
outcomes in HF, in terms of both morbidity and mortality rates
[51–58]. Efforts have been made to restore Hb levels as a poten-
tial therapeutic approach to HF using erythropoietin-stimulating
agents (ESAs) and this resulted in improvements in exercise toler-
ance, peak V˙O2, N-terminus of the prohormone brain natriuretic
peptide (NT-proBNP) and left ventricular performance in patients
with HF [59]. However, some major clinical trials that evalu-
ated the effect of treating anaemia with the ESA darbepoetin α
for cardiovascular events or HF have consistently suggested that
darbepoetin α did not significantly improve HF outcomes. One of
the earlier trials was the STudy of AneMIa in Heart Failure Trial
(STAMINA-HeFT), which involved 319 patients with systemic
HF, left ventricular EF <40% and Hb level between 9.0 g/dl and
12.5 g/dl, inwhich they found a 1-year treatmentwith darbepoetin
α failed to associate with any significant clinical benefits [60].
The Trial to Reduce cardiovascular Events with Aranesp (darbe-
poetin α) Therapy (TREAT) was initiated in 2004 to provide
a robust estimate of the safety and efficacy of darbepoetin α
[61]. This event-driven study continued to grow until it reached
approximately 1203 patients with Type 2 diabetes, chronic kid-
ney disease (CKD) and anaemia, who have experienced primary
events, including the composite end-point of death, cardiovascu-
lar morbidity or the need for long-term renal replacement therapy.
TREAT initially showed that ESA treatment in diabetic and an-
aemic patients with CKD did not demonstrate clinical benefits in
terms of mortality, morbidity or quality of life [62]; instead, car-
diovascular risk was most strongly predicted by age, HF history,
and several other established renal and cardiovascular biomark-
ers [63]. In addition, most of these patients were able to maintain
a stable Hb level without having any long-term ESA therapy
[64], and long-term (2 years) ESA therapy to treat anaemia did
not confer significant benefits [65]. The most recent update from
TREAT suggests that the cardiovascular or non-cardiovascular
mortality rates, particularly those from sudden death and infec-
tion, were associated with lower baseline glomerular filtration
rate and higher protein/creatinine ratio in diabetic CKD patients
[66].
Another large-scale clinical trial, the Reduction of Events
with Darbepoetin α in Heart Failure (RED-HF) trial, was also
launched to evaluate the effect of darbepoetin α on mortality and
morbidity, and quality of life in patients with HF and anaemia
[67]. Over 2600 patients with NYHA class II–IV, EF 40% and
Hb between 9.0 g/dl and 12.0 g/dl were subcutaneously admin-
istered darbepoetin α or placebo until the primary end-point was
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met [67]. The RED-HF study, compared with other recent clin-
ical trials in HF, had patients who were older, with moderately
to markedly symptomatic HF and extensive co-morbidity [68].
The study showed that darbepoetin α did not significantly alter
primary or secondary outcomes, concluding that darbepoetin α
did not improve clinical outcomes in patients with systolic HF
and mild-to-moderate anaemia [69]. Thus, based on all available
evidence, it has been suggested that anaemia may serve only as a
surrogate marker rather than an end-point target in HF.
CELLULAR MECHANISMS THAT UNDERLIE
THE ASSOCIATION OF IRON AND
CARDIOMYOPATHY
Iron and oxidative stress
Free iron is highly-redox reactive and can participate in a redox
reaction that leads to the generation of reactive oxygen species
(ROS). ROS include not only a range of free radicals such as su-
peroxide radical anion (O2•−), carbonate radical anion (CO3•−),
hydroperoxyl radical (HOO•), hydroxyl radical (HO•), peroxyl
radical (ROO•) and alkoxyl radical (RO•), but also non-radicals
such as hydrogen peroxide (H2O2), hypochlorous acid (HClO)
and ozone (O3). Among them, H2O2 and O2•− are the major
ROS in living organisms and are continuously produced by cells
and must simultaneously be removed by antioxidant enzymes.
Neither H2O2 nor O2•− is a strong oxidizing agent, but the ex-
tremely reactive hydroxyl radical HO• can be produced on reac-
tion with iron or iron-containing molecules through the Fenton
reaction. H2O2 oxidizes Fe2+ to Fe3+, producing the hydroxyl
radical HO• and hydroxide ion OH− (eqn 1); Fe3+ is then re-
duced back to Fe2+ by another H2O2 molecule, forming a hy-
droperoxyl radical HOO• and a proton H+ (eqn 2), or by super-
oxide radical anion (O2•−) to produce oxygen (O2) (eqn 3). In
this way, iron acts as a catalyst to generate plentiful amounts of
ROS.
Fe2++ H2O2 → Fe3++ HO•+OH− (1)
Fe3++ H2O2 → Fe2++ HOO•+H+ (2)
Fe3+ + O2•− → Fe2++ O2 (3)
Although ROS have important physiological functions, e.g. to
combat invading pathogens, excess ROS can result in oxidative
stress that damages intracellular proteins, lipids and nucleic acids.
Indeed, specific parts of the genome were found to be damaged
by the Fenton reaction, and are termed ‘genomic sites vulnerable
to the Fenton reaction’ [70]. Ferroptosis, as the name implies, is a
recently identified form of cell death that is morphologically, bio-
chemically and genetically distinct from apoptosis and necrosis,
and is found to depend on intracellular iron; it can be preven-
ted by iron chelators and antioxidants [71]. The use of the iron
chelator desferrioxamine has demonstrated significant reduction
of neutrophil-mediated free radical production and amplification
of the inflammatory response during cardiopulmonary bypass in
humans [72] and in in vivo studies [73–75]. In summary, iron can
potently enhance oxidative stress and consequently contribute to
cardiomyopathy.
Iron and mitochondrial dysfunction
In eukaryotic cells, mitochondria are themain consumers of intra-
cellular iron [76]. With mitochondria being the respiratory centre
of the cell, plentiful oxygen can rapidly react with unregulated
free iron to produce ROS. To avoid ROS-induced damage, mi-
tochondrial iron level and homoeostasis are tightly regulated by
different transport, storage and regulatory proteins [77]. Through
different biosynthesis pathways, iron is transferred in the mito-
chondria to its bioactive forms, haem and iron–sulfur cluster
(ISC). MitoNEET is an ISC-containing protein tethered to the
outer mitochondrial membrane that facilitates transfer of iron
into the mitochondria [78]. Not only does it play an essential
role in redox signalling [79], but also it dictates the metabolic
functions of mitochondria [78,80–82]. An increased level of mi-
toNEET can lead to accumulation of iron within the mitochon-
dria, which in turn results in dysfunction [83,84], a hallmark
of various diseases. MitoNEET is recognized as a target for the
thiazolidinedione class of anti-diabetic drugs [79,85], and its
genetic manipulation was shown to have striking anti-diabetic ef-
fects [86]. Mitochondrial ferritin stores and supplies iron within
the mitochondria. Its expression is restricted to highly metabol-
ically active cells such as cardiomyocytes, in order to supply iron
when demand is increased during active respiration or intense
metabolic activities. Frataxin is another mitochondrial protein
that handles iron in the mitochondrial matrix assembling ISC
[87]. It can act either as a chaperone for ferrous iron or as an iron
storage protein that can mineralize iron as ferrihydrite. There
is great interest in improving mitochondrial dysfunction as a
potential therapeutic approach for HF [88,89], and the underap-
preciated contribution of iron homoeostasis is worthy of more
consideration.
Iron and endoplasmic reticulum stress
Various pathophysiological situations can elevate stress in the
endoplasmic reticulum (ER). One of the major functions of the
ER is proper protein folding, and accumulation of misfolded
proteins can normally be relieved by cellular responses such as
ER-associated protein degradation (ERAD) and unfolded protein
response (UPR). These ER stress responses are important defence
mechanisms when the amount of unfolded protein exceeds the
folding capacity of the ER [90]. ER stress has been strongly im-
plicated in cardiovascular disease, e.g. ER stress can lead to car-
diomyocyte death in vivo and ex vivo [91], and in patients with
HF [92]. Interestingly, it was suggested that ER stress may be
cardioprotective during constriction-induced hypertrophy [93],
perhaps by inducing compensatory cellular mechanisms such as
autophagy (see below). Similarly, ER stress induction protec-
ted cardiomyocytes from oxidative damage [94]. Iron overload-
induced ER stress was shown in vivo in hearts under acute and
chronic conditions [95], and had been demonstrated in other tis-
sue types, including neurons [96] and liver [97]. In reverse, ER
stress can modulate iron metabolism. Hepcidin, as mentioned
above, degrades the iron efflux transporter FPN, thus leading to
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a systemic hypoferraemic environment. ER stress was found to
induce hepcidin expression [98]; the UPR signalling pathway
was further shown to increase the transcription of FPN and fer-
ritin [99]. Thus, based on available evidence, ER stress and iron
homoeostasis appear to have a reciprocal relationship such that
they can tightly regulate each other. ER stress and UPR-related
proteins will serve as interesting targets for future clinical studies.
Iron and autophagy
Macroautophagy (hereafter referred to as autophagy) is an in-
tracellular degradation system that involves the sequestration
of cytoplasmic components within a double-membrane vesicle
termed an ‘autophagosome’, in which the cargo content is de-
graded by the acidic hydrolases on fusion with a lysosome [100].
It has a wide variety of physiological and pathophysiological
roles including energy homoeostasis, cell survival and host de-
fence against pathogen invasion [101].
In the heart, autophagy typically occurs at low levels, yet it
is nevertheless important in maintaining cellular homoeostasis
under normal conditions. Autophagy is typically up-regulated in
times of stress, e.g. during ischaemia/reperfusion, pressure over-
load and cardiac toxicity induced by chemicals such as the ath-
racycline doxorubicin [102]. Although increased autophagy can
promote cell survival by degrading damaged organelles, such as
mitochondria and protein aggregates, to recycle catabolites and
maintain ATP production, either excess or lack of autophagy can
result in cell death and cardiac dysfunction. Thus, the role of
autophagy can often appear controversial between different stud-
ies when different degrees of autophagy, time course and patholo-
gical conditions being studied have led to variable observations.
In vivo data have shown that expression of multiple autophagy-
related genes was altered in IOC, possibly contributing to cardiac
diastolic dysfunction [103].
Specifically, it is now appreciated that iron can regulate auto-
phagy and that autophagy has an important role in iron homoeo-
stasis. Nuclear receptor co-activator 4 (NCOA4) was recently
identified using quantitative proteomics as the cargo receptor
that mediates autophagy of ferritin, a process termed ‘ferritino-
phagy’. NCOA4 is required for the delivery of ferritin to the
lysosome; without NCOA4, cells are malfunctional in ferritin
degradation and this can result in a decreased bioavailability of
intracellular iron [104]. However, excessive ferritinophagy may
result in insufficient ferritin, thus reducing its buffering effect on
binding intralysosomal low-mass iron, and can lead to lysosomal
fragility and increased sensitivity to oxidative stress [105]. Ana-
lysis of autophagy in iron-associated cardiomyopathy is relatively
new with limited mechanistic and clinical studies; however, we
believe that this must be rapidly developed because it has great
potential as a therapeutic target.
REGULATION OF CARDIOMYOPATHY BY NGAL
Themaintenance of optimal iron levels in the body is largely con-
trolled and influenced by endocrine regulation, and this is likely
to be of major significance in cardiomyopathy. In this section,
we highlight the importance of NGAL in the regulation of iron
homoeostasis and other possible mechanisms in the context of
cardiomyopathy (see Figure 2).
Neutrophil gelatinase-associated lipocalin
Lipocalins are a diverse family that generally bind small and
hydrophobic ligands, but can also bind soluble extracellular
macromolecules and specific cell surface receptors [106,107].
NGAL (human orthologue), also termed ‘lipocalin 2’ (Lcn2)
or ‘24p3’ (murine orthologue), is a 25-kDa secretory protein.
NGAL was originally identified as a component of neutrophil
granules that bound to and prevented the degradation of matrix
metalloproteinase-9, and was later found to be secreted by a num-
ber of cells including macrophages, endothelial cells [108], epi-
thelial cells [109], cardiomyocytes (Chan, Y.K., Sung, H.K. and
Sweeney, G., unpublished work), hepatocytes [110] and adipo-
cytes [111].
Epidemiology of NGAL and heart failure
In clinical settings, NGAL is now regarded as the best biomarker
for acute kidney injury, and is also emerging as a promising
biomarker for HF. The heart and kidney have numerous similar-
ities and their interdependent relationship makes it understand-
able that renal dysfunction often accompanies cardiac failure,
and that cardiac dysfunction is frequently seen with renal failure
[112]. Therefore, many biomarkers for kidney or tubular dys-
function, e.g. kidney injury molecule 1 (KIM-1) and N-acetyl-
β-D-glucosaminidase, rather than just serving as ameans to assess
kidney function, also provide insights into the cardiac prognosis
in patients with HF. However, unlike other renal biomarkers, the
NGAL level was not affected by diuretic withdrawal in patients
with chronic systolic HF [113], and administration of NGAL in
an animal model of acute ischaemic renal injury actually attenu-
ated tubular injury [114]. Moreover, in patients with chronic HF,
NGAL has been shown to be a more effective marker than cre-
atinine for the cardiorenal syndrome; NGAL could detect renal
injury earlier than creatinine, and was an independent and novel
risk predictor of mortality in chronic HF [115]. Indeed, the el-
evation of NGAL seen in HF, and its association with different
parameters of HF, has affirmed its potential as a HF biomarker.
First, serum NGAL predicted the outcome of HF, e.g. the GAL-
LANT (NGAL evaluationAlongwith B-typeNaTriuretic peptide
in acutely decompensated heart failure) trial concluded that, at the
time of discharge, plasma NGAL was a strong prognostic indic-
ator of 30-day outcomes in patients admitted for acute HF [116];
it independently predicted worse short-term prognosis in patients
with acute HF [117], and NGAL levels correlated well with HF-
related functional assessment parameters, including the 6-min
walk test [118]. Secondly, the CORONA (COntrolled ROsuvast-
atin multiNAtional trial in heart failure) study suggested that
NGAL was associated with the severity of HF [119], the elevated
serum NGAL in patients with acute post-myocardial infarction
and chronic HF was found to be associated with more adverse
outcome [120], and the NGAL level was shown to correlate with
HF severity and haemodynamic improvements after placement
of a ventricular assist device [121]. Thirdly, serum NGAL pre-
dicted severity of chronicHF in terms ofNYHAclassification and
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mortality in elderly patients [122], and plasma NGAL also pre-
dicted mortality in HF patients with or without CKD [123], and
in community-dwelling older adults independent of traditional
risk factors and kidney functions [124]. Clearly, there is strong
evidence for NGAL being a useful biomarker to assess severity,
prognosis and mortality in HF suggested by various individual
cohorts.
Possible mechanisms via which NGAL may mediate
cardiomyopathy
Iron transport
NGAL is most well known for its participation in innate im-
munity to limit bacterial growth by sequestrating iron. One way
to secure iron from the host by bacteria is by synthesizing and
secreting siderophores to extract iron from iron-containing com-
pounds such as Tf and lactoferrin; NGAL is secreted by the host
to tightly bind to bacterial catecholate-type ferric siderophores,
competing for iron and preventing such uptake [108]. NGAL
saturated with iron (holo-form) can increase intracellular iron
levels by transporting and then releasing iron into the cytoplasm;
in contrast, when NGAL is iron-free (apo-form), it can deplete
intracellular iron and transport it to the extracellular space via
its receptor NGAL-R [125]. Bacterial infection is often associ-
ated with hypoferrinaemia [126] which limits iron availability to
pathogens; accordingly, mice deficient in NGAL exhibit elevated
intracellular labile iron and lowered circulating iron levels [127].
Overall, NGAL, as an iron-trafficking protein, can be regarded
as an alternative to a Tf-mediated iron-delivery pathway [128].
Although limited studies are available, it is speculated that
circulating NGAL levels may reflect the body’s iron status, at
least in haemodialysis patients [129]. In haemodialysis patients,
it was found that plasma NGAL was significantly lower within
those who had ID, with TSat <20%, and that the level of NGAL
was positively correlated with circulating iron, TSat and fer-
ritin. NGAL was significantly increased after correction of ID
with intravenous iron administration [130]. Similar results were
also observed in another two studies supporting the potential use
of NGAL to identify iron deficiency in haemodialysis patients
[129,131]. Likewise, a lowered NGAL level was also recorded in
patients with iron deficiency anaemia [132] and, in patients with
chronic HF (both HFpEF and HFrEF), the significantly higher
circulating NGAL levels also correlated with higher serum iron
concentrations in the EPOCARES (ErythroPOietin in the CAr-
dioREnal Syndrome) study [133]. As circulating NGAL is often
recorded as significantly increased in patients experiencing HF
[117,120–123], and local NGAL production in the heart is also
increased significantly (Chan, Y.K., Sung, H.K. and Sweeney,
G., unpublished work) [120,134], we believe that it will be of
great interest to elucidate the role of NGAL in iron-associated
cardiomyopathy further. It is interesting that we previously iden-
tified NGAL leading to cardiomyocyte apoptosis by causing in-
tracellular iron accumulation [16]. Further mechanistic studies
are definitely warranted.
Pro-inflammatory actions of NGAL
As NGAL is involved in defending the host during bacterial
infection, it comes as no surprise that NGAL is regarded as
a pro-inflammatory cytokine. In the fourth Copenhagen Heart
Study, which involved more than 5000 patients and a follow-up
period of 10 years, it was shown that plasma NGAL strongly as-
sociated with all inflammatory markers investigated, including
high-sensitivity C-reactive protein, and total leucocyte and neut-
rophil count; increasedNGALwas also shown to correspond to an
increased risk of all-causemortality andmajor adverse cardiovas-
cular events [135]. It was suggested that NGAL expression and
secretion can be induced by interferon γ (IFN-γ ) and tumour nec-
rosis α (TNF-α), and that the transcription factors, signal trans-
ducer and activator of transcription 1 (STAT1) and nuclear factor
κB (NF-κB), were shown to bind to the human NGAL promoter
[136]. Likewise, in elucidating the inflammatory mechanisms of
NGAL with animal models, NGAL mRNA and proteins were
up-regulated on vascular injury in an NF-κB-dependent manner
[137]. NGAL can enhance cardiac inflammation by promoting
polarization of the macrophage pro-inflammatory M1 phenotype
[138]. Thus, a vicious cycle exists whereby NGAL can intensify
inflammation by inducing the expression of TNF-α and other
pro-inflammatory mediators [139]. It is of interest that preven-
tion of the clearance of NGAL from the circulation was shown
to promote vascular inflammation and endothelial dysfunction
[140]. In both HFpEF and advanced HFrEF, elevated systemic
and local inflammation with increased circulating TNF-α have
indispensable roles in disease pathogenesis [141]. It will be in-
teresting to explore how NGAL contributes to cardiomyopathy
in an inflammation-dependent and -independent manner.
CONCLUSION
Iron is a micronutrient that is integral to the function of many pro-
teins required in cells with high metabolic activity. It is involved
in regulating various cellular mechanisms including oxidative
stress, mitochondrial dysfunction, ER stress and autophagy, all
of which can contribute to cardiac dysfunction when perturbed.
NGAL, an adipokine that mediates iron transport through asso-
ciation with a siderophore, can increase or decrease intracellular
iron content based on the body iron store and its iron satura-
tion, making it a malleable factor in the maintenance of iron
homoeostasis. Indeed, elevation of NGAL is well documented in
various instances of HF with strong association to severity of HF
and resulting morbidity and mortality. Furthermore, NGAL is an
inflammatory biomarker that can be induced by endotoxaemia
and myocarditis. It can also contribute to atherosclerosis and in-
sulin resistance. Future work to fully characterize the association
of NGAL with iron overload and deficient cardiomyopathy, and
in particular to understand the precise mechanisms of NGAL ac-
tion contributing to cardiac dysfunction, are needed. These would
both validate the potential use of NGAL as a biomarker and allow
the development of novel therapeutic targets for the treatment of
heart failure.
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Review
Introduction
Iron is an essential trace element required for various critical pro-
cesses in the human body. The majority of the iron is used for eryth-
ropoiesis in the bone marrow, and any remaining iron can be used 
for other functions or stored as ferritin in various organs. Disturbed 
iron homeostasis is associated with various pathological conditions, 
including obesity. In this review, we will summarize the current lit-
erature pertaining to iron overload or deficiency in obesity and dis-
cuss endocrine regulatory mechanisms, with a focus on lipocalin-2 
(Lcn2) (Fig. 1). We also highlight current diagnostics and therapeu-
tics related to altered iron status in clinical settings. 
1. Iron transport
An average adult human contains approximately 3-4 g of iron1, of 
which the single largest component is the hemoglobin in erythro-
cytes. Approximately 90% of iron in the body is recycled by old and 
damaged erythrocyte phagocytosis with release of iron for new red 
blood cells synthesis. A small proportion of iron is lost in urine, feces 
and menstrual blood (1-2 mg/day), and this must be replaced via di-
etary iron intake. The recommended dietary allowance (RDA) for 
iron varies with gender and age, with an average of 8 mg/day re-
quired by an adult male and 18 mg/day and 8 mg/day for premeno-
pausal and postmenopausal women, respectively.1 Dietary iron, 
while coming in many forms, is usually classified as either heme or 
non-heme iron. Animals are the biggest source of heme iron whereas 
non-heme iron encompasses many forms of iron from both animal 
and plant sources. The latter can be better absorbed along with ascor-
bic acid or vitamin C.2 The duodenum is the primary site for iron ab-
sorption, where divalent metal ion transporter 1 (DMT-1), expressed 
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on the apical side of duodenal enterocytes, is responsible for the ab-
sorption of non-heme iron or inorganic iron. Ferric iron (Fe3+) is re-
duced by the adjacent duodenal cytochrome B (DcytB) to ferrous 
iron (Fe2+), which is the substrate of DMT-1 and is internalized in en-
terocytes. On the other hand, heme iron is likely absorbed through 
the transporter heme carrier protein 1 (HCP-1). Ferrous iron in the 
cytoplasm is either stored as ferritin, or transported to the basolateral 
membrane and released to the bloodstream via ferroportin (FPN). 
Hephaestin facilitates the conversion of ferrous iron to its ferric form, 
which is then bound to transferrin (Tf) and transported in circula-
tion. Tf contains two ferric iron binding sites and is approximately 
30% saturated with iron under physiological conditions. The high 
unsaturated apo-Tf confers a high buffering capacity to accommo-
date any increase in plasma iron and prevent build-up of non-trans-
ferrin bound iron (NTBI), which would otherwise promote oxidative 
injury.3 At extracellular pH (~7.5), iron-transferrin has a high affinity 
for transferrin receptor 1 (TfR1). The Tf-TfR1 complex is endocytsed, 
and ferric iron released from transferrin at the endosomal pH (~6.2). 
Ferric iron is reduced by Steap family reductases and transported 
across the endosomal membrane by DMT-1 to reach the ferrous pool 
in the cytoplasm. Ferrous iron can now be stored as ferritin, incorpo-
rated into heme for erythropoiesis, or exported by FPN to circulation 
to repeat the iron-transferrin cycle described. With FPN as the only 
known exporter of inorganic iron in mammalian cells, hepcidin, a 
liver-derived hormone that promotes FPN internalization and lyso-
somal degradation, plays a key role in iron trafficking and regulation.4
2. Iron & obesity 
1) Evidence of an association between obesity and iron levels
The first evidence of an inverse correlation between plasma iron 
and adiposity was reported more than 40 years ago.5 Subsequent 
work has validated this phenomenon, for example a study involving 
321 children and adolescents showed that low iron levels were pres-
ent in 38.8% of obese children, in 12.1% of overweight and only 4.4% 
of those of normal weight children.6 Another study that involved al-
most 10,000 children also reported a higher prevalence of iron defi-
ciency in children with increased BMI, concluding that children who 
were overweight are twice as likely to be iron-deficient than those 
who were not.7 Furthermore, obesity or excessive weight gain during 
pregnancy was found as an independent risk factor for iron deficien-
Fig. 1. An imbalance of iron homeostasis has been observed in obesity. Iron overload (blue box, right) and iron deficiency (ID; blue box, left) have both been reported and 
the latter can be either absolute or functional. Both iron overload and ID have been associated with development of complications which occur in obesity (green box, top). 
Various therapeutic strategies commonly used to correct iron overload or ID and restore normal iron homeostasis are shown (orange boxes). 
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cy in the newborn.8
2) Iron deficiency in obesity
Iron deficiency (ID) is the most common nutritional deficiency 
worldwide and affects more than one-third of the population.9 In 
particular, ID is observed at a high prevalence (between 30% to 50%) 
in patients with heart failure, and this is often associated with poorer 
clinical outcomes and greater risk of death, independent of anemia.10 
There are two distinct types of ID – absolute and functional ID.11,12 
Absolute ID reflects depleted iron stores even when iron homeosta-
sis mechanisms and erythropoiesis often remain intact. Absolute ID 
development in humans can result from inadequate dietary iron in-
take, impaired gastrointestinal absorption/transport, drug interac-
tions and gastrointestinal blood loss.11 In contrast, in functional ID 
iron homeostasis is malfunctional and this renders cells and tissues 
with an inadequate iron supply despite normal whole body iron stor-
age. For example, iron may be trapped inside cells, especially of the 
reticuloendothelial system, and thus be unavailable for cellular me-
tabolism.
Serum ferritin, a biomarker that is used to reflect iron store, was 
found enhanced in obese subjects.13 Yet, ferritin is an acute phase 
protein that is elevated during inflammation that does not corre-
spond to iron store, and it was suggested that correction to inflam-
mation should be made if this parameter was to be used to reflect 
iron deficiency.14 Soluble transferrin receptor (sTfR), on the other 
hand, should be preferably used as it is not an acute-phase reactant 
and is not dynamically affected by the confounding pathologies in 
obesity.15 When iron delivery to target tissues does not meet the met-
abolic demand, expression of TfR increase, leading to a consequent 
increase in circulating sTfR. Thus, sTfR reflects tissue iron demand 
and has been found to be significantly higher in obese subjects.16 
Thus, taking transferrin saturation into account will give a better in-
dication to the type of ID present. In that sense, absolute ID is de-
fined when serum ferritin is lower than 100 μg/L, while functional 
ID is defined as a serum ferritin of 100-299 μg/L accompanied by a 
transferrin saturation less than 20%.12
3) Iron deficiency anemia
ID usually appears before the onset of anemia, yet anemia and ID 
can exist independently.17 As mentioned above, ID is related to iron 
insufficiency in regard to body demand, and can be defined with 
iron related parameters like ferritin and transferrin saturation; ane-
mia, on the other hand, is related to oxygen carrying capacity and is 
defined as a blood hemoglobin level less than 13 mg/dL and 12 mg/
dL in men and women, respectively.18 While ID anemia may be the 
most common form of anemia, there are different forms of anemia, 
such as those related to vitamin deficiency, chronic disease, bone 
marrow disease, or those that are inherited such as hemolytic and 
sickle cell anemia. In general, the main causes of anemia include de-
ficiency in iron, deficient production of erythropoietin (EPO) and 
resistance to endogenous EPO.19 EPO resistance may be initiated via 
the upregulation of proinflammatory cytokines that exert inhibitory 
effects on erythroid progenitor cells; act negatively on EPO receptors 
that result in their defective activation and decrease in numbers and 
elevate hepcidin, thus disrupting iron homeostasis, as well as neocy-
tolysis.19
Several theories have been proposed to explain why ID is associat-
ed with obesity. Firstly, there may be increased consumption of ener-
gy dense but nutrient poor foods with inadequate iron level.6 It was 
found that the diet of severely obese patients was unbalanced, with 
high calorie intake paralleled by insufficient micronutrient intake – 
only 66.2% of the severely obese patients had an adequate intake of 
iron.20 Secondly, obesity inherently translates to increased body mass 
and blood volume, thus a higher iron requirement. The higher iron 
need was not met, despite greater food consumption, indicating 
obese subjects have higher susceptibility to ID.21 Another widely ac-
cepted mechanism is increased hepcidin production as a result of 
chronic inflammation in obesity.22 Indeed the iron abnormality in 
obesity is often characterized by hypoferremia, higher iron body 
store, lower iron bioavailability and high to normal concentration of 
serum ferritin that mimics anemia of chronic inflammation.23 In the 
obese state, cytokines such as IL-624 and leptin25 increase and elicit 
upregulated hepatic gene expression and production of hepcidin, 
such that iron release from macrophages, hepatocytes and entero-
cytes were blocked, resulting in a functional ID. Mice fed with high 
fat diet for 24 weeks were shown to display increased hepcidin ex-
pression in adipose tissue.26 While both liver and adipose hepcidin 
mRNA expressions were increased during obese states, the hepatic 
expression was ~700 times greater than that of the adipose tissue and 
is thought to be primarily responsible for the elevated circulating 
hepcidin levels.27 Moreover, mRNA and protein expression of the 
membrane bound hemojuvelin, which can stimulate hepcidin ex-
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pression through the bone morphogenetic protein (BMP) pathway, 
was found to be high in adipose tissue from obese individuals.28 In-
deed, this was positively correlated with hepcidin expression levels.28 
Obesity has long been viewed as a major contributor to the develop-
ment of insulin insensitivity and type 2 diabetes and although many 
mechanisms have been proposed29, the role of iron may be underes-
timated. Iron was found to interfere with insulin action in the liver, 
such that ferritin levels correlate positively with blood glucose and 
fasting serum insulin30 and negatively with insulin sensitivity.31 Re-
ciprocally, insulin was also shown to cause rapid stimulation of iron 
uptake by fat cells and hepatocytes.32
3. Iron overload 
Iron overload is diagnosed when plasma transferrin saturation is 
greater than 55% and serum ferritin more than 200 μg/L or 300 μg/L 
for women and men, respectively.33 Accumulation of iron in tissues 
may occur via increased iron absorption from the gastrointestinal 
enterocytes (hemochromatosis); excess exogenous iron intake such as 
by dietary supplements, or blood transfusions (hemosiderosis). While 
obesity is primarily associated with ID, it was recently proposed that 
obesity was a potential consequence of increased availability of iron 
supplement and fortification in the last several decades.34 Iron over-
load, without direct evidence as a cause or result of obesity, is associ-
ated to many obesity-related metabolic conditions. For example, iron 
overload was shown to cause insulin deficiency in ob/ob mice of type 
2 diabetes, and upon feeding an iron restricted diet or iron chelator, 
insulin sensitivity and beta cell functions was significantly in-
creased.35 An early initiation of removal of iron through phlebotomy 
in patients with hereditary hemochromatosis, an autosomal disorder 
involving mutation of specific genes involved in iron metabolism that 
leads to increased gastrointestinal absorption, was shown effective in 
ameliorating defective insulin secretion.36
1) Iron and bacterial infection
Besides being essential in maintaining daily metabolic functions, 
iron is also a key regulator of host-pathogen interactions at times of 
infection. Iron is one of the most important macronutrients required 
for microbial growth. Iron acts as the global regulator for many cellu-
lar and metabolic processes in microbes, including DNA synthesis, 
electron transport system, heme formation and oxygen transport.37 
The competition for iron between microbes and the human host is a 
crucial factor for the success of bacterial invasion. Bacteria can ac-
quire iron from the host by either synthesizing high iron affinity 
binding compounds such as siderophores, or directly capturing iron 
from iron binding proteins such as transferrin or ferritin. In defend-
ing the battle over iron, factors such as lipocalin-2 (Lcn2; also called 
siderocalin, 24p3, neutrophil gelatinase associated lipocalin [NGAL]) 
are secreted by the host to sequestrate siderophores and thus limit 
bacterial growth.38 Lcn2 is internalized into bacterial infected cells, a 
process mediated by its putative receptor 24p3R or megalin, where it 
then intercepts bacterial siderophores and trafficks them to extracel-
lular space. Lcn2 helps to supply iron for non-bacteria infected cells of 
the host, the Lcn2:mammalian siderophore-iron complex binds to 
24p3R, and is endocytosed to the intracellular space then releases 
iron.39 Interestingly, an increase in circulating Lcn2 is not only seen in 
acute immune response, but is also regarded as a biomarker for cardi-
ac disease and other features of metabolic syndrome.40,41
4. Endocrine regulation of iron levels in obesity 
Iron homeostasis, especially in obesity, is controlled to a large ex-
tent by the endocrine system. Here we will highlight and discuss the 
importance of Lcn2 and hepcidin in iron regulation.
1) Lipocalin-2 (Lcn2) 
Lipocalins are a diverse family that generally bind small and hy-
drophobic ligands, but can also bind soluble macromolecules and 
specific cell surface receptors.42 Lcn2 is a 25 kDa secretory protein 
predominantly expressed in adipose tissue and plays an important 
role in innate immunity and inflammation, including defense against 
bacterial invasion by sequestering iron, although more widespread 
actions in metabolic diseases are now emerging.41
Of particular importance here, Lcn2 is crucial in maintaining iron 
homeostasis during infectious conditions such as endotoxemia or 
myocarditis. Dysbiosis of the gut microbiota has been found in vari-
ous disease states, including obesity.43 In such cases, gut microbial 
diversity tends to decrease with a relative increase of Gram negative 
bacteria. Gut epithelial integrity is also disrupted, increasing the 
chances of bacteria and bacterial products leakage to the circulation, 
and thus endotoxemia. It has been postulated that increased circu-
lating LPS concentrations are sufficient to dysregulate the inflam-
matory status and initiate the onset of obesity and insulin resis-
tance.44 Indeed, LPS can induce increases in systemic Lcn2 by 150 
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fold within 24 hours.45 Lcn2 deficient mice were shown to have de-
layed LPS-induced hypoferremia in induced sepsis, indicating a role 
for Lcn2 in limiting circulating iron levels by enhancing intracellular 
iron content during inflammatory states. Mice deficient in Lcn2 also 
had exacerbated endotoxin-induced sepsis, increased immune cell 
apoptosis and increased mortality.45 MyD88-dependent signaling is 
required for the induction of Lcn2 and iron sequestration to main-
tain the hypoferric response during endotoxemia.46 Thus, Lcn2 can 
act as an influencer for the development of endotoxemia and derived 
metabolic disease by its effect on LPS. 
As indicated above, elevated Lcn2 levels are associated with obesity 
and insulin resistance. In studies of diabetic patients, it was found that 
serum Lcn2 concentration significantly associated with fasting tri-
glycerides and LPS binding protein, acutely increased after fat admin-
istration and associated with fasting insulin and homeostasis model 
assessment of insulin resistance (HOMA-IR).47 Similarly, serum level 
or adipose tissue Lcn2 content was found to be elevated in overweight 
pregnant women and associate with several insulin resistance mark-
ers including HOMA-IR, fasting plasma insulin and glucose.48 Gene 
and protein expression of Lcn2 increased in visceral adipose tissue of 
obese compared to lean subjects.49 Inversely, weight loss caused a sig-
nificant reduction of circulating Lcn2 in overweight/obese women 
with polycystic ovary syndrome.50
One established mechanism via which Lcn2 leads to obesity in-
duced insulin resistance may be its capacity to stimulate the expres-
sion of 12-lipoxygenase, an enzyme that metabolizes arachidonic 
acid, and TNFα in adipose tissue.51 We propose that Lcn2 can also 
alter iron homeostasis in adipose tissue, particularly in macrophages, 
and that this may contribute to iron overload in adipose tissue. As in-
dicated above, obese adipose tissues are marked by infiltration and 
accumulation of macrophages with a M1, or proinflammatory, phe-
notype. When comparing to the nonpolarized M0 macrophages, M1 
macrophages had repressed ferroportin and induced H-ferritin gene 
expression that promoted iron sequestration in the reticuloendothe-
lial system.52 On the contrary, M2 macrophages that possess an anti-
inflammatory profile had upregulated ferroportin as well as down-
regulated H-ferritin and heme oxygenase that enhanced efficient 
FPN- mediated iron export.52 Moreover, it was shown that in obesity, 
the percentage of adipose tissue macrophages rich in iron was de-
creased due to impaired capacity to handle iron, and this coincided 
with adipocyte iron overload in obese mice.53 Lcn2 can have differ-
ent effects on macrophages depending on the physiological condi-
tion. For example, Lcn2 can amplify M1 polarization in brain mi-
croglial cells54, but can also deactivate macrophages and exacerbate 
bacterial pneumonia.55 To our knowledge, the role of Lcn2 on the 
iron homeostasis of adipose tissue macrophages in obese states has 
not yet been studied. We hypothesize that the elevated Lcn2 in 
chronic inflammatory states hampers iron metabolism in macro-
phages in adipose tissue, and potentially other tissues, and this is as-
sociated with iron-induced insulin resistance.
2) Hepcidin
Hepcidin is a systemic iron-regulatory hormone that is primarily 
produced in liver, but also in other tissues including heart, adipo-
cytes and macrophages.56-58 It functions to maintain a stable iron 
concentration through the degradation of the cellular iron exporter 
– FPN. FPN is found in duodenal enterocyptes and thus increased 
hepcidin will limit dietary iron absorption. Hepcidin is abundantly 
expressed in reticuloenothelial macrophages and is particularly im-
portant in regulating iron concentration in liver, spleen and bone 
barrow. While body iron content and hematopoiesis are the princi-
pal endogenous regulators of hepcidin synthesis59, inflammation 
also acts as a pathological regulator.60 LPS, IL-6 and leptin are also 
direct stimulants of hepcidin secretion.25 Moreover, as mentioned 
earlier, hepcidin can be upregulated by BMP. Increased expression of 
hemojuvelin, a co-receptor of BMP, associated with increased hepci-
din expression in adipocytes in obesity.28 As FNP on adipocytes61 is 
internalized and degraded by hepcidin, the efflux of iron is reduced, 
leading to iron overload in adipocytes.62 Iron overloaded adipocytes 
can induce dysfunctional endocrine regulation, with one important 
example being a reduction in adiponectin expression.61
5. Iron diagnostics and therapeutics
1) Current diagnostics for iron status - Serology
There are several blood tests that reflect the amount of iron in the 
body; ferritin level, iron level, total iron binding capacity (TIBC) and 
transferrin saturation.63 Blood ferritin levels usually are low in pa-
tients with ID anemia and are high in patients with hemochromato-
sis and other conditions that cause an increase in body iron levels. 
Since ferritin can also be elevated in certain infections like viral hep-
atitis and other inflammatory conditions, an elevated ferritin level 
alone is not sufficient to accurately diagnose chronic iron overload.64 
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Serum iron, TIBC and transferrin saturation are often performed 
together instead. TIBC is a measure of the total amount of iron that 
can be carried in serum by transferrin, a protein that carries iron in 
serum from one anatomical location to another. Transferrin satura-
tion value is calculated by dividing serum iron by TIBC, thus reflect-
ing the percentage of the transferrin that is being used to transport 
iron. In healthy individuals the transferrin saturation is between 20 
and 50 percent.65
2) Therapeutics - iron deficiency
ID anemia describes a scenario where iron stores have been de-
pleted and the body is unable to maintain levels of haemoglobin in 
the blood. Too little iron can interfere with these vital functions and 
lead to morbidity and death. ID patients exhibit symptoms of weak-
ness, fatigue, glossitis, stomatitis, Plummer Vinson syndrome, pica 
and restless legs syndrome while extreme cases lead to morbidity 
and mortality.66
Oral iron supplementation is commonly recommended as a front 
line treatment of ID. There are two types of iron supplements; fer-
rous iron is the most efficiently absorbed form and the majority of 
iron supplement pills contain ferrous iron in the forms of ferrous sul-
fate, ferrous fumarate, and ferrous gluconate.67 Absorption requires 
an acidic gastric environment and is therefore limited in patients re-
ceiving acid-suppression therapy. Hence, although oral iron supple-
ments are commonly used, poor absorption and gastrointestinal in-
tolerance in some individuals limit their use.68 Blood transfusion is 
useful in more severely ill patients with chronic ID and Hb less than 
7 g/dL.69,70 However, blood transfusion is not recommended as long-
term therapy due to risks such as infection and iron overload.70 Intra-
venous iron therapy has been adopted in management of patients 
with ID and although animal studies showed a resultant increase in 
indicators of oxidative stress, this has not been observed in clinical 
trials.69 Another option for treatment of anemia is erythropoietin 
stimulating agents (ESAs).71 As an example, meta-analysis of 11 ran-
domized clinical trials, 9 placebo-controlled and 5 double-blinded, 
of a total of 794 patients with anemia and heart failure treated with 
ESAs concluded that there were improvements in functional capacity 
and a reduction in clinical events. However, another study did not 
demonstrate an impact of ESAs on heart failure in anemia.72 Fur-
thermore, ESAs can cause serious side effects, including blood clots, 
and they are now approved only for treating severely ill anemic pa-
tients, such as those with cancer or chronic kidney failure.
3) Therapeutics - iron overload
A common treatment for iron overload in otherwise healthy indi-
viduals consists of iron removal via regularly scheduled phleboto-
mies.12 When first diagnosed, phlebotomies may be performed once a 
week until iron levels can be brought to within normal range. Once 
iron and other markers are within the normal range, phlebotomies 
may be scheduled every other month or every three months depend-
ing upon the patient’s rate of iron loading. Some patients treated with 
phlebotomy are given erythropoietin to maintain erythropoiesis.72 
However, phlebotomies are not recommended for many patients, 
such as those with Hb level <10 g/dL, who may develop symptoms of 
anemia after phlebotomy. Instead, a second approach for removing 
iron, iron chelating therapy, is recommended for these individuals. 
Nevertheless, the decision to initiate chelation therapy depends upon 
several factors, including the patient’s overall health, hematologic val-
ues and tissue iron level determination. There are three main iron 
chelating drugs in clinical use at present and these are mainly used for 
the treatment of transfusional iron overload, namely deferoxamine 
(DF), deferiprone (L1) and deferasirox (DFRA).73 DF binds with iron 
in the bloodstream and enhances its elimination via urine and faeces. 
Typical treatment for chronic iron overload requires subcutaneous 
injection over a period of 8-12 hours daily. The other two, L1 and 
DFRA are newer iron chelating drugs that are licensed for use in pa-
tients receiving regular blood transfusions to treat thalasaemia.74 
Beneficial aspects of iron chelation therapy have been shown, such as 
prevention of complications and early death in iron loading anemia 
in patients with thalassaemia.74
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Abstract: Lipocalin-2 (also known as NGAL) levels are elevated in obesity and diabetes yet relatively little is known 
regarding effects on the heart. We induced pressure overload (PO) in mice and found that lipocalin-2 knockout (LKO) 
mice exhibited less PO-induced autophagy and NLRP3 inflammasome activation than Wt. PO-induced mitochondrial 
damage was reduced and autophagic flux greater in LKO mice, which correlated with less cardiac dysfunction. All of 
these observations were negated upon adenoviral-mediated restoration of normal lipocalin-2 levels in LKO. Studies 
in primary cardiac fibroblasts indicated that lipocalin-2 enhanced priming and activation of NLRP3-inflammasome, 
detected by increased IL-1β, IL-18 and Caspase-1 activation. This was attenuated in cells isolated from NLRP3-
deficient mice or upon pharmacological inhibition of NLRP3. Furthermore, lipocalin-2 induced release of HMGB1 
from cells and NLRP3-inflammasome activation was attenuated by TLR4 inhibition. We also found evidence of 
increased inflammasome activation and reduced autophagy in cardiac biopsy samples from heart failure patients. 
Overall, this study provides new mechanistic insight on the detrimental role of lipocalin-2 in the development of 
cardiac dysfunction.
Keywords: Lipocalin-2, pressure overload, NLRP3 inflammasome, HMGB1, toll-like receptor (TLR)-4
Introduction
Heart failure (HF) incidence is increased in 
patients with obesity and diabetes and inflam-
mation is one underlying mechanism [1]. 
Lipocalin-2 (LCN2) is a proinflammatory adipo-
kine which is elevated in obesity and diabetes 
[2] and clinical studies have also established 
strong positive correlations between circulating 
LCN2 and various types of HF [3]. Thus, LCN2 
has been proposed as an important contributor 
to the pathophysiology of HF and potentially a 
useful biomarker for HF. Neutrophils are a 
major source of LCN2 which is also known 
as neutrophil gelatinase-associated lipocalin 
(NGAL) [4]. Mice lacking LCN2 were first shown 
to exhibit an increased susceptibility to bacteri-
al infections due to lack of antibacterial innate 
immune response [5] and subsequently shown 
to be protected from obesity- and aging-associ-
ated insulin resistance, endothelial dysfunction 
and hypertension [6-9]. However, the precise 
mechanisms via which LCN2 can regulate the 
progression of HF remain to be resolved.
In contrast to the paucity of information on car-
diac effects of LCN2, the pathophysiological 
role of LCN2/NGAL in kidney dysfunction is 
much better understood and measurement of 
LCN2/NGAL has recently become established 
as a common clinical diagnostic test for acute 
kidney damage [10]. Inflammation, including 
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NLRP3 (nucleotide-binding domain, leucine-
rich-containing family, pyrin domain-contain-
ing-3) inflammasome activation, and autopha-
gy have recently been established as important 
mechanisms regulating cardiac dysfunction 
[11, 12] although their regulation by LCN2 is 
unclear. We have recently shown that LCN2 
attenuates cardiomyocyte autophagy [13].
We hypothesized that LKO mice would have 
less pressure overload-induced cardiac dys-
function than wild type (WT) and that reduced 
autophagy or elevated NLRP3 inflammasome 
activation may be potential mechanisms of 
action. To examine this, we induced cardiac 
pressure overload (PO) in WT and LCN2 knock-
out mice (LKO) ± restoration of normal circulat-
ing LCN2 levels using adenovirus (L2AV). We 
first examined functional outcomes using echo-
cardiography, then analyzed mechanisms via 
which LCN2 contributed to cardiac dysfunction 
by focusing on fibrosis, autophagy and NLRP3 
inflammasome activation in these animal mod-
els as well as in primary cells isolated from 
heart of WT and NLRP3-deficient mice.
Material and methods 
Animals, induction of pressure overload and 
analysis of cardiac function
Male WT and LKO mice aged eight weeks with 
C57BL/6J background were studied using pro-
tocols approved by the Animal Care Committee 
at York University and the Committee on the 
Use of Live Animals for Teaching and Research 
of the University of Hong Kong and all methods 
were performed in accordance with these 
guidelines and regulations. Pressure overload 
was induced by transverse aortic banding as 
described previously [14]. Briefly, surgery was 
performed on the transverse aortae of mice 
under general anesthesia (ip; xylazine 0.15 
mg/g; ketamine 0.03 mg/g) with a titanium 
microligation clip using banding calipers cali-
brated to a 27-g needle. Sham surgery was per-
formed as outlined above without the place-
ment of a ligation clip. The recombinant adeno-
virus for LCN2 (108 plaque-forming units) was 
injected via tail vein of mice one day prior to 
surgery to achieve normal circulating levels [7] 
and echocardiography was performed using 
the Vevo2100 system (Visual Sonics) [15]. Sera 
were collected every week from tail vein and 
hearts were harvested at the ends points (four 
weeks). 
Cardiac biopsy from human subjects with or 
without heart failure (HF) 
Patients with end-stage dilated cardiomyopa-
thy (DCM) who met institutional criteria for 
LVAD device implantation as a bridge to trans-
plant or as destination therapy at the New York 
Presbyterian-Columbia Campus were included 
in this study and processed as previously 
described [14, 16]. Cardiac biopsy tissue used 
in this study (n=5) were all male, aged 
41.0±21.4 years and HF etiology ischemic or 
diabetic cardiomyopathy. All tissue obtained at 
LVAD implantation represented a decompen-
sated heart failure state. Normal patients were 
subjects with no known cardiopulmonary dis-
ease whose organs were listed but were unable 
to be placed at the time of organ recovery for 
heart transplantation and who consented to 
tissue for research purposes by the New York 
Organ Donor Network were included in this 
study. This study met all institutional guidelines 
of the Institutional Review Board of Columbia 
University and New York State organ donation 
guidelines regarding the use of clinical data, 
ethical treatment of patients adhering to the 
Declaration of Helsinki principles, and procure-
ment of tissue for research. All subjects were 
recruited at the New York Presbyterian Hospital-
Columbia University campus between 2008-
2014, and informed consent was waived for 
use of discarded, de-identified tissue.
Analysis of cardiac function using echocar-
diography
Echocardiography was performed using the 
Vevo2100 system (Visual Sonics, MS550D 
transducer) as previously described [15]. 
Cardiac systolic functions of ejection fraction, 
fractional shortening and strain rate calcula-
Table 1. Genes detected in fibrosis PCR array
Col1a1 Mmp8
Col3a1 Mmp9
Col4a1 Mmp13
Timp1 Mmp14
Timp2 Gapdh
Timp3 Actb
Mmp1a MGDC
Mmp2 PPC
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tion were based on M-mode images of the 
parasternal short-axis view at papillary level. All 
parameters were averaged over at least 3 car-
diac cycles for analysis.
Histological analysis of cardiac structure
Animals were sacrificed and hearts were iso-
lated and perfused with ice-cold cardioplegic 
solution (30 mM KCl in PBS) and stored in 10% 
neutral-buffered formalin 24 hours for further 
processing. Paraffin sections (5 μm) were pre-
pared for trichrome staining and immunostain-
ing using antibodies against HMGB1, desmin, 
vimentin or α-SMA as described previously [17]. 
Immunofluorescent analysis in cultured cells
Rat neonatal fibroblast cells were cultured in 
12-well plates, after treatment with or without 
murine recombinant LCN2 (1 μg/ml) protein for 
48 hours. Cells were fixed in 4% paraformalde-
hyde (PFA) for 15 minutes, quenched with 1% 
glycine for 10 minutes, and permeabilized with 
0.1% Triton X-100 for one minute. After blocking 
with 3% BSA, cells were incubated with murine 
LCN2 (1:200) and HMGB1 primary antibody 
(1:100) overnight at 4°C, and incubated with 
Alexa Fluor 488 goat anti-rabbit IgG (Life 
Technologies) at 1:1000 for one hour at room 
temperature. Images were taken using a 60 
objective with confocal microscope (Olympus, 
BX51).
Transmission electron microscopy (TEM)
TEM was performed as described previously 
[15]. In brief, LV myocardium was cut to 1 
mm3 and fixed with 2.5% glutaraldehyde in 
0.1 M cacodylate buffer (pH 7.4) overnight at 
4°C. After brief washing, the specimens were 
post-fixed in 1% osmium tetroxide, dehydrat-
ed, embedded in epoxy resin, and polymer-
ized overnight at 60°C. Ultra-thin sections 
(100 nm) were cut and post-stained with 
Reynold’s lead citrate and uranyl acetate to 
increase contrast. Sections were viewed and 
photographed using a P FEI CM100 TEM and 
Kodak Megaplus camera. 
Western blot analysis
Heart tissue was snap frozen and then lysed 
in modified RIPA buffer by the Tissue Lyser II 
(Qiagen) for two minutes at full speed. The 
lysates were then centrifuged at full speed for 
Table 2. Sequences of QPCR primers
Gene Name Primer Sequences
Murine Forward 5’CAGAACATCATCCCCTGCATC3’
Gapdh Reverse 5’CTGCTTCACCACCTTCTTGA3’
Murine Forward 5’GGTCACCCATGGCACCATAA3’
Nfκb1 Reverse 5’AGCTGCAGAGCCTTCTCAAG3’
Murine Forward 5’GCCACCTTTTGACAGTGATGAG3’
Il1β Reverse 5’AAGGTCCACGGGAAAGACAC3’
Murine Forward 5’GACACGAGTCCTGGTGACTT3’
Nlrp3 Reverse 5’GTCCACACAGAAAGTTCTCTTAGC3’
Murine Forward 5’AACGCCATGGCTGACAAGA3’
Casp1 Reverse 5’TGATCACATAGGTCCCGTGC3’
Murine Forward 5’CTG CGC TTG CAG AGA TTA AA3’
Tgfβ1 Reverse 5’GAA AGC CCT GTA TTC CGT CT3’
Rat Forward 5’ATGTGCCGGACCTTGGAAG3’
Gapdh Reverse 5’CCTCGGGTTAGCTGAGAGATCA3’
Rat Forward 5’CACTGCTCAGGTCCACTGTC3’
Nfkb1 Reverse 5’CTGTCACTATCCCGGAGTTCA3’
Rat Forward 5’CACCTCTCAAGCAGAGCACAG3’
Il1β Reverse 5’GGGTTCCATGGTGAAGTCAAC3’
Rat Forward 5’CCAGGGCTCTGTTCATTG3’
Nlrp3 Reverse 5’CCTTGGCTTTCACTTCG3’
Rat Forward 5’AGGAGGGAATATGTGGG3’
Casp1 Reverse 5’AACCTTGGGCTTGTCTT3’
10 minutes. Supernatants were harvested and 
quantified by BCA assay. Tissue lysates (30 or 
50 μg) were incubated with Laemmli sample 
buffer at 95°C for 10 minutes and then resolved 
by SDS-PAGE. After transferring to polyvinyli-
denedifluoride (PVDF) membranes, Western 
blotting was performed by incubating with anti-
bodies. The following antibodies were used for 
immunoblot analysis: LC3-II (1:1000), BECLIN-1 
(1:1000), Caspase-1 (1:1000), HMGB1 (1: 
1000), phospho-NF-κB p65 (Ser536) (1:750), 
NF-κB p65 (1:750), GAPDH (1:2000) and β-actin 
(1:2000) from Cell Signaling; p62 (1:1000) 
from BD Transduction Laboratories; LCN2 
(1:2000) from Antibody and Immunoassay 
Services; IL-1β (1:1000) from R&D systems. 
IL-18 (1:1000) from MBL Life science. After 
incubation with secondary antibodies, the imm- 
une complexes were detected with enhanced 
chemiluminescence (ECL) reagents from GE 
Healthcare (Uppsala, Sweden).
Quantitative reverse-transcription polymerase 
chain reaction
The custom fibrosis PCR array was purchased 
from SABiosciences-61 (QIAGEN Inc.). Total 
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RNA was isolated from heart tissues or cultured 
mice and rat fibroblasts using TRIzol® Reagent 
according to the manufacturer’s instructions, 
and purified using the RNeasyMinElute Cleanup 
Kit to attain an A260/A280 ratio between 1.9 
and 2.0. First-strand cDNA, synthesized from 
0.5 μg RNA using the RT2 First Strand kit, was 
used in a custom PCR array comprising of 
96-well plates pre-coated with primers listed in 
Table 1. Quantitative real-time PCR was con-
ducted using a Chromo4™ Detection system 
(Bio-Rad Laboratories Canada Ltd., Mississ- 
auga, ON, CA) according to cycling conditions 
outlined by the PCR array manufacturer. Data 
were analyzed using RT2 Profiler PCR Array Data 
Analysis software (Version 3.5; QIAGEN Inc.) 
and normalized to GAPDH mRNA expression. 
For other genes detected listed in the Table 2, 
they were analyzed through real-time PCR using 
the following cycling conditions: 95°C/15 min, 
followed by 35 cycles of [95°C/30 sec, 55°C/30 
sec, 72°C/30 sec], then 72°C/10 min. Melting 
curve analysis was used to ensure primer spec-
ificity. Data were then analyzed using the 2-ΔΔCt 
method.
Cultured adult fibroblasts from mice, adult and 
neonatal rat fibroblasts from rats
Mice (male, 8 weeks) or rat heart (Wistar rats 
male, 6 months) was isolated from anesthe-
tized animal and perfused with Ca2+ free 
K-H buffer for 6 minutes and then with 
LiberaseBlendyzme 4 (Roche) contained K-H 
Figure 1. Inflammasome activation is attenuated in LKO mice challenged with PO. (A) IL-1β levels were determined 
by ELISA in serum collected from WT and LKO mice subjected to either sham or PO surgery. (B) qPCR was per-
formed for gene expressions of inflammasome markers (Caspase-1, IL-1β, NLRP3 and NF-κB) in heart tissues col-
lected from WT and LKO mice subjected to either sham or PO surgery. (C, D) Western blotting and densitometric 
quantifications was performed to analyze HMGB1 protein levels in the heart tissues from the above treated mice. 
(E) Immunofluorescence was performed for HMGB1 in heart tissue sections collected from WT and LKO mice sub-
jected to either sham or PO surgery. Protein levels of LCN2 in heart tissue (F), densitometric quantification (F, left 
panel) and LCN2 level in circulation (F, right panel) were determined by Western blotting and ELISA, respectively. (G) 
Western blotting was performed to examine the protein levels of inflammation markers (LCN2, HMGB1, NF-κB and 
Caspase-1) in heart tissue lysates from healthy human subjects (Con) or patients with HF, with quantification shown 
in (H). *, P<0.05 vs. WT Sham or healthy human subjects and, #, vs. LKO PO, n=5-6.
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buffer for 3 times (10 ml per heart for mice, 20 
ml per heart for rat). The hearts were perfused 
with 5% BSA K-H buffer before mincing. After 
stabilization for 3 hours, fibroblasts were stimu-
lated with LCN2 (1 μg/ml) for 24 hours. Hearts 
were collected from 1- to 2-day-old neonatal rat 
pups, promptly after euthanasia by decapita-
tion, and primary cultures of neonatal rat car-
diomyocytes were performed as described pre-
viously [17]. After stabilization for 24 hours, 
neonatal rat fibroblasts were stimulated with 
LCN2 (1 μg/ml) for 48 hours. Samples were col-
lected to examine the expression levels of 
HMGB1 by western blot analysis and mRNA by 
quantitative RT-PCR. 
Statistical analysis
All results were derived from at least three sets 
of repeated experiments. The statistical calcu-
lations were performed by one-way analysis of 
variance followed by Tukey’s multiple compari-
Figure 2. LCN2 deficiency protects against loss of mitochondrial morphology and autophagy flux disruption induced 
by PO. A: Mitochondria integrity was evaluated using TEM from heart tissue sections of WT and LKO (±L2AV) mice 
that had undergone either sham or pressure overload (PO) surgery. Autophagosomes were indicated by arrows. 
B: Autophagic flux was analyzed by examining the protein expression of P62, LC3-II and BECLIN-1 in heart tissue 
lysates from WT and LKO (±L2AV) mice that have undergone either sham or PO surgery. C: Densitometric quantifica-
tions of western blots in B. D: Autophagic flux was analyzed by examining the protein expression of P62, LC3-II, and 
BECLIN-1 in heart tissue lysates from healthy human subjects (Con) or patients with heart failure (HF). E: Densito-
metric quantifications of western blots in D. *, P<0.05 vs. WT Sham or healthy human subjects and, #, vs. LKO PO, 
n=5-6.
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son post-test using Prism version 5 (Graph- 
PadSoftware; San Diego, CA, USA). Independent 
t tests were performed when there are compar-
isons between two groups. All values are pre-
sented as means ± SD and where arbitrary and 
not absolute value were involved the final graph 
displays fold over control values. For all statisti-
cal comparisons, a P value less than 0.05 was 
accepted to indicate significant differences.
Results
PO-induced inflammasome activation is at-
tenuated in LKO mice
We examined NLRP3 inflammasome in WT and 
LKO (±LCN2 restoration using L2AV) mice four 
weeks after transverse aortic banding surgery. 
Serum interleukin (IL)-1β measurement by 
ELISA demonstrated increased IL-1β in WT 
and LKO+L2AV with PO, although IL-1β was 
increased in LKO, the magnitude of change 
under PO was greatly reduced (Figure 1A). 
Inflammasome-priming, measured via expres-
sion levels of caspase-1, NLPR3, IL-1β and 
nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) showed similar signifi-
cant increases in WT and LKO+L2AV after PO at 
the mRNA level (Figure 1B) [18]. Having shown 
that LCN2 positively regulates inflammasome 
activation in PO, we sought to decipher the 
mechanism of this action. NLRP3 inflamma-
some activation was previously shown to be 
regulated by the release of HMGB1 (high mobil-
ity group box chromosomal protein 1) from 
cells, after HMGB1-BECLIN-1 complex dissocia-
tion, via a mechanism involving toll-like recep-
tor (TLR)4-mediated signaling [19-21]. Both 
Western blotting of heart homogenates (Figure 
1C and 1D) and immunofluorescent detection 
in tissue sections (Figure 1E) demonstrated 
that HMGB1 was significantly decreased in WT 
but not LKO mice after PO. Under PO, restoring 
LCN2 in LKO mice with L2AV decreased cellular 
HMGB1 to amount similar as WT mice (Figure 
1E). After four weeks PO, a significant increase 
of LCN2 in both serum and heart tissue was 
detected in WT mice with PO (Figure 1F). In 
agreement with our mouse data, HMGB1 levels 
were significantly decreased in heart tissues of 
HF patients compared to healthy individuals 
(Figure 1G and 1H). Furthermore, cardiac con-
tent of LCN2, NF-κB and Caspase-1 were all sig-
nificantly increased in HF patients.
Figure 3. Development of PO-induced fibrosis is at-
tenuated in LKO mice. A: Masson’s trichrome staining 
of heart tissue taken from WT and LKO (±L2AV) mice 
four weeks following PO or sham surgery. Cardiomyo-
cytes are stained red, nuclei are stained black, and 
collagen is stained blue. B: Fibrosis PCR array was 
performed using heart tissues. Genes detected in this 
array are shown in Table 1. MMP-1, MMP-8, MMP-9 
are present. C: Fibroblast to myofibroblast differen-
tiation was assessed by co-staining with vimentin, 
α-SMA, and desmin in heart tissue sections from WT 
and LKO (±L2AV) mice that have undergone either 
sham surgery or PO. *, P<0.05 vs. WT Sham and, #, 
vs. LKO PO, n=4.
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LCN2 exacerbates mitochondrial deterioration 
and attenuates autophagic flux in response to 
PO 
Transmission electron microscopy indicated 
LCN2 deficiency greatly attenuated PO-induced 
mitochondria damage in cardiomyocytes, as 
shown by the presence of clear well-structured 
cristae in LKO mice before and after PO (Figure 
2A). This protective effect was partially lost 
with the administration of L2AV (Figure 2A). 
Transmission electron microscopy is a gold-
standard approach for analysis of autophagic 
structures, and our data indicated induction 
of autophagy in mice lacking LCN2 after 
PO-treatment (Figure 2A, arrow), with less 
observed in WT mice. Next, autophagic flux was 
evaluated by examining cardiac protein expres-
sion levels of P62, LC3-II, BECLIN-1. Western 
analysis showed increased protein expression 
of P62 and decreased LC3-II and BECLIN-1, 
suggesting less flux in WT versus LKO mice 
after PO (Figure 2B and 2C). Analysis of cardiac 
biopsy tissue samples obtained from human 
subjects with or without HF indicated increased 
P62 plus decreased LC3-II and BECLIN-1 levels 
(Figure 2D and 2E), indicative of less autopha-
gy when compared with control. It is conceiv-
able that signals such as reactive oxygen spe-
cies or mitochondria DNA released from dam-
aged mitochondria might be responsible for 
priming or activation of NLRP3 inflammasome 
[22, 23], whereas LCN-2 deficiency preserved 
mitochondria morphology and autophagic flux 
under PO.
LCN2 deficiency protects mice from PO-in-
duced development of fibrosis
Fibrosis is an established component of ven-
tricular remodeling in HF patients [14, 24]. Ma- 
sson’s trichrome staining revealed enhanced 
accumulation of collagen after PO in WT and 
LKO+L2AV, but not in LKO mice (Figure 3A). 
Assessing mRNA levels of fibrosis-related ge- 
nes showed matrix metalloproteinases (MMP)-
1, MMP-8 and TGF-β1 increased significantly 
after PO in WT and LKO+L2AV mice but not in 
LKO mice (Figure 3B). MMP-9 levels increased 
after restoring LCN2 in LKO with L2AV under 
both sham, and to a greater extent, PO condi-
tions (Figure 3B). Immunofluorescence staining 
showed that LKO mice were somewhat protect-
ed against PO-induced occurrence of vimentin-
positive fibroblasts (Figure 3C). Administration 
of L2AV to LKO mice negated these protective 
Figure 4. Temporal analysis of car-
diac dysfunction using echocardiog-
raphy after thoracic aorta banding 
or sham surgery. A: Ejection Fraction 
(EF); B: Fractional Shortening (FS); C: 
Circumferential systole strain rate; D: 
Circumferential diastole strain rate; 
E: Circumferential strain change 
percentage. *, P<0.05 vs. WT Sham 
and, #, vs. LKO PO, n=5-7. L2AV, li-
pocalin-2 adenovirus. LKO PO, lipo-
calin-2 knock-out mice with pressure 
overload surgery.
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effects; however, there was much less accumu-
lation of fibroblasts compared to WT mice with 
PO (Figure 3C). Immunostaining for smooth 
muscle actin (SMA) showed that there was no 
interstitial activation of myofibroblast after PO 
in all six groups, as expected from this model of 
mild PO (Figure 3C).
LCN2 deficiency protects mice from PO-in-
duced development of cardiac dysfunction
Cardiac function of WT and LKO (±LCN2 resto-
ration using L2AV) mice was evaluated by echo-
cardiography four weeks after transverse aortic 
banding surgery. Consistent with previous 
reports [9], LKO mice demonstrated a higher 
ejection fraction (EF) and fractional shortening 
(FS) compared to age-matched WT mice that 
showed significant PO-induced cardiac dys-
function (Figure 4A and 4B). This heart protec-
tive effect in LKO mice was abolished by admin-
istration of LCN2 (Figure 4A and 4B) as the 
basal level of EF and ES in LKO mice treated 
with L2AV was similar to WT mice (Figure 4A 
and 4B). Importantly, we validated the effec-
tiveness of adenoviral LCN2 delivery by show- 
ing that circulating LCN2 produced by L2AV 
reached a peak above normal level observed 
in WT mice one week after virus injection 
(Supplementary Figure 1) [7]. An inherent limi-
tation of this approach is that levels gradually 
decline after 2 and 4 weeks yet we did not per-
form a second adenovirus injection to avoid 
confounding effects from immune system acti-
vation and inflammation. As visualized in repre-
sentative short axis images of M-mode and 
speckle tracking echocardiography (Supple- 
mentary Figure 2), ventricular wall constriction 
and both systole (Figure 4C) and diastole 
(Figure 4D) circumferential strain rate in WT 
and LKO+L2AV mice under PO dropped signifi-
cantly four weeks after PO, but were preserved 
in LKO mice (Figure 4E; Supplementary Table 
1). PO induced increased LV mass and the 
response was similar in both genotypes and in 
LKO with LCN2 replenishment (Supplementary 
Figure 5. LCN2 treatment of rat neo-fibroblasts interrupts autophagic flux and induces inflammasome activation by 
releasing HMGB1. Rat neo-fibroblasts were isolated and treated with recombinant LCN2 (1 μg/ml) or control for 48 
hours. Immunofluorescence (A) and Western blotting (B) were performed to examine the localization and protein 
expression levels of HMGB1 fibroblasts and IL-18 and IL-1β in medium. Expression levels of inflammasome markers 
showed in the graph (C) were examined by qPCR. (D) Western blotting was performed to examine the protein levels 
of autophagic markers (LCN2, LC3-II, P62 and BECLIN-1) with quantification shown in (E). (F, G) Co-immunoprecipita-
tion (Co-IP) was performed in neonatal fibroblast cells to evaluate the binding status between BECLIN-1 and HMGB1. 
*, P<0.05, **, P<0.01 vs. corresponding control, n=3.
Lipocalin-2 regulates NLRP3 inflammasome
2731 Am J Transl Res 2017;9(6):2723-2735
Figure 3). In summary, these data indicate a 
detrimental role of LCN2 in the development of 
cardiac dysfunction.
LCN2 acts directly on primary cardiac fibro-
blasts to decrease intracellular HMGB1 levels, 
induce NLRP3 inflammasome activation and 
attenuate autophagy
During pathological conditions, cardiac fibro-
blasts play a crucial role in maintaining normal 
cardiac function by modulating the synthesis 
not only via deposition of extracellular matrix, 
but also upon autocrine and paracrine cell-to-
cell communication [25]. We observed accumu-
lation of fibroblasts after PO model and these 
may play a role in NLRP3 inflammasome com-
plex formation. To test this possibility, we iso-
lated primary cardiac fibroblasts from neonatal 
rats and treated with recombinant LCN2 for 48 
hours. Immunofluorescent staining indicated 
increased LCN2 signal in the cytosol and 
reduced cytosolic HMGB1 levels in cells treated 
with LCN2 (Figure 5A). Western blotting data 
also confirmed that total cellular HMGB1 levels 
were decreased after LCN2 treatment (Figure 
5B, lower). Meanwhile, HMGB1 was detected in 
concentrated conditioned medium after LCN2 
treatment (Figure 5B, top). Protein levels of 
IL-1β and IL-18 were also increased in this 
medium after LCN2 treatment (Figure 5B, top). 
Gene expressions of Caspase-1, IL-1β, NLRP3 
and NF-κB in fibroblasts (Figure 5C) were 
induced by LCN2 treatment. We found that 
LCN2 also had direct effects on protein mark-
ers of autophagy with decreased LC3-II and 
elevated P62 levels and a reduction in BECLIN-1 
(Figure 5D and 5E). HMGB1 also regulates 
autophagy by competing for BECLIN-1 binding 
with Bcl-2. To determine whether the interrup-
tion of autophagy is due to decreased binding 
between HMGB1 and BECLIN-1 after LCN2 tre- 
atment of cells, we immunoprecipitated BEC- 
LIN-1 and observed less association of HMGB1 
after LCN2 treatment (Figure 5F and 5G).
LCN2 induced inflammasome activation is 
attenuated by NLRP3 deficiency and TLR4 
inhibition
Primary cardiac fibroblasts from WT and NLRP3 
knockout (NLRP3-/-) adult mice were treated 
in culture with recombinant LCN2 or NLRP3 
inflammasome activator lipopolysaccharide/
adenosine triphosphate (LPS/ATP) for 24 h 
[26]. LCN2 treatment increased mRNA levels of 
inflammasome related genes Caspase-1 and 
IL-1β in WT mice but not in NLPR3-/- mice 
Figure 6. LCN2 induced inflammasome activation is attenuated by NLRP3 deficiency. Wild type and NLRP3-/- mice 
heart fibroblasts were isolated and treated with recombinant LCN2 (1 μg/ml) or ATP plus LPS for 24 hours. Expres-
sion levels of inflammasome markers, Caspase-1 (A), IL-1β (B), NF-κB (C) and NLRP3 (D) were examined by qPCR. 
Adult rat heart fibroblasts were isolated and treated with recombinant LCN2 (1 μg/ml) or ATP (5 μM) plus LPS (2.5 
μg/ml) for 24 hours in the presence or absence of NLRP3 inhibitor MCC-950 (0.1 μM). (E) Western blotting was per-
formed to examine the protein levels of LCN2 and inflammatory markers in medium (IL-1β) and fibroblasts (HMGB1, 
Caspase-1, pNF-κB, tNF-κB). Caspase-1 (F) and IL-1β (G) mRNA levels were checked by qPCR. *, P<0.05, **, P<0.01 
vs. corresponding control, n=3.
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(Figure 6A-D). When treat-
ed with LCN2 and LPS/ATP 
in the presence or absence 
of NLRP3 inhibitor (MCC-
950) or TLR4 inhibitor (Cli-
095), mRNA levels of Ca- 
spase-1 and IL-1β were sig-
nificantly attenuated (Fig- 
ures 6F, 6G, 7B and 7C). 
Figure 7. LCN2 induced inflammasome activation is attenuated by TLR4 inhibition. Adult rat heart fibroblasts were 
isolated and treated with recombinant LCN2 (1 μg/ml) or ATP (5 μM) plus LPS (2.5 μg/ml) for 24 hours in the pres-
ence or absence of TLR4 inhibitor Cli-095 (1 μg/ml). (A) Western blotting was performed to examine the protein 
levels of LCN2 and inflammatory markers in medium (IL-1β) and fibroblasts (HMGB1, Caspase-1, pNF-κB, tNF-κB). 
Caspase-1 (B) and IL-1β (C) mRNA levels were checked by qPCR. *, P<0.05, **, P<0.01 vs. corresponding control, 
n=3.
Figure 8. Schematic model depicting mechanisms via which LCN2 regulates 
NLRP3 inflammasome. LCN2 disrupts the association of BECLIN-1 and HMGB1, 
one consequence of which is altered autophagic flux (left side). Another is 
HMGB1 release from cells which can then induce an inflammatory response 
by binding to TLR4 receptors (right side). LCN2 also induced mitochondrial 
dysfunction and we propose that consequent increases in ROS or mtDNA may 
contribute to priming and activation of the NLRP3 inflammasome. The end re-
sult of NLRP3 inflammasome activation is production and cleavage of proin-
flammatory cytokines (IL-1 β 
and IL-18) via Caspase-1 acti-
vation. Together these effects 
may dictate cardiac remodel-
ing events such as fibrosis. 
ASC, apoptosis-associated sp- 
eck-like protein; Bcl-2, B-cell 
lymphoma 2; CARD, caspase 
activation and recruitment 
domain. IL-1β, interleukin-1β; 
IL-18, interleukin-18; NF-κB, 
transcription factor nuclear 
factor kappa-light chain-en-
hancer of activated B cells; 
NLRP3, NACHT, LRR and PYD 
domains-containing protein 3; 
TLR-4, toll-like receptor 4.
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MCC-950 and Cli-095 also attenuated the level 
of LCN2 induced IL-1β release into the media, 
as well as Caspase-1 and phospho-NF-κB p65 
(Ser536) content in rat adult fibroblasts 
(Figures 6E and 7A). Consistently, the protein 
expression level of HMGB1 decreased after 
LCN2 treatment, but not LPS/ATP treatment, 
indicating the role of LCN2 in releasing HMGB1 
from the cytosol (Figures 6E and 7A). 
Discussion
Our analysis of the contribution by LCN2 to car-
diac dysfunction, and in particular the discov-
ery of novel mechanisms of LCN2 action has 
wide-ranging diagnostic and therapeutic impli-
cations, not only in heart failure but also other 
conditions such as kidney dysfunction. A princi-
pal novel discovery of this study was that LCN2 
induced NLRP3 inflammasome activation via 
release of the danger-associated molecular 
pattern (DAMP) protein HMGB1 and subse-
quent TLR4-dependent signaling. Our results 
revealed that lack of LCN2 in mice mitigates 
maladaptive fibrotic remodeling and facilitates 
adequate induction of autophagic flux in 
response to PO, in keeping with our previous 
work indicating that LCN2 directly attenuated 
autophagic flux [13]. Thus, we have validated 
the functional consequences of cardiac LCN2 
actions and provided new insight into the 
mechanisms involved (Figure 8).
An important impact of NLRP3 inflammasome 
activation in diabetes and cardiovascular dis-
ease is well documented [11, 27, 28]. Previous 
studies showed that serum LCN2 levels corre-
late positively with various cardiovascular dis-
eases including HF [2]. Basal expression of 
LCN2 in heart tissue is low and we found that 
direct administration of LCN2 accelerated the 
progression of HF [6]. One of the best charac-
terized DAMPs is HMGB1 which promotes 
NLRP3 inflammasome and NF-κB activation 
[29]. Effects of HMGB1 can be mediated via 
several mechanisms, including HMGB1 binding 
to receptor for advanced glycation end prod-
ucts (RAGE) and toll-like receptors TLR2 and 
TLR4 [21, 29]. In astrocytes, the inhibition of 
TLR4, rather than RAGE or TLR2 attenuated 
HMGB1-induced IL-18 production [30]. We 
found decreased intracellular HMGB1 levels in 
rat adult and neonatal fibroblasts treated with 
LCN2, suggesting that LCN2 induces release 
of HMGB1 into the extracellular space by an 
as yet unknown mechanism. Furthermore, we 
found decreased HMGB1 levels in WT and 
LKO+L2AV, but not LKO mice after PO as well 
as in cardiac biopsy samples of human HF 
patients. Our data indicated that NLRP3 inflam-
masome was initiated by LCN2 via the release 
of HMGB1 followed by TLR-4 activation and 
mitochondria damage, thus assembling various 
lines of evidence in the literature into a detailed 
cohesive mechanism of LCN2 action. The 
induction of the NLRP3 inflammasome complex 
and subsequent inflammatory effects are then 
reasonably considered to contribute to cardiac 
dysfunction.
Reciprocal crosstalk between NLRP3 inflam-
masome activation and LCN2 action was sug-
gested by studies showing that stimulation of 
TLR4 induces the formation of the inflamma-
some complex and production of LCN2 [31]. 
Many studies have now indicated that the 
degree of autophagy changes in the failing 
heart although the functional significance is 
still contentious [32]. Disruption of autophagy 
by cardiac-specific knockdown of Atg5 in mice 
leads to cardiomyopathy [33]. We believe that 
LCN2 is an important suppressor of cardiac 
autophagy and have recently shown reduced 
autophagic flux in cardiomyoblast cells treated 
with LCN2 [13]. Our current study provides evi-
dence that the increase in cardiac autophagy 
normally seen in response to PO, and which is 
generally regarded as a beneficial adaptive 
response, is enhanced in LKO mice and attenu-
ated by adenoviral delivery of LCN2 to these 
mice. Together, these data indicate that LCN2 
acts to suppress cardiac autophagic flux and 
this likely contributes to cardiac dysfunction. 
Interestingly, sustained autophagy upon trans-
genic Atg7 overexpression in mice decreased 
cardiac fibrosis and dysfunction [34]. We 
showed that LKO mice were somewhat protect-
ed against PO-induced induction of vimentin-
positive fibroblasts and fibrosis, while adminis-
tration of L2AV to LKO mice negated these pro-
tective effects. In addition to the classic role of 
extracellular matrix regulation, MMP-9 activity 
can also contribute to inflammation in the fail-
ing heart via activation of inflammatory cyto-
kines such as IL-1β, IL-8 and tumor necrosis 
factor alpha (TNF-α) [35].
In conclusion, our study confirms the detrimen-
tal role of LCN2 in development of cardiac dys-
function and provides new mechanistic insight 
on mechanisms of LCN2 action. Indeed, the 
effects which we have observed in this study 
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could well be at least in part mediated via sys-
temic effects of LCN2 in other tissues which 
causes crosstalk with the heart. A principal 
novel discovery of this study was that LCN2 
induced NLRP3 inflammasome activation via 
release of the danger-associated molecular 
pattern (DAMP) protein HMGB1 and subse-
quent TLR4-dependent signaling. This study 
also provided further evidence that LCN2 acts 
to suppress stress-induced autophagic flux. 
Our focus was on the heart yet this data has 
potentially wide-ranging diagnostic and thera-
peutic implications, since the physiological sig-
nificance of LCN2, also commonly referred to 
as NGAL, is perhaps most well established in 
kidney. Nevertheless, potential for suppressing 
neutrophil-derived LCN2-mediated inflamma-
tion must be balances by potential adverse 
effects of over-suppression due to the benefi-
cial role of neutrophils in cardiac repair by 
polarizing macrophages towards a reparative 
phenotype [36]. This work will also likely stimu-
late interest in new avenues of research on the 
regulation of NLRP3 inflammasome, autophagy 
and fibrosis by LCN2 in other target tissues. In 
summary, we have characterized the cardiac 
functional consequences of LCN2 deletion, 
with or without readministration, in mice and 
provided new insight into the mechanisms 
involved.
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Supplementary Figure 1. Sera were collected in both 8- and 12-weeks-old WT mice and LKO mice with L2AV restora-
tion for 1, 2 and 4 weeks. Sera LCN2 were evaluated by Elisa. n=3-5.
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Supplementary Figure 2. Representative M-mode images of short-axis view of LV and representative images of 
circumferential strain rate during 5 cardiac cycles. 
Supplementary Table 1. Analysis of cardiac parameters of mice heart four weeks after thoracic aorta 
banding surgery
WT SHAM WT PO LKO SHAM LKO PO LKO+L2AV SHAM LKO+L2AV PO
Cardiac output (ml/min) 21.12±3.16 21.14±4.24 21.98±3.97 22.26±6.79 20.83±3.14 17.35±3.20*
LVEDD (mm) 3.21±0.31 3.71±0.39* 3.23±0.32 3.66±0.32 3.51±0.29 3.87±0.31*
LVESD (mm) 1.86±0.25 2.42±0.29* 1.70±0.26 2.22±0.35 2.04±0.24 2.68±0.27*
LVEDV (μl) 42.23±9.77 59.25±14.35* 42.63±10.28 57.34±11.03* 51.96±10.98 65.72±12.56*
LVESV (μl) 11.22±3.75 23.15±4.83* 8.78±3.42 17.36±6.71* 13.88±4.20 27.90±11.56*,#
LV mass (mg) 89.03±17.01 117.85±6.72* 94.05±32.04 121.99±4.62* 88.99±18.50 114.02±8.77*
StrokeVolume (μl) 31.00±6.57 38.57±8.45* 33.85±6.86 39.96±7.51* 38.07±6.94* 37.80±3.10*
Left ventricular end-systolic diameter (LVESD); Left ventricular end-diastolic diameter (LVEDD); Left ventricular end-systolic volume (LVESV); Left 
ventricular end-systolic volume (LVEDV). *, P<0.05 vs. corresponding WT shamand, #, vs. LKO PO, n=5-7.
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Supplementary Figure 3. Protein level of ANP (A, 
B) and gene expression level of ANP, BNP (C) were 
checked from heart tissues collected from each 
group. (D, E) WGA staining were performed to 
checked the cardiomyocytes remodeling in heart tis-
sue sections collected from WT and LKO mice chal-
lenged with pressure overload. *, P<0.05 vs. corre-
sponding WT sham, n=4.
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